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General Introduction 
The incidence of Abdominal Aortic Aneurysms (AAA), defined as a permanent 
dilation of the abdominal aorta to at least 1.5 times its normal diameter,1 has 
persistently increased over the past decades.2 This can be attributed to the 
combined effects of aging of the population, improved diagnostic tools and the 
introduction of screening programmes.3 To date, AAAs are responsible for 1.3% 
of all deaths among men aged between 65-85 years in developed countries.3 
This percentage is probably even higher due to underestimation of AAA related 
mortality, since AAAs generally exist without symptoms.4 
Patients with an acute AAA could either present with a symptomatic 
(unruptured) AAA or with a ruptured AAA. In patients with a symptomatic AAA, 
defined as abdominal and/or back pain in combination with pain at aneurysm 
palpation, pending rupture of their aneurysm is generally assumed. However, 
evidence for a symptomatic AAA representing pending rupture is lacking.5  
In patients with a ruptured AAA, the mortality rate is as high as 80%.6-8 Forty 
percent of the patients with a ruptured AAA do not reach the hospital alive8 and 
in patients reaching the hospital and undergoing surgery, the mortality rate is 
approximately 50%.9 Despite progression in surgical techniques, anesthetical 
management, vascular prostheses and perioperative care, there is only a 
gradual decline in operative mortality rate over the past decades.10,11  
In 1991, a new minimally invasive technique to treat AAA was described by 
Parodi et al., endovascular aneurysm repair (EVAR).12 In the elective setting, 
EVAR showed an absolute and relative mortality risk reduction of approximately 
3 and 75%, respectively.13,14 In the acute setting, emergency EVAR (eEVAR) is a 
strategy that might allow for improvement in above-mentioned poor prognosis. 
Since 1994 an increasing amount of publications of eEVAR to treat acute AAA is 
published. Currently, eEVAR has become an accepted treatment option, which 
is increasingly being performed to treat acute AAA. However, the potential 
reduction in peri-operative mortality of eEVAR compared to conventional open 
repair in patients with an acute AAA is still open to debate.  
In an era where EVAR and eEVAR are increasingly performed, drawbacks of this 
minimally invasive technique are more enlightened. A frequently mentioned 
disadvantage of EVAR is the requirement of long-term imaging surveillance 
after EVAR in order to detect stent graft related complications.15 Computed 
tomography angiography (CTA) is the most widely used technique for post-
EVAR surveillance.16 However, repetitive CTA has several important drawbacks, 
including cumulative radiation dose, and nephrotoxic contrast load.17 
Therefore, a less harmful alternative for follow-up after EVAR is desirable. 
Chapter 1  
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PART I 
Acute abdominal aortic aneurysms and 
paraanastomotic aneurysms, EVAR or open surgery? 
Treatment options 
In patients presenting with an acute AAA, a choice can be made whether or not 
to offer treatment at all (selective treatment policy). When decided to perform 
an intervention, two treatment options are available; conventional “open” AAA 
repair or the minimally invasive endovascular AAA repair. 
Conventional ‘open’ acute AAA repair 
Conventional open repair of an AAA was performed for the first time in 1951, 
replacing the AAA by a homograft.18 Two years later, open repair was 
performed using synthetic grafts.19 The open procedure to treat ruptured as 
well as unruptured AAA has almost been consistent over time and known as 
being an invasive, but generally durable procedure. In case of a ruptured AAA, a 
laparotomy is performed immediately after induction of general anesthesia in 
patients often suffering from hypovolemic shock. Subsequently, the aorta 
and/or iliac arteries are clamped proximally and distally from the aneurysm. 
After clamping, the aneurysm is opened in order to provide access for 
placement of a polyester tube or bifurcated graft. The aneurysm sac is left in 
situ and secured around the graft in order to cover it.  
This major operation carries a significant mortality and morbidity, due to the 
combined effects of general anesthesia, surgical exposure, hemorrhage, and 
aortic clamping with related lower torso ischemia-reperfusion injury.20 General 
anesthesia is required with associated inhibition of sympathetic arterial tone, 
which might lead to acute hemodynamical changes. Furthermore, loss of 
abdominal muscle tone during induction of general anesthesia might convert a 
retroperitoneal hematoma into an intraperitoneal bleeding with related 
hemodynamical consequences.21 During surgical exposure, blood loss is 
generally extensive.22 Hypotension and subsequent inadequate oxygenation 
might induce or accelerate cerebral en cardiac ischemia, resulting in poor 
clinical prognosis. Furthermore, after removing the clamps, considerable 
ischemia-reperfusion injury of the lower extremities and the intra-abdominal 
organs might occur.23 
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Minimally invasive endovascular acute AAA repair 
In 1991, Parodi described a less invasive alternative to conventional ‘open’ 
aneurysm repair for the treatment of AAA, the so-called EVAR.12 EVAR implies 
groin incisions in order to expose the femoral arteries, whereas percutaneous 
techniques are also possible. Using a catheter and guidewire, a synthetic stent 
graft is fed through the artery up to the AAA neck until positioned correctly just 
below the renal arteries and subsequently unfolded, excluding the aneurysm 
sac from blood flow and pressure. Control angiography is performed to assure 
correct placement of the endovascular stent graft. Aorto-uni-iliac stent grafts, 
reaching one of the common iliac arteries as well as bifurcated stent grafts, 
reaching both iliac arteries are available. In case of an aorto-uni-iliac stentgraft, 
femoro-femoral bypass graft surgery has to be performed in order to restore 
blood flow to the contralateral leg. A controlateral endovascular occluder is 
used to stop retrograde bleeding up the iliac artery into the aneurysm sac. Due 
to increasing expertise and continuous improvement of both stent grafts and 
their delivery systems, increasing success rates and decreasing complications 
and reintervention rates are observed.24 
After several years of experience in EVAR for unruptured AAAs this technique 
has gradually extended its indication and is currently used to treat feasible 
patients with acute AAA.25 The applicability for ‘emergency EVAR’ (eEVAR) 
depends on several anatomical and logistic conditions. Anatomical suitability for 
EVAR is assessed on a preoperative CTA scan and evaluated for infrarenal aortic 
neck length, neck angulation, amount of circular thrombus or atherosclerosis, 
and iliac and femoral access arteries.26 Approximately half of the acute AAA is 
considered anatomically suitable for eEVAR according to the preoperative CTA 
scan.27 However, logistic problems are often reported which frequently led to 
the exclusion of EVAR-suitable patients for undergoing endovascular repair.26,28-
33 Logistic criteria for eEVAR are the instant availability of a CT-scanner, the 24/7 
availability of an operating room that is adequately equipped to perform 
endovascular procedures as well as an endovascular trained staff. Financial 
burden is sometimes the availability of a large variety of ‘off-the-shelf’ 
stentgrafts.34  
EVAR versus open surgery 
In a recent systematic review of 61 controlled and uncontrolled clinical studies 
of patients with an unruptured AAA, EVAR is described as a feasible and safe 
technique, showing decreased mortality and morbidity rates compared to a 
conventional open procedure.35 Since its first description in 1994 by Yusuf et 
Chapter 1  
 12 
al.,25 over 400 reports of eEVAR for patients with an acute AAA are available. 
Based on results of elective AAA studies and based on several 
pathophysiological and surgical theories, it seems reasonable to prefer 
endovascular repair in the acute setting as well. 
The minimal invasive approach implies the opportunity to use local anesthesia, 
which has been proven to be feasible and effective in EVAR.36,37 Local 
anesthesia is not attended with the acute hemodynamical changes as seen 
during induction of general anaesthesia.21 However, these benefits did not lead 
to standard application of local anesthesia, since 19 comparative observational 
studies show considerable variation in the percentages of patients undergoing 
local anesthesia (0-97%). Furthermore, eEVAR involves no crossclamping and 
minor surgical exposition compared to open surgery. 
These advantageous consequences of the minimally invasive endovascular 
approach to treat acute AAA might reflect on perioperative mortality. 
Approximately 26 studies comparing EVAR with conventional open surgery in 
patients with an acute AAA can be identified, mostly concerning ruptured 
AAA.26,28-33,38-56 Twenty-four of these studies compared early mortality of EVAR 
with open surgery.26,28-33,38-42,44-51,53-56 One of these studies is a prospective 
randomized trial by Hinchliffe et al., which showed identical 30-day mortality 
rates in both treatment groups (9/17 in the open surgery group versus 8/15 in 
the EVAR group).45 However, the study is underpowered and served as a pilot 
study for future randomized studies. The remaining 23 studies are 
observational studies of which 4 showed no reduction in early mortality 
compared to open surgery.45,49,53,54 Using Review Manager 4.2.10, provided by 
the Nordic Cochrane center, a forest-plot can be created (Figure 1.1). The 
overall effect of EVAR compared to open surgery, taking 1 randomized 
controlled trail and 23 available observational studies into account, showed a 
38% decrease in 30-day or hospital mortality rate (peto-odds ratio 0.62; 95% CI 
0.52 to 0.74).  
Additionally, the 30-day, or hospital mortality is reported in five recent 
systematic reviews (Table 1.1).22,57-60 Two reviews only discuss the results of the 
endovascular procedure58,59 and three reviews compared the endovascular with 
the open procedure.22,57,60 The first review showed a pooled mortality rate after 
EVAR of 24% (95% CI 20-28%) across 31 studies concerning 982 patients.59 In 18 
observational studies describing 436 people who underwent EVAR, the second 
review found a pooled mortality of 21% (95% CI 13-29%).58 In two reviews 
comparing both treatment groups, pooled mortality was 18%57 and 22%60 in the 
EVAR group compared to 34%57 and 38%60 in the open surgery group. In the 
General introduction 
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 Study  EVAR  open surgery  Peto OR  Peto OR
or sub-category  n/N  n/N  95% CI  95% CI
 Acosta et al              19/56              48/106           0.63 [0.33, 1.21]    
 Alsac et al                4/17              10/20            0.33 [0.09, 1.25]    
 Anain et al                5/30               4/10            0.27 [0.05, 1.47]    
 Arya et al                 4/17              16/34            0.38 [0.12, 1.24]    
 Brandt et al               0/11               2/13            0.15 [0.01, 2.49]    
 Coppi et al               10/33              42/91            0.52 [0.23, 1.17]    
 Dalainas et al             8/20               5/8             0.42 [0.08, 2.10]    
 Franks et al               2/21              12/23            0.15 [0.04, 0.51]    
 Greco et al              114/290           2627/5508          0.71 [0.56, 0.91]    
 Hinchliffe et al           8/15               9/17            1.02 [0.26, 3.99]    
 Kapma et al                5/40              64/213           0.41 [0.19, 0.88]    
 Larzon et al               2/5               12/26            0.79 [0.12, 5.21]    
 Lee et al                  1/13               1/4             0.21 [0.01, 6.08]    
 Moore et al                1/20               9/36            0.26 [0.06, 1.08]    
 Ockert et al               9/29               9/29            1.00 [0.33, 3.01]    
 Ohki et al                 2/20               0/5             3.69 [0.11, 126.93]  
 Peppelenbosch et al       17/49              20/51            0.83 [0.37, 1.85]    
 Reichart et al             1/6                4/13            0.50 [0.06, 4.26]    
 Resch et al                4/14               8/23            0.76 [0.19, 3.08]    
 Sambeek, van et al         0/6                0/6                Not estimable     
 Vaddineni et al            2/9                4/15            0.80 [0.12, 5.16]    
 Verhoeven et al            1/16               7/31            0.32 [0.07, 1.58]    
 Visser et al               8/26               9/29            0.99 [0.32, 3.07]    
 Yilmaz et al               4/24              13/40            0.45 [0.14, 1.40]    
Total (95% CI) 787                6351      0.62 [0.52, 0.74]
Total events: 231 (EVAR), 2935 (open surgery)
Test for heterogeneity: Chi² = 17.72, df = 22 (P = 0.72), I² = 0%
Test for overall effect: Z = 5.35 (P < 0.00001)
 0.001  0.01  0.1  1  10  100  1000
 Favours EVAR  Favours Open surgery
fifth review, Sadat et al. showed that EVAR is associated with a significant 
reduction in mortality with a pooled odds ratio of 0.62 (95% CI 0.52-0.75).22 
Visser et al. found similar results with an odds ratio of 0.45 (95% BI 0.28-0.72).60 
However, after adjustment for patients' hemodynamic condition, the odds ratio 
was 0.67 (95% CI 0.31-1.44) and therefore no longer significant. 
In addition, the systematic reviews showed that EVAR is associated with 
significant reduction in blood loss, reduced procedure time, reduction in 
systemic complications and reduced intensive care and hospital stay compared 
to open surgery.22,57,58,60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Forest plot of 30-day or hospital mortality in 24 studies comparing EVAR and open 
surgery in patients with a ruptured AAA. 
 
Table 1.1 30-day or in-hospital mortality in patients treated with open or endovascular repair 
according to five systematic reviews. 
Review Studies Patients 30‐day/in‐hospital mortality 
 n n 
EVAR 
% (95% CI) 
Open 
% (95% CI) 
Odds ratio 
EVAR vs Open 
Rayt et al.59 31   982 24% (20-28) - - 
Mastracci et al.58 18   436 21% (13-29) - - 
Harkin et al.57 34   891  18% (0-53) *  34% (0-70) * - 
Visser et al.60 10   478 22% (16-29) 38% (32-45) 0.45 (0.28-0.78) 
Sadat et al.22 23 7040 - - 0.62 (0.52-0.75) 
CI = confidence interval, vs = versus; * = % (range included studies) 
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Other potential indications for endovascular repair: paraanastomotic 
aneurysms 
A typical complication after conventional aortic prosthetic reconstruction is 
paraanastomotic aneurysm formation. Paraanastomotic aneurysms after 
previous open reconstruction may present as continuing dilatation of the aorta 
(true paraanastomotic aneurysms) or as disruption of the anastomosis leading 
to pseudoaneurysm formation (false paraanastomotic aneurysms).61 Most 
reinterventions after initial abdominal aortic prosthetic reconstruction are for 
repair of these anastomotic pseudoaneurysms and true paraanastomotic 
aneurysms, since they are at risk for rupture.62,63 The reported rupture rate in 
patients who did not receive surgery ranges from 15-55%.64-66 An open 
procedure in order to treat these paraanastomotic aneurysms in generally high-
risk patients is technically challenging with mortality and morbidity rates (24-
70% and 70-83%, respectively) higher than those associated with primary 
prosthetic reconstructions.67-69 Endovascular repair however, allows for local or 
regional anesthesia without requiring dissection through previous scarred 
operative sites, potentially resulting in decreased mortality and morbidity rates 
compared to an open reintervention. 
PART II 
Follow-up after endovascular aneurysm repair, 
depicting stent graft related complications 
Stent graft related complications might cause re-establishment of circulation in 
the aneurysm sac resulting in aneurysm expansion and ongoing rupture risk.13 
Complications, including aneurysm growth, endoleak, migration, and kinking, 
are observed in approximately 40% of patients by 4 years after EVAR, resulting 
in a 20% reintervention rate to reduce the ongoing rupture risk.13 Long-term 
imaging surveillance in terms of CTA is required to detect stent graft related 
complications with related cumulative radiation dose, and nephrotoxic contrast 
load.15,17 Therefore, alternatives to CTA for surveillance after EVAR are 
desirable.  
According to the practical guidelines of the Society of Interventional Radiology, 
three parameters should be included for imaging surveillance: diameter 
measurements of the aortic aneurysm, detection of morphologic details of the 
stent grafts, and detection and classification of endoleaks.70 
General introduction 
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Gradually decreasing AAA diameter after endovascular repair is presumed to 
reflect successful treatment and low rupture risk,15 whereas increasing AAA 
diameters in the follow-up after EVAR indicates continued rupture risk.71 
Currently, maximal diameter is the most widely used parameter for aneurysm 
size measurements. Alteration of stent grafts, including migration, kinking and 
fracture, are the result of hemodynamic stress, aortic morphologic changes 
and/or device inadequacy. These stent graft deformations may cause 
endoleakage, continued rupture risk or obstruction of blood flow through the 
device. 
Endoleak formation, defined as a blood flow external to the stent graft and 
inside the aneurysm sac,15,72,73 is the most common complication of EVAR with a 
reported incidence varying from 2 to 45%.16,74-77 Based on the origin of the leak, 
endoleaks can be organized into five categories. Persistent endoleak is 
considered a procedural failure because it may cause enlargement and rupture 
of the aneurysm, representing the main indication for surgical late conversion.78 
Since endoleakage may cause aneurysm expansion and ongoing rupture risk, 
modalities in order to identify them are essential in the post-EVAR surveillance. 
Among various imaging modalities, CTA is the most widely used technique for 
post-EVAR surveillance.16 However, repetitive CTA has several important 
drawbacks, including cumulative radiation dose, nephrotoxic contrast load, and 
high costs.17 Contrast enhanced or unenhanced ultrasonography, magnetic 
resonance angiography, digital subtraction angiography, and potential 
biomarkers might all have a role in endoleak detection and are therefore 
potential alternatives to CTA. 
A number of studies have indicated that color Duplex ultrasound may be used 
for post-EVAR surveillance.79-82 Sonographic contrast agents enhance the 
capability of color duplex to detect endoleaks.83-87 However, accuracy and 
reproducibility of contrast-enhanced ultrasound (CEUS) as an alternative to CTA 
in the follow-up of patients after EVAR with regard to detection of changes in 
AAA dimensions and endoleaks is required for clinical applicability. 
Regarding potential biomarkers, Sangiorgi et al. were the first to report that a 
decrease of plasma matrix metalloproteinase (MMP)-3 and MMP-9 during post 
EVAR surveillance might indicate successful EVAR and that an increase in MMP 
concentration after EVAR may help to identify patients with aneurysm sac 
growth and/or endoleakage.88 Since increased circulating concentrations of 
MMP-2, -9 and tissue inhibitor of MMP-1 (TIMP-1) are associated with presence 
and size of AAA,89-91 there might be a potential clinical applicability of MMP-2, 
-9, and TIMP-1 as a diagnostic tool for presence of endoleakage.  
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Possibilities for research 
The reported reduction in early mortality after eEVAR in the treatment of rAAA 
compared to conventional ‘open’ surgery seems conclusive. However, the 
available studies have considerable heterogeneity and methodological 
limitations.  
At first, heterogeneity is caused by differences in definitions: e.g. the definition 
of hemodynamical instability varied from a systolic blood pressure below 50 
mmHg to 100 mmHg. Heterogeneity is further illustrated with the range of 
percentages of patients with a rAAA treated with eEVAR (15-50%) as well as the 
percentage of hemodynamical unstable patients (33-73%) within the eEVAR 
group.  
Furthermore, in most studies a limited number of patients were included and 
comparative studies are flawed by methodological inadequacies such as high 
potential of selection bias and lack of randomisation.20 Selection bias is created 
by selecting patients for EVAR constituting a lower-risk category, presuming 
they need to be hemodynamically more stable for preoperative imaging and 
have a more favorable (EVAR-suitable) anatomic configuration. A well-
conducted large randomized controlled trial (RCT) could provide useful data, 
but has not been published so far. Furthermore, a RCT may give ethical 
concerns, given the accumulation of superior results with EVAR based on the 
available observational studies. In addition, a RCT in an acute, severe condition 
like a ruptured AAA, appears difficult to perform.45  
Research is needed to clarify certain aspects of endovascular repair in an era in 
which endovascular repair is increasingly performed for extending indications.  
 
A large prospective controlled trial in which selection bias is made unlikely is 
needed to identify possible benefits of EVAR over open surgery in patients with 
an acute AAA.  
Long-term results of patients treated either with EVAR or open repair for acute 
AAA are lacking and desires further investigation.  
A few small series of endovascular treatment of paraanastomotic aneurysms 
after primary conventional open aortic reconstruction are reported. However, 
larger study populations with longer follow-up are required to assess long-term 
feasibility.  
Alternatives to CTA as life-long annual surveillance after EVAR is desirable in 
order to restrain the cumulative CTA related burden in patients, especially in an 
era in which endovascular repair is increasingly performed.  
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Therefore, objectives addressed in this thesis can be summarized by: 
1. To assess whether endovascular aneurysm repair decrease early and 
midterm mortality in patients with an acute AAA. 
2. To evaluate the role of selection bias in the current available observational 
studies comparing EVAR with open repair in patients with a ruptured AAA. 
3. To assess the widely assumed necessity for acute intervention in patients 
with a symptomatic acute AAA. 
4. To evaluate the outcome of a multicenter series of patients who were 
treated with endovascular repair for paraanastomotic aneurysms after 
previous open reconstruction.  
5. To describe and assess potential alternatives to CTA in post-EVAR 
surveillance. 
Chapter 1  
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Aim and outline of this thesis 
This thesis focuses on the refinement of the role of endovascular repair in 
‘patients with an acute (symptomatic or ruptured) AAA’ or ‘paraanastomotic 
AAA after previous conventional open surgery’ and possibilities to replace the 
current repetitive CTA scans for surveillance after endovascular aneurysm 
repair by less harmful alternatives. A number of studies were performed 
focusing on type and timing of treatment in patients with an acute AAA, 
treatment of paraanastomotic aneurysms, as well as strategies and diagnostic 
accuracy to detect changes in AAA size and endoleaks during follow-up after 
endovascular aneurysm repair. 
PART I 
The minimally invasive endovascular procedure (EVAR) is likely to reduce early 
mortality in patients with an acute AAA. The majority of the studies comparing 
EVAR with conventional open surgery show a clear trend towards an improved 
short-term effect of EVAR and a significant reduction in early mortality 
compared to conventional open surgery. However, these results have to be 
interpreted with caution due to the likelihood of methodological inadequacies 
such as selection bias, heterogeneity, and lack of randomization.  
 
Chapter 2 describes a study in which EVAR is compared to conventional open 
surgery in patients with a ruptured AAA. Selection bias to be treated with EVAR 
or open repair based on anatomical or hemodynamical criteria has been made 
unlikely, since all patients were suitable for EVAR and had the same pre-
operative imaging protocol. Mortality rates where determined at 30 days and 6 
months of follow-up. 
Chapter 3 contains an observational study in which EVAR is compared to 
conventional open surgery in all patients with an acute AAA (symptomatic or 
non-ruptured acute AAA as well as ruptured AAA). Follow-up was 1 year and 
mortality rates were divided in all cause mortality and aneurysm related 
mortality. 
As mentioned before, observational studies, such as chapter 2, comparing EVAR 
with open surgery in patients with ruptured AAA, are generally flawed by 
methodological inadequacies. The main methodological aspect is selection bias 
by selecting patients for EVAR constituting a lower-risk category in terms of 
hemodynamic and anatomic condition. The weight of this selection bias on 
outcome after open repair is observed in chapter 4 by comparing EVAR-suitable 
General introduction 
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with EVAR-unsuitable ruptured AAAs in patients who had the same 
preoperative imaging protocol and who all underwent conventional open 
repair. 
In chapter 5 we investigated whether a symptomatic AAA needs acute 
intervention (within 12 hours after presentation). When operated within 12 
hours, the risk of rupture prior to surgery with related worsening of prognosis 
might be reduced. On the other hand, in an acute setting there is little time for 
preoperative optimization of patients’ and operative conditions. Chapter 4 
compares patients with a symptomatic AAA who were treated within 12 hours 
after presentation with patients who were treated after 12 hours after 
presentation. 
Most reinterventions after abdominal aortic prosthetic reconstruction are for 
repair of paraanastomotic pseudoaneurysms and true paraanastomotic 
aneurysms. These reoperations are technically challenging procedures requiring 
dissection through previous scarred operative sites in generally high-risk 
patients. Chapter 6 describes a multicenter series of patients treated with 
endovascular repair for paraanastomotic aneurysms after a previous open 
aorto-iliac reconstruction. 
PART II 
Endovascular aortic aneurysm repair is a less invasive alternative to open 
surgical repair in selected patients with AAA. In the elective setting, this 
technique has an initial postoperative benefit over open AAA repair due to 
decreased early morbidity and mortality. However, long-term imaging 
surveillance in terms of CTA is required to detect stent graft related 
complications. This lifelong requirement for patient surveillance accentuates 
certain drawbacks of CTA, including ionizing radiation burden and nephrotoxic 
contrast load. Are there clinically applicable alternatives to CTA in the follow-up 
after endovascular aneurysm repair? 
 
Chapter 7 discusses the strategies for endoleak detection in the follow up after 
EVAR in terms of imaging techniques (CTA, CEUS, and MRA) and biochemical 
assays (MMP-2, and MMP-9).  
Since no major side effects, including nephrotoxic effects and radiation burden, 
have been reported for ultrasound contrast agents, this favors the potential use 
of CEUS for post-EVAR follow-up. Chapter 8 describes a study comparing the 
diagnostic accuracy between contrast-enhanced ultrasound (CEUS) and CTA to 
detect changes in AAA size and endoleaks during follow-up after EVAR. 
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Endoleakage is the most common complication of EVAR and it is clinically 
important since it may cause enlargement and eventually rupture of the 
aneurysm sac. Increased circulating concentrations of MMP-2, -9 and TIMP-1 
are associated with presence and size of AAA. In Chapter 9 the potential clinical 
applicability of MMP-2, -9, and TIMP-1 as a diagnostic tool for presence of 
endoleak was evaluated.  
Conclusions of the thesis and prospects for the treatment of acute AAA and 
imaging follow-up after EVAR are outlined in a general discussion of the results 
of these studies in Chapter 10. 
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Abstract 
Objective 
Efficacy results of ruptured endovascular aneurysm repair (rEVAR) compared to open 
surgery for ruptured abdominal aortic aneurysms (rAAA) are based on several 
observational studies containing selection bias. In the present study rEVAR is compared 
with open surgery in EVAR-suitable patients with a ruptured abdominal aortic aneurysm 
(rAAA) who all underwent the same preoperative imaging protocol.  
Materials and Methods 
Our policy is to perform a CTA on all patients with a suspected rAAA. rEVAR was 
performed when the rEVAR-vascular surgeon was on call and the rAAA was EVAR-
suitable. Afterwards, two experienced independent blinded experts assessed all CTA 
scans on EVAR-suitability. Only EVAR-suitable patients were included in the main 
analyses. Outcome parameters included: intra-operative, 30-day and 6-month mortality, 
complications, re-interventions, and length of hospital stay.  
Results 
From April 2002 until March 2008, 132 consecutive patients with suspected rAAA were 
presented. In 104 patients rAAA was confirmed by preoperative CTA scan. Of these, 
25 patients underwent rEVAR and 79 underwent open surgery. In retrospect all 25 rEVAR 
patients and 33 patients in the open group were judged EVAR-suitable by the experts. At 
baseline there was an equal distribution of patients’ physiologic and anatomic 
characteristics as well as co-morbidity. In EVAR-suitable patients, the intra-operative, 30-
day and 6-month mortality was 4.0% (1/25), 20.0% (5/25) and 28.0% (7/25) after rEVAR 
compared to 6.1% (2/33) (P=1.00), 45.5% (15/33) (P=0.04) and 54.5% (18/33) (P=0.04) 
after open surgery, respectively. Median length of hospital stay was 9.5 days 
(interquartile range 5.0-20.5) after rEVAR and 17.0 days (interquartile range 9.5-28.0) 
after open surgery (P=0.03). 
Conclusions 
In EVAR suitable patients, an absolute perioperative mortality reduction of 25.5% of 
rEVAR over open surgery was found, which was still present at 6 months follow-up. 
These data suggest that rEVAR is a superior treatment option for EVAR-suitable patients 
with a ruptured AAA compared to open surgery. 
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Introduction 
Until 1994 ruptured abdominal aortic aneurysms (rAAA) were treated with open 
surgery, carrying a significant mortality and morbidity. When rupture occurs, 
40% of the patients do not reach the hospital alive.1. In patients reaching the 
hospital and undergoing conventional open surgery, reported 30-day mortality 
and morbidity rates are as high as 38-49% and 56-62%, respectively.2-6 Despite 
medical and surgical progress, there has been only a gradual decline in 
mortality over the past fifty years.3 This might be due to the combined effects 
of general anesthesia, surgical exposure, hemorrhage, and aortic clamping with 
lower torso ischemia-reperfusion injury.7 
 
In 1991 Parodi et al. introduced a minimally invasive technique for abdominal 
aortic aneurysm (AAA) repair. This so called endovascular aneurysm repair 
(EVAR)8 can be performed under local anesthesia with less blood loss and no 
need for aortic cross-clamping.9 In the elective setting endovascular repair has 
been associated with lower 30-day mortality and morbidity rates compared to 
open repair.10,11 Since its first description by Yusuf et al. in 1994, EVAR has 
successfully been used in feasible patients to treat rAAA (rEVAR).12 However, it 
is still open to debate whether rEVAR will lead to important improvement in 
outcomes compared to conventional open surgery in patients with a rAAA. 
Several studies compare early mortality and morbidity in endovascular repair 
versus open repair,13-22 most of them showing a reduction in early 
complications and mortality.13-19,21 In acute conditions like rAAA, truly 
randomized studies are difficult to perform. As a result of lack of randomization, 
comparative studies so far are flawed by methodological inadequacies such as 
selection bias, which is created by inadequate control of potential confounding 
secondary to inadequate patient matching.7 Patients who are selected for 
rEVAR constitute a lower-risk category, presumably because they need to be 
hemodynamically more stable for preoperative imaging and have a more 
favorable anatomic configuration.  
 
In the present study, selection bias due to inadequate patient matching is 
eliminated by reporting a comparison of emergency endovascular repair and 
open surgery in patients with a rAAA who all had the same preoperative 
imaging protocol, irrespective of hemodynamic condition, and who were all 
anatomically suitable for EVAR. 
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Materials and Methods 
Population and treatment protocol 
All patients presenting at the emergency department of a non-academic 
teaching hospital (Atrium Medical Center, Heerlen, the Netherlands), with 
clinically suspected rAAA received immediate abdominal Ultrasonography to 
look for presence of an AAA and signs of rupture. In patients with a suspected 
rAAA a computed tomography angiography (CTA) scan (nonenhanced and 
arterial phase acquisition) was performed within 30 minutes after presentation 
in order to confirm rupture and to assess EVAR suitability and AAA diameter. A 
multidetector 16 slice spiral CT scanner (Somaton sensation; Siemens, 
Forccheim, Germany) was used with the following parameters: high-speed 
mode capability, rotation time 0.5 seconds, table speed 24 mm per rotation, 
collimation 1.5 mm, and a slice thickness of 3 mm. Rupture was defined as 
extravasation of blood or hematoma outside the AAA on CT examination and/or 
hematoma outside the AAA during open repair or at autopsy. Patients with a 
confirmed rAAA on CTA were eligible for the study. In patients with a rAAA, the 
emergency treatment protocol allows hypotension to a systolic blood pressure 
of 70 mm Hg to reduce the risk of ongoing bleeding, if consciousness is 
maintained (permissive hypotension). While the CTA scan was being performed, 
the vascular surgeon on call was informed. In the Atrium MC we have a mean 
annual rAAA rate of 22 and three vascular surgeons, two with experience in 
open rAAA repair (non-rEVAR-vs, both >20 years of experience) and one with 
experience in both open as well as endovascular rAAA repair (rEVAR-vs, 8 years 
of experience). rEVAR was performed when the rEVAR-vs was on call and the 
CTA was suitable for EVAR according to the rEVAR-vs. Conventional open 
surgery was performed when the rEVAR-vs was not on call, irrespective of CTA 
findings (Figure 2.1). Informed consent was waved by the Institutional Review 
Board because the analyzed patient data was documented as part of routine 
clinical care. Patients’ formal written informed consent was not necessary for 
use of data according to good clinical practice in The Netherlands. 
Definitions  
rEVAR was described as the endovascular repair of a rAAA. Suitability rate for 
rEVAR was defined as the percentage of patients with a rAAA evaluated by CTA 
scan, who were anatomically candidates for rEVAR. A systolic blood pressure 
lower than 100 mmHg was defined as hemodynamically unstable. Cardio-
vascular co-morbidity included history of ischemic heart disease, cerebro-
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vascular accident (CVA) or transient ischemic attack (TIA), hypertension, cardiac 
failure, coronary arterial bypass graft, percutaneous transluminal coronary 
angioplasty, valvular disease, rhythm disorders and a history of aortic 
operation. Pulmonary co-morbidity was defined as the presence of at least one 
of the following: asthma, chronic obstructive pulmonary disease (COPD), 
emphysema, or lung carcinoma. Renal dysfunction was defined as a blood 
creatinine level higher than 140 μmol/l. We defined diabetes mellitus (DM) as 
receiving either oral medication and/or insulin therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Clinical flowchart. 
 US=Ultrasonography, CTA=Computed Tomography Angiography, VS=vascular surgeon. 
 
Procedure 
A fully equipped operation room (OR) with a mobile C-arm imaging system 
(Philips Endura, Philips Medical Systems, Eindhoven, the Netherlands), trained 
OR-staff with EVAR experience and two angiography assistants are permanently 
available. Patients with a rAAA who underwent open repair received general 
anesthesia, whereas patients who underwent endovascular repair preferentially 
received local anesthesia. Open repair was performed using the regular inlay 
History
Physical
examination
US
Suspected
rAAA
rAAA
not suspected
CTA Call VS on call
rEVAR VS non rEVAR VS
Assessment EVAR suitability
by rEVAR VS
rEVAR OPEN OPEN
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technique, replacing the aneurysm by a bifurcated or tube-graft and leaving the 
aneurysmal sac in situ. rEVAR was performed by the rEVAR-vs without the aid of 
an interventional radiologist, by bilateral groin incision to provide access to the 
common femoral artery. In case of aorto-uni-iliac stentgrafting, femoro-femoral 
bypass graft surgery was performed under local anesthesia in order to restore 
blood flow to the contralateral leg. Correct infrarenal placement of the aorto-
uni-iliac or aorto-bi-iliac endograft was obtained with fluoroscopy and intra-
operative angiography. A control angiography was performed after completion 
of the procedure.  
Since April 2002 a standard emergency set of aorto-uni-iliac endografts and 
distal extender iliac device limbs (Talent®, Medtronic, Santa Rosa, CA) was 
available, as described previously.19 Since April 2006 a full stock of bifurcated 
devices (Talent®, Medtronic, Santa Rosa, CA) was permanently available in the 
OR. 
Clinical follow‐up and outcomes 
Follow-up after rAAA repair consisted of visiting the vascular surgery 
outpatients department at 2 weeks, 3 and 12 months after discharge, and 
yearly thereafter. Follow-up imaging after open rAAA repair (ultrasound) and 
rEVAR (multiphasic CTA imaging - nonenhanced, arterial, and delayed phase 
acquisition 70 seconds after intravenous contrast medium injection) were 
scheduled at 3 and 12 months follow-up and yearly thereafter. 
At baseline, gender, age, Body Mass Index (BMI), blood pressure, mean heart 
rate, blood creatinine levels and co-morbidity were recorded. The outcomes 
evaluated were intra-operative, 30-day and 6-month mortality, all 
complications, re-interventions, and length of stay in hospital. Complications 
were classified in deployment/procedure-related complications, implant-
related complications and systemic complications according to Reporting 
Standards for Endovascular Aortic Aneurysm Repair.23 
CTA evaluation for EVAR‐suitability 
Two independent experienced external experts (product specialists of 
Medtronic®), blinded for earlier evaluation and intervention as well as outcome, 
assessed all preoperative CTA scans on EVAR-suitability. In case of disagreement 
between the experts, consensus was found in collaboration with an arbiter who 
was also blinded for earlier evaluation, intervention, and outcome. Suitability 
for endovascular repair, based on CTA, was evaluated according to guidelines 
for elective EVAR including proximal neck length of at least 15 mm, neck 
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diameter less than 32 mm with less than 90° angulation and less than 50% of 
circumferential thrombus and calcification. A conical shaped neck towards the 
aneurysm was considered to be unfavorable for endovascular repair, but was 
addressed in the view of other anatomical contra-indications. Furthermore, 
access vessels had to be larger than 6 mm without severe iliac tortuosity to 
accommodate the introducer sheaths.  
Patients and study design 
Inclusion criteria for the main analyses were ruptured AAA, availability of a 
preoperative computed tomography angiography (CTA) scan and suitability for 
endovascular repair on CTA scan according to the experts. The primary 
comparison of this prospective controlled study concerned consecutive patients 
with a ruptured AAA on preoperative CTA who were considered suitable for 
endovascular repair. EVAR suitable patients who received rEVAR were 
compared to EVAR suitable patients who received open surgery. 
Data analysis 
Statistical analyses were performed with the SPSS statistical software package 
for Windows (Microsoft, Redmond, Wash), version 15.0 (SPSS inc, Chicago, Ill). 
Patient characteristics, clinical outcomes and follow-up were compared in 
patients with a rAAA undergoing rEVAR versus conventional open repair using 
the Chi-square test or Fisher’s Exact test, student’s t-test, and Mann Whitney U-
test (two-sided; α=0.05). Categorical variables were presented as frequency 
with percentages. Nominal variables were expressed as mean ± standard 
deviation (SD) for a normal distribution and for a skewed distribution in terms 
of median and inter-quartile-range (IQR). Values of P<0.05 were considered 
statistically significant. 
Results 
Population 
Between April 2002 and March 2008, 132 patients had a suspected rAAA. In 
28 patients (21%) a CTA was not performed: 6 patients were deemed unfit for 
any treatment, in 7 cases the CTA scanner was not instantly available within 
30 minutes after presentation, in 1 case the rAAA was revealed during surgery 
since preoperative US did not show an AAA. In the other 14 cases preoperative 
CTA scanning was not performed due to protocol violation by a non-rEVAR-vs, 
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since CTA scanning did not influence treatment selection (rEVAR or open repair) 
when a non-rEVAR-vs was on call. In 104 patients a preoperative CTA scan was 
performed of which 58 rAAAs were considered EVAR-suitable according to the 
external experts (55.8% suitability rate). Of 46 patients who were considered 
unsuitable, 33 (72%) had inadequate neck length, 5 (11%) had a neck diameter 
>32 mm, 8 (17%) had severe neck angulation, and 9 (20%) patients had 
unsuitable iliac access. In patients with an EVAR-suitable rAAA, mean age was 
73 years (SD 8) and 93.1% were male. 
Baseline characteristics for both treatment groups were comparable (Table 2.1). 
 
Table 2.1 Baseline characteristics. 
 
rEVAR 
n=25 
Open surgery 
n=33 
P‐value 
 
Mean age in years (SD)  72.2 (8.2)  74.3 (7.1) 0.312 
Male  22/25 (88.0%)  32/33 (97.0%) 0.305 
Mean BMI (SD)  27.5 (5.5)  25.3 (2.1) 0.416 
Cardiovascular co-morbidity  16/25 (64.0%)  24/33 (72.7%) 0.477 
Pulmonary co-morbidity  7/25 (28.0%)  6/33 (18.2%) 0.375 
Renal dysfunction (creat >140 µmol/l)  10/24 (41.7%)  9/33 (27.3%) 0.255 
Diabetes Mellitus  3/25 (12.0%)  4/33 (12.1%) 1.000 
Mean AAA diameter mm (SD)  70.8 (16.7)  70.4 (17.6) 0.932 
SBP <100 mmHg  9/16 (56.3%)  13/24 (54.2%) 0.897 
Mean heart rate (SD)  93.0 (21.8)  92.9 (22.1) 0.995 
SD=standard deviation, BMI=body-mass index, creat=blood creatinine level, mm=millimeter, 
SBP=systolic blood pressure, mmHg=millimeter Mercury. 
 
Treatment 
The rEVAR-vs was on call in 25 of the 58 EVAR suitable rAAA cases and thus 
rEVAR was performed (Figure 2.2, group 1; mean age 72.2 years (SD 8.2)). All 25 
patients who were considered suitable for EVAR by the rEVAR-vs were 
considered suitable by the experts as well. None of the EVAR suitable patients, 
according to the experts, who presented during the time that the rEVAR-vs was 
on call underwent open repair. Local, spinal and general anesthesia was used in 
12 (48.0%), 5 (20.0%) and 8 (32.0%) patients, respectively. In 9 cases (36.0%) a 
Talent bifurcated endograft was placed and in 16 cases (64.0%) a Talent aorto-
uni-iliac endograft, mainly because of the later introduction of the bifurcated 
graft. 
In 33 of the 58 EVAR suitable rAAA cases open surgery was performed (Figure 
2.2, group 2; mean age 74.3 years (SD 7.1)). All 33 patients received general 
anesthesia. In none of the patients suprarenal aortic clamping was needed, 
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since all patients had aortic neck lengths that would have been suitable for 
rEVAR. Twenty-eight patients (84.8%) received a tube-graft and 5 patients 
(15.2%) received a bifurcated prosthesis. 
Mortality 
All outcomes are presented in Table 2.2. Thirty-day mortality rate after rEVAR 
and conventional open surgery was 20.0% (5/25) and 45.5% (15/33), 
respectively; accounting for a difference in mortality of 25.5%, 95% CI 0.8 to 
43.6% (P=0.04). In the rEVAR group three patients died from progressive cardiac 
failure, one patient from a septic state with multi-organ failure and one patient 
from extensive ischemia of the sigmoid for which no further treatment was 
instigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Study flowchart. 
 CTA=Computed Tomography Angiography.  
 * = assessment on EVAR suitability in retrospect by 2 independent experienced 
reviewers. 
 
 
For the patients in the open surgery group the causes of death were cardiac 
arrest (n=6), infectious complications (n=4), ongoing bleeding resulting in multi 
organ failure (n=3), abdominal compartment syndrome (n=1) and respiratory 
failure (n=1). After 6 months of follow-up, the difference in mortality rate 
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remained (28.0% after rEVAR and 54.5% after open surgery) with a difference of 
26.5%, 95% CI 0.8 to 47.6% (P=0.04). 
Complications 
Follow-up varied from 6 months to 6 years. In both treatment groups 6 patients 
needed a re-intervention with a re-intervention rate of 24.0% after rEVAR and 
18.2% after open surgery, which was not statistically significant (P=0.59). Re-
interventions in the rEVAR group were performed for endoleak (n=3), endograft 
infection needing replacement by a rifampicin soaked bifurcated prosthesis 
(n=1), endograft obstruction (n=1), and ischemia of the sigmoid colon (n=1). Re-
interventions after open repair of the rAAA were performed for intra-abdominal 
bleeding (n=2), ischemic colon (n=1), anastomotic aneurysm with an aorto-
enteral fistula (n=1), and increasing renal dysfunction needing a dialysis 
catheter (n=1). One patient required two re-interventions for both intra-
abdominal bleeding and an ischemic colon.  
Overall complication rates were similar in both treatment groups, 56.0% after 
endovascular repair and 63.6% after open repair (P=0.56). No statistical 
significance was found between the treatment groups regarding 
deployment/procedure related complications, implant related complications 
and systemic complications.  
In 6 patients (24.0%) treated with endovascular repair an endoleak was 
detected during follow-up, showing a type II endoleak in 5 patients (20.0%) and 
a type I endoleak for which an extension was placed in 1 patient (4.0%). Median 
postoperative length of hospital stay was significantly reduced in patients 
treated with rEVAR compared to open surgery, 9.5 (IQR: 5.0-20.5) days and 17.0 
(IQR: 9.5-28.0) respectively (P=0.03). 
Additional findings 
Of the 46 patients (Figure 2.2) who were not EVAR suitable on pre-operative 
CTA scan, 30-day and 6-month mortality rates were 47.8% (n=22) and 58.7% 
(n=27), respectively. Of the 28 patients who had no pre-operative CTA scan, 30-
day and 6-month mortality rates were 50.0% (n=14) and 71.4% (n=20), 
respectively. 
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Table 2.2 Intra-operative, 30-day and 6-month mortality, complications, re-interventions and 
admissions. 
 
rEVAR 
n=25 
Open surgery 
n=33 
P–value 
 
Intra‐operative mortality  1 (4.0%)  2 (6.1%) 1.000 
30‐day mortality  5 (20.0%)  15 (45.5%) 0.043 
6‐month mortality  7 (28.0%)  18 (54.5%) 0.043 
Overall complication rate*  14 (56.0%)  21 (63.6%) 0.556 
Complications requiring surgical intervention  6 (24.0%)  6 (18.2%) 0.588 
Deployment/procedure related complications*  7 (28.0%)  11 (33.3%) 0.664 
   Extensive peroperative bleeding  2 (8,0%)  8 (24.2%) 0.163 
   Aortic dissection  0 (0%)  0 (0%) - 
   Arterial perforation or rupture  1 (4.0%)  2 (6.1%) 1.000 
   Peripheral embolization  0 (0%)  0 (0%) - 
   Access site hematoma  1 (4.0%)  0 (0%) 0.431 
   False aneurysm  0 (0%)  0 (0%) - 
   Access site lymphocele/lymphorrhea/lymphedema  0 (0%)  0 (0%) - 
   Access site infection  3 (12.0%)  0 (0%) 0.075 
   Fever of unknown origin (< 6 days after surgery)  3 (12.0%)  2 (6.1%) 0.643 
Implant related complications*  4 (16.0%)  5 (15.2%) 1.000 
   Anastomotic aneurysm  0 (0%)  1 (3.0%) 1.000 
   Graft migration  0 (0%)  0 (0%) - 
   Graft infection  1 (4.0%)  0 (0%) 0.431 
   Postoperative graft limb obstruction  1 (4.0%)  1 (3.0%) 1.000 
   Buttock/leg claudication/ischemia  1 (4.0%)  0 (0%) 0.431 
   Leaking prosthesis  1 (4.0%)  3 (9.1%) 0.627 
Systemic complications*  7 (28.0%)  15 (45.5%) 0.175 
   Cardiac  3 (12.0%)  5 (15.2%) 1.000 
   Pulmonary  2 (8.0%)  5 (15.2%) 0.687 
   Renal insufficiency  0 (0%)  1 (3.0%) 1.000 
   Bowel ischemia  2 (8.0%)  3 (9.1%) 1.000 
   Sepsis  1 (4.0%)  3 (9.1%) 0.627 
   Abdominal compartment syndrome  0 (0%)  1 (3.0%) 1.000 
PostoperaƟve days in hospital (IQR) †  9.5 (5.0-20.5)  17 (9.5-28.0) 0.032 
* Number of paƟents with one or more complicaƟons. † Data is presented as median (inter-
quartile-range) 
 
Discussion 
We found a reduced 30-day mortality of rEVAR compared to open repair which 
remained for 6 months after surgery in patients with a ruptured AAA who 
underwent preoperative CTA scanning and who were all anatomically suitable 
for endovascular repair. The mortality rate among the EVAR suitable patients 
treated with open surgery was similar to the rate in patients who were 
anatomically unsuitable for EVAR or in patients without preoperative CTA scan. 
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Open surgery as well as endovascular repair showed early mortality rates 
corresponding with the literature.13-17,19,20,24-35 However, most of these studies 
did not report on patients’ co-morbidity. Note that in our setting we have the 
intention to treat all patients presenting with a ruptured AAA, irrespective of 
patients’ co-morbidity and hemodynamic stability. Furthermore, these studies 
have a higher potential for selection bias, assigning patients who were 
hemodynamically stable enough to undergo preoperative imaging and who had 
a potentially more favorable anatomic configuration to the EVAR group. Two 
Dutch studies attempted to compare rEVAR versus open repair more 
adequately, one by focusing on hemodynamically stable patients20 and the 
other by relying on an intention-to-treat by EVAR protocol.32 However, despite 
these methodological adjustments, the potential for selection bias was still 
present. 
Our study was based on the fact that of three vascular surgeons in the Atrium 
MC, only one performed EVAR in patients with a ruptured AAA. Furthermore, all 
patients underwent preoperative CTA as part of a uniform protocol in our 
emergency department. However, patients who were considered EVAR-suitable 
could only be treated by EVAR if the rEVAR-vs was on call. Suitability for EVAR 
was retrospectively determined (confirmed for the rEVAR treated group) in all 
patients by experienced, external, blinded experts.  
Although this study is not randomized, selection bias regarding to anatomical or 
hemodynamical criteria in the presented setup is highly unlikely. Moreover, all 
outcomes were recorded prospectively. Therefore, the present study provides a 
fair comparison between EVAR and open repair.  
Limitations of the study  
In 28 patients (21%) no CTA was performed. These patients could not be 
evaluated for EVAR suitability. Furthermore, suitability for EVAR was assessed in 
retrospect based on anatomical criteria, whereas EVAR suitability in daily 
practice is also based on logistic considerations. Furthermore, this study is 
limited to one non-academic teaching hospital, so individual experience of the 
three involved surgeons could be of influence.  
Future need of a RCT 
Based on the mentioned limitations of this study, results from a randomized 
controlled trial comparing rEVAR with open surgery in patients with a ruptured 
AAA are needed. However, a pilot study showed that it is challenging to 
perform such a randomized study.22 Problems include obtaining informed 
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consent in hemodynamically unstable patients, inclusion of patients unsuitable 
for either open surgery or EVAR, instant accessibility of a CT-scanner at all 
times, permanent availability of a vascular surgeon who is capable of 
performing emergency EVAR, permanent availability of a vascular team 
dedicated to EVAR, availability of an OR that is adequately equipped to perform 
EVAR and availability of a variety ‘off-the-shelf’ stent grafts.22,36,37 Yet, based on 
its relative non-invasiveness, endovascular repair is gradually more performed 
and data on its effectiveness in comparison to the conventional surgical 
approach are much needed.38 
Conclusion  
The present study showed an absolute 30-day and 6-month mortality reduction 
of 25.5% and 26.5% respectively of rEVAR over open surgery in EVAR suitable 
patients who underwent preoperative CTA scanning. rEVAR is accompanied 
with a significant reduction in postoperative length of hospital stay compared to 
open repair. Complication rates and re-intervention rates did not differ 
significantly. These data strongly suggest that rEVAR is a valuable treatment 
option for EVAR suitable patients with a ruptured AAA. 
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Abstract 
Objective 
To prospectively describe early and midterm outcomes for emergency endovascular 
aneurysm repair (eEVAR) versus open surgery in acute abdominal aortic aneurysms 
(aAAA), both unruptured (symptomatic) and ruptured. 
Materials and Methods 
We enrolled all consecutive patients treated for aAAA at our center between April 2002 
and April 2008. Main outcome parameters: 30-day, 6-, and 12-month mortality (all cause 
and aneurysm-related). 
Results 
240 patients were enrolled in the study. In the unruptured aAAA group (n=111), 47 (42%) 
underwent eEVAR. The 30-day, 6- and 12-month mortality rates were 6%, 13%, 15% in 
the eEVAR group versus 11% (NS), 13% (NS), 16% (NS) in the open group, respectively. In 
the ruptured aAAA group (n=129), 25 (19%) underwent eEVAR (mortality rates: 20%, 
28%, 36%, respectively) compared to 104 (81%) patients who underwent open surgery 
(mortality rates: 45% (P=0.021), 60% (P=0.004), 63% (P=0.014), respectively).  
Conclusions 
The present study showed a reduced 30-day, 6- and 12-month mortality of eEVAR 
compared to open surgery in all patients with aAAA, mainly due to a lower mortality in 
the ruptured aAAA group. Late aneurysm-related mortality occurred only in the eEVAR 
group. 
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Introduction 
In patients with an acute abdominal aortic aneurysm (aAAA) who are treated 
with conventional open surgery, perioperative morbidity and mortality remain 
high. Despite advances in surgical and anesthetic techniques, aortic graft 
materials and design, and perioperative care, mortality has declined only 
gradually in recent decades.1,2 A review of the literature on emergency open 
surgical repair for symptomatic unruptured aAAA found a 30-day or in-hospital 
mortality rate of 15.8% (207 of 1312 patients).3 For patients with ruptured AAA 
who do arrive at the hospital alive and undergo emergency open surgery, 
operative mortality has been estimated at approximately 48%.2 
 
Since the first reported successful endovascular aneurysm repair (EVAR) in 1991 
by Parodi et al,4 this technique has been embraced for repair of AAA in the 
elective setting, with reduced early morbidity and mortality compared to 
conventional open surgical repair.5-7 In the setting of aAAA, emergency EVAR 
(eEVAR) has successfully been introduced to treat feasible patients since 1994.8 
Several observational studies have compared eEVAR with open surgery,9-17 
and most observed a reduction in early complications and mortality with 
eEVAR.9-13,15,17 Systematic reviews of these studies have estimated an absolute 
reduction in early mortality of approximately 16% with eEVAR versus open 
surgery.18-20 This reduction has been attributed to the combined effect of 
minimal surgical exposure, the use of local anesthesia, and avoidance of aortic 
cross clamping.21 
 
However, in patients treated with EVAR, the aneurysm is left intact. Late stent 
graft related complications, as observed in approximately 40% of patients by 
4 years after EVAR in the elective setting according to the EVAR 1 trial7 might 
result in ongoing risk of rupture and therefore ongoing risk of implant or 
procedure related (aneurysm-related) mortality. However, in the acute setting, 
most studies only report 30-day or in-hospital mortality. Furthermore, these 
studies focused mainly on patients who underwent emergency repair of 
ruptured aAAA leaving unruptured aAAA out of consideration.3 Despite of 
lacking evidence, emergency open repair of unruptured acute aneurysm, in 
order to prevent hemodynamic instability related to aneurysm rupture, is a 
widely accepted practice.22,23 Therefore, not only short but also longer-term 
efficacy results of patients treated with eEVAR or open repair for unruptured as 
well as ruptured aAAA are needed.  
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The present study expands upon a previous report24 and describes the early and 
1-year results of a prospective single-center observational study comparing 
emergency EVAR with open surgery for both ruptured and unruptured acute 
AAA. 
Materials and Methods 
Patients and baseline characteristics 
All consecutive patients treated for aAAA between April 2002 and April 2008 
were eligible for the study. After 4 months of gaining experience with 
performing endovascular repair in patients with an aAAA, April 2002 marked 
the initiation of routinely performing eEVAR.  
Acute AAA was categorized as either unruptured or ruptured. An unruptured 
(symptomatic) aAAA was defined as the existence of an AAA with acute onset of 
abdominal or back pain combined with pain at aneurysm palpation. Rupture 
was defined as extravasation of blood/contrast or hematoma outside the AAA 
on computed tomography angiography (CTA) examination and/or hematoma 
outside the AAA during open repair. 
Systolic blood pressure was recorded at arrival at the emergency department. 
Baseline comorbidities that were tracked included cardiovascular and 
pulmonary comorbidity, renal dysfunction, and diabetes mellitus. Cardio-
vascular comorbidity included history of ischemic heart disease, cerebro-
vascular accident or transient ischemic attack, hypertension, cardiac failure, 
coronary artery bypass graft, percutaneous transluminal coronary angioplasty, 
valvular disease, rhythm disorders, or history of aortic operation. Pulmonary 
comorbidity included the presence of at least one of the following: asthma, 
chronic obstructive pulmonary disease, emphysema, or lung carcinoma. Renal 
dysfunction was defined as a blood creatinine level higher than 140 μmol/l. To 
be characterized as diabetic, the patient had to be receiving oral medication 
and/or insulin therapy. 
Treatment protocol 
Our policy is to perform a CTA scan in all patients presenting with an aAAA, with 
the purpose of assessing EVAR suitability and/or performing the visual 
preparation for conventional open surgery. EVAR suitability was initially defined 
as a proximal neck length >15 mm with <60 degrees angulation and access 
vessels large enough to accommodate the introducer sheaths.13 As time went 
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by, we began accepting patients for eEVAR with more challenging anatomies, 
including proximal neck lengths as low as 10 mm and more severe angulations 
of aortic neck and aneurysm. Patients who were judged to be hemodynamically 
too unstable to undergo a CTA scan according to the attending vascular surgeon 
were treated with immediate open surgical repair. 
The protocol allowed for permissive hypotension25: patients with hypotension 
(systolic pressure <100 mmHg) were accepted without massive fluid 
resuscitation in order to prevent further bleeding, but with maintenance of 
consciousness. Overall, our policy is to treat all patients with either eEVAR or 
open surgery, regardless of age, comorbidity, or hemodynamic condition. It was 
only in exceptional cases that neither treatment was provided. 
Procedure 
The operating room (OR) was fully equipped for EVAR as well as open surgical 
repair, with a mobile C-arm imaging system (Philips Endura, Philips Medical 
Systems, Eindhoven, the Netherlands). Patients who underwent open surgical 
repair received general anesthesia. Patients who underwent eEVAR 
preferentially received local or regional (spinal) anesthesia. In order to perform 
eEVAR, a bilateral groin incision was made to provide access to the common 
femoral artery. Correct infrarenal placement of the bifurcated or aorto-uni-iliac 
device was guided by fluoroscopy and intra-operative angiography. After 
completion of the procedure, control angiography was performed. The OR staff 
was trained and experienced with EVAR, and angiography staff was available 
24/7. The initiation of eEVAR procedures in our center occurred with the use of 
the Talent aorto-uni-iliac emergency kit (Medtronic Vascular, Santa Rosa, CA).26 
Since January 2006, the Talent bifurcated stent graft (Medtronic Vascular, Santa 
Rosa, CA) was available in a broad range of sizes and the preferred choice for 
treatment. 
Data collection 
Patient data were obtained prospectively with the use of a paper case record 
form added to the patient chart. Since December 2007 an electronic case 
record form was available.  
Follow‐up 
Follow-up for patients who underwent open surgical repair consisted of 
ultrasonography and visits to the vascular surgery outpatient department 
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scheduled at 3 months and 12 months post-operatively. Follow-up for patients 
who underwent eEVAR consisted of CTA at 3 and 12 months following the 
procedure and yearly thereafter. The time of follow-up ranged from 1 to 
6 years. 
Outcome measures 
The outcomes evaluated were intra-operative, 30-day, 6- and 12-month overall 
as well as aneurysm-related mortality; all complications (as delineated by the 
reporting standards published by the Society for Vascular Surgery/American 
Association for Vascular Surgery27); re-interventions; and postoperative hospital 
length of stay. Complications were classified as deployment/procedure-related, 
implant-related, and systemic.27  
Data analysis 
Data were collected and analyzed using SPSS 15.0 for Windows. Patient 
characteristics, mortality, complications, reinterventions, and admissions were 
compared using the chi-square test, Student t-test, Mann Whitney U test (two-
sided; ∂=0.05), and ANOVA for trends. If during subgroup analysis the esƟmated 
patient group size was below 5, a 2-sided Fisher’s exact test was used. Mortality 
rates during follow-up were calculated on the basis of absolute patient numbers 
due to minimal loss to follow-up. Categorical variables are presented as 
frequency with percentages. Nominal variables are presented as mean 
± standard deviation (SD) for a normal distribution or as median and inter-
quartile-range (IQR) for a skewed distribution. Values of P<0.05 were 
considered statistically significant. 
Results 
Patient characteristics 
Between April 2002 and April 2008, a total of 246 patients presented at our 
center’s emergency department with an aAAA. Six patients with ruptured aAAA 
were considered unsuitable for an intervention because of severe comorbidity 
in combination with a quick deterioration of hemodynamic condition (2%). Of 
the remaining 240 patients, 111 (46%) presented with unruptured aAAA and 
129 (54%) with ruptured aAAA (Figure 3.1). In 22 patients (17%) with a ruptured 
aAAA a pre-operative CTA scan was not performed (in 7 cases the CTA scanner 
was not instantly available within 30 minutes after presentation, in 1 case the 
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ruptured aAAA was revealed during surgery since preoperative US did not show 
an AAA, and in the other 14 cases preoperative CTA scanning was not 
performed at the discretion of the attending surgeon. There was no baseline 
difference in mean systolic blood pressure between patients with and without 
pre-operative CTA scanning (P=0.347). Patients who presented with unruptured 
aAAA were slightly younger, had a lower prevalence of renal dysfunction and a 
smaller diameter of the AAA compared to patients with ruptured AAA (Table 
3.1). Among the patients who presented with unruptured AAA, there were 
significantly more males in the eEVAR group than in the open surgery group 
(92% vs. 77%, P=0.039). Otherwise, no significant differences at baseline were 
recorded in both unruptured and ruptured aAAA group. Among those with 
ruptured AAA, approximately 55% had a systolic blood pressure of <100 mmHg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 3.1 Patients with unruptured and ruptured aAAA enrolled between April 2002 and April 
2008 for treatment with emergency endovascular aneurysm repair (eEVAR) or open 
surgery. 
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Table 3.1 Baseline characteristics in 240 patients presenting with unruptured and ruptured 
aAAA. 
 Unruptured aAAA Ruptured aAAA 
Total eEVAR Open 
surgery
Total eEVAR Open 
surgery 
 Variable 
n=111 n=47 n=64 
P 
n=129 n=25 n=104 
P 
Mean age in years 
(SD) 
71.4 
(8.3) 
71.7 
(8.2) 
71.1 
(8.3) 
0.725 73.4 
(7.8) 
72.2 
(8.2) 
73.7 
(7.7) 
0.416 
Male 92/111 
(82.9%) 
43/47 
(91.5%) 
49/64 
(76.6%) 
0.039 114/129
(88.4%) 
22/25 
(88.0%) 
92/104 
(88.5%) 
1.000 
Mean body mass 
index (SD) 
25.8 
(4.2) 
26.1 
(4.5) 
25.4 
(3.8) 
0.542 26.6 
(4.5) 
27.5 
(5.5) 
26.0 
(3.6) 
0.410 
Cardiovascular 
comorbidity 
85/111 
(76.6%) 
38/47 
(80.9%) 
47/64 
(73.4%) 
0.362 89/129 
(69.0%) 
16/25 
(64.0%) 
73/104 
(70.2%) 
0.548 
Pulmonary 
comorbidity 
22/111 
(19.8%) 
12/47 
(25.5%) 
10/64 
(15.6%) 
0.196 29/129 
(22.5%) 
7/25 
(28.0%) 
22/104 
(21.2%) 
0.462 
Renal dysfunctiona 12/109 
(11.0%) 
7/46 
(15.2%) 
5/63 
(7.9%) 
0.230 45/127 
(35.4%) 
10/24 
(41.7%) 
35/103 
(34.0%) 
0.478 
Diabetes mellitus 11/111 
(9.9%) 
7/47 
(14.9%) 
4/64 
(6.3%) 
0.198 14/129 
(10.9%) 
3/25 
(12.0%) 
11/104 
(10.6%) 
0.734 
Mean AAA diameter 
mm (SD) 
64.3 
(16.9) 
63.3 
(19.0) 
65.0 
(15.2) 
0.617 73.9 
(17.2) 
70.8 
(16.7) 
74.9 
(17.2) 
0.293 
Systolic BP<100 
mmHg 
0/60 
(0.0%) 
0/23 
(0.0%) 
0/37 
(0.0%) 
- 51/93 
(54.8%) 
9/16 
(56.3%) 
42/77 
(54.5%) 
0.901 
BP=blood pressure; eEVAR=emergency endovascular aneurysm repair; SD=standard deviation.  
a Serum creatinine level >140 µmol/l 
 
Procedures 
Overall, 72 of the 240 patients (30%) were treated with eEVAR and 168 patients 
(70%) with open surgical repair. Of the 111 patients with unruptured aAAA, 47 
(42%) underwent eEVAR and 64 (58%) underwent open surgical repair; of the 
129 patients with ruptured AAA, 25 (19%) underwent eEVAR and 104 (81%) 
underwent open surgical repair (Figure 3.1). 
All 64 patients who underwent open surgery for unruptured aAAA repair had 
general anesthesia. Among the 47 patients treated with eEVAR, 3 (6%) had local 
anesthesia, 40 (85%) had spinal anesthesia, and 4 (9%) had general anesthesia. 
All 104 patients who underwent open surgery for ruptured aAAA repair had 
general anesthesia. Among the 25 patients with ruptured AAA treated with 
eEVAR, 12 (48%) had local anesthesia, 5 (20%) had spinal anesthesia, and 
8 (32%) had general anesthesia. 
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Mortality 
The intra-operative, 30-day, 6- and 12-month all cause mortality rates are listed 
in Table 3.2 and the aneurysm-related mortality rates are listed in Table 3.3. 
Two patients were lost to follow-up, one patient in the unruptured aAAA group 
after 8 months of follow-up and one patient in the ruptured aAAA group after 
7 months of follow-up, both due to geographical inaccessibility. Among all 
240 patients, the intra-operative, 30-day, 6- and 12-month mortality rates were 
9 (4%), 62 (26%), 83 (35%), and 91 (38%), respectively. The mortality rate was 
significantly lower for aAAA patients treated with eEVAR than for those treated 
with open surgery at 30-day follow-up (11% vs. 32%, P=0.001), 6-month follow-
up (18% vs. 42%, P<0.001), and 12-month follow-up (22% vs 45%, P=0.001). 
Intra-operatively, at 30 days, 6 months, and 12 months of follow-up, overall 
mortality was dramatically lower for patients with unruptured aAAA than for 
those with ruptured aAAA. This difference was registered almost entirely in the 
group treated with open surgery. 
For the 111 patients with unruptured aAAA, all cause intra-operative, 30-day, 6- 
and 12-month mortality rates were 0 (0%), 10 (9%), 14 (13%), and 17 (16%), 
respectively. All cause mortality rates for patients treated with eEVAR were 0%, 
6%, 13%, and 15% vs. 0%, 11% (P=0.514), 13% (P=0.967), and 16% (P=0.888) for 
patients treated with open surgery, respectively (Table 3.2). Increasing 
aneurysm-related mortality results during follow-up were observed in the 
eEVAR group (0%, 6%, 9%, 11%, respectively), whereas aneurysm-related 
mortality in the open repair group was stable between 1 and 12 months of 
follow-up (11%) (Table 3.3, Figure 3.2). A test for comparing trends using a 
regression model showed significance (P=0.028). No statistical differences in 
aneurysm-related mortality between eEVAR and open repair were observed in 
patients with an unruptured aAAA. 
For the 129 patients with ruptured aAAA, overall intra-operative, 30-day, 6- and 
12-month mortality rates were 9 (7%), 52 (40%), 69 (54%), and 74 (58%), 
respectively. Mortality rates for patients treated with eEVAR were 4%, 20%, 
28%, and 36% vs. 8% (P=1.000), 45% (P=0.021), 60% (P=0.004), and 63% 
(P=0.014) for patients treated with open surgery, respectively (Table 3.2). 
Increasing aneurysm-related mortality results during the 12 months of follow-
up were observed in the eEVAR group (4%, 20%, 28% and 32%, respectively), 
whereas aneurysm-related mortality in the open repair group seemed to be 
stabilized between 6 and 12 months of follow-up at approximately 58% (Table 
3.3, Figure 3.3), but trends were not significant (P=0.349). Significant 
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differences in aneurysm-related mortality between the treatment groups were 
observed at 30 days, 6 months and 12 months of follow-up. 
 
 
Table 3.2 All cause mortality rates of patients with unruptured and ruptured aAAA. 
   eEVAR Open surgery  
   n Mortality n Mortality P 
Intra-operative mortality Unruptured aAAA 47 0 (0.0%)   64 0 (0.0%) - 
 Ruptured aAAA 25 1 (4.0%) 104 8 (7.7%)   1.000 
 Total 72 1 (1.4%) 168 8 (4.8%)   0.285 
       
30-day mortality Unruptured aAAA 47 3 (6.4%)   64   7 (10.9%)   0.514 
 Ruptured aAAA 25   5 (20.0%) 104 47 (45.2%)   0.021 
 Total 72   8 (11.1%) 168 54 (32.1%)   0.001 
       
6-month mortality Unruptured aAAA 47   6 (12.8%)   64   8 (12.5%)   0.967 
 Ruptured aAAA 25   7 (28.0%) 104 62 (59.6%)   0.004 
 Total 72 13 (18.1%) 168 70 (41.7%) <0.001 
       
12-month mortality Unruptured aAAA 47   7 (14.9%)   63 10 (15.9%)   0.888 
 Ruptured aAAA 25   9 (36.0%) 103 65 (63.1%)   0.014 
 Total 72 16 (22.2%) 166 75 (45.2%)   0.001 
 
 
Table 3.3 Aneurysm-related mortality rates of patients with unruptured and ruptured aAAA. 
   eEVAR Open surgery  
   n Mortality n Mortality P 
Intra-operative mortality Unruptured aAAA 47 0 (0.0%)   64 0 (0.0%) - 
 Ruptured aAAA 25 1 (4.0%) 104 8 (7.7%)   1.000 
 Total 72 1 (1.4%) 168 8 (4.8%)   0.285 
       
30-day mortality Unruptured aAAA 47 3 (6.4%)   64 7 (10.9%)   0.514 
 Ruptured aAAA 25   5 (20.0%) 104 47 (45.2%)   0.021 
 Total 72   8 (11.1%) 168 54 (32.1%)   0.001 
       
6-month mortality Unruptured aAAA 47   4 (8.5%)   64   7 (10.9%)   0.757 
 Ruptured aAAA 25   7 (28.0%) 104 60 (57.7%)   0.008 
 Total 72 10 (13.9%) 168 67 (39.9%) <0.001 
       
12-month mortality Unruptured aAAA 47   5 (10.6%)   63   7 (11.1%)   0.937 
 Ruptured aAAA 25   8 (32.0%) 103 60 (58.3%)   0.018 
 Total 72 12 (16.7%) 166 67 (40.4%) <0.001 
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Figure 3.2 All cause and aneurysm-related mortality results of eEVAR compared to open surgery 
in patients with an unruptured acute (symptomatic) AAA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 All cause and aneurysm-related mortality results of eEVAR compared to open surgery 
in patients with a ruptured AAA. 
Complications 
All complications are listed in Table 3.4. Among all patients, the overall 
complication rate was 47% (110/235), with 21% (50/240) of all patients 
requiring surgical re-intervention. Overall complication rates were higher in 
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patients treated for ruptured aAAA (58%) than in patients treated for 
unruptured aAAA (34%).  
Among patients with unruptured aAAA, the overall complication rate was 
similar in patients treated with eEVAR and open surgery (P=0.935). However, 
extensive intra-operative bleeding was significantly reduced (P=0.039) and 
postoperative fever of unknown origin was significantly more common in 
patients treated with eEVAR (P=0.031). Surgical re-intervention was required 
more often in patients treated with eEVAR (13 of 47; 28%) compared to those 
treated with open surgery (8 of 64; 13%) (P=0.044). Indications for surgical re-
intervention included: postoperative hemorrhage of a femoro-femoral 
crossover bypass (n=2), thrombectomy after occlusion of a femoro-femoral 
crossover bypass (n=1), endoleakage (n=5), aortic rupture at the origin of the 
right renal artery (n=1), sigmoidal ischemia (n=1), in-stent occlusion (n=1), re-
exploration because of severe septic shock (n=1), and migration of the 
endograft (n=1) for eEVAR and severe postoperative bleeding (n=6) (in 2 cases 
followed by abdominal compartment syndrome), anastomotic aneurysm (n=1), 
and cicatricial hernia (n=1) for open repair. An endoleak occurred in 15 of the 
47 (32%) patients treated with eEVAR: 2 type I endoleaks (4%), and 13 type II 
endoleaks (28%). 
Among patients with ruptured aAAA, the overall complication rate was similar 
in patients treated with eEVAR and open surgery (P=0.838). However, the 
incidence of access site infection was significantly greater for those treated with 
eEVAR (P=0.007). Surgical re-intervention rates were comparable for both the 
eEVAR (6/25; 24%) and open surgery group (23/104; 22%) (P=0.839). An 
endoleak occurred in 6 of the 25 (24%) patients treated with eEVAR, including 1 
type I endoleak (4%) for which an extension was placed and 5 type II endoleaks 
(20%). 
Duration of hospital stay 
In patients with unruptured aAAA, median postoperative days in hospital were 
3 (IQR: 2.0-7.0) after eEVAR vs. 8 (IQR: 7.0-13.8) after open surgery (P<0.001) 
(Table 3.4). Similar results were observed in the ruptured aAAA group, showing 
median postoperative days in hospital of 9.5 (IQR: 5.0-20.5) after eEVAR vs. 16 
(IQR: 9.0-27.0) after open surgery (P=0.023). 
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Discussion 
The present study showed a reduced 30-day, 6- and 12-month all cause 
mortality of eEVAR compared to open surgery in all patients with acute AAA. 
This reduction was almost entirely due to a lower mortality in the ruptured 
aAAA group, while comparable mortality results were observed in patients with 
an unruptured aAAA. Note that late aneurysm-related mortality occurred only 
in the eEVAR group. Furthermore, the duration of hospitalization after eEVAR 
compared to open surgery in patients with unruptured aAAA and ruptured 
aAAA was reduced by 5 and 6.5 days, respectively. 
In the present study, the ratio of unruptured to ruptured aAAA was 111:129. 
However, Kapma et al. described a smaller proportion of patients with 
unruptured aAAA (56:197).13 This difference in proportion might be attributed 
to a variation in definitions employed for unruptured acute AAA. We defined 
unruptured acute AAA as the existence of an AAA with acute onset of 
abdominal or back pain combined with pain at aneurysm palpation, as 
described by Peppelenbosch et al.9 However, abdominal pain and pain at 
aneurysm palpation might have causes other than an aneurysm in a state of 
pending rupture indicating potential false positive diagnoses. The lack of 
definitive criteria for acute unruptured AAA may explain the differences in 
incidence between studies. 
In patients with ruptured aAAA, only 19% (25 of 129) were treated with eEVAR 
since availability of a vascular surgeon who is capable of performing emergency 
EVAR could not be guaranteed 24 hours each day. However, in case of an 
unruptured acute AAA, which can be treated more easily within routine working 
hours, the availability of an EVAR-experienced operating team is less 
problematic. Therefore, 42% (47 of 111) were treated by eEVAR in the 
unruptured aAAA group, which corresponds with the EVAR suitability rates in 
other studies.26,28  
The present study had several limitations. Intention to treat by eEVAR protocol 
was not part of the study design because availability of a vascular surgeon 
performing emergency EVAR in patients with ruptured AAA could not be 
guaranteed. Secondly, differences in baseline characteristics with more males in 
the unruptured eEVAR group due to a nonrandomized allocation of patients 
over the treatment groups prevented a proper comparison, since female 
gender is associated with increased mortality after both AAA and ruptured AAA 
repair.29,30 A third limitation involved selection bias, with anatomically favorable 
patients and patients with severe comorbidity preferably treated with eEVAR. In 
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the present study, a non-significant trend toward a higher number of patients 
with severe comorbidity treated with eEVAR was observed. 
The increasing trend of centers adopting an eEVAR–first approach whenever 
feasible is supported by comparative studies with improved outcomes 
regarding early morbidity, mortality, and length of hospital stay.17,31 However, 
there is much heterogeneity between studies, as well as selection bias and lack 
of generally accepted reporting standards, making comparisons and conclusions 
regarding the value of eEVAR in acute AAAs cumbersome. The heterogeneity 
includes the number of patients excluded from the studies, the percentage of 
patients treated by endovascular repair, the fraction of patients that undergo 
preoperative CTA scanning, the use of local anesthesia, the percentage of 
hemodynamically unstable patients, and the definition of hemodynamic 
stability. Furthermore, in most comparative studies, patient cohorts are small 
(n<50), especially regarding ruptured AAA.10-12,15  
To withstand selection bias, randomized controlled trials are needed. Hinchliffe 
et al described the possibility of recruiting patients with ruptured AAA for 
eEVAR and open repair in a randomized study setting.32 However, to date, no 
large randomized controlled trials for ruptured AAA have been published. We 
await results from the randomized controlled Amsterdam Acute Aneurysm 
Trial.33 At the same time, based on the observation of Benson et al.34 that 
observational studies and randomized controlled trials usually produce similar 
results, and given the fact that most observational studies show reduction in 
early mortality after eEVAR compared to open surgery, there might be ethical 
issues associated with trials that randomize patients to these treatments. 
 
In conclusion, this study showed an overall reduction in early and midterm 
mortality, associated with eEVAR compared to conventional open surgical 
repair in ruptured AAA. eEVAR is associated with a reduction of hospital stay in 
all acute AAA presentations, but also with a significant increase in the need for 
later surgical re-interventions with ongoing aneurysm-related mortality. 
However, due to the methodological limitations we have discussed, cautious 
interpretation of the results is urged. 
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Abstract 
Objective 
The reported mortality reduction of emergency endovascular aneurysm repair (eEVAR) 
compared to open repair in patients with a ruptured abdominal aortic aneurysm (rAAA), 
as observed in observational studies, might be flawed by selection bias based on 
anatomical suitability for eEVAR. In the present study, we compared mortality in EVAR 
suitable versus non EVAR suitable patients with a ruptured AAA who were all treated 
with conventional open repair. 
Materials and Methods 
In all patients presenting with a suspected rAAA CTA scanning was performed. All 
consecutive patients with a confirmed rAAA on preoperative CTA scan and treated with 
open repair between April 2002 and April 2008, were included. Anatomical suitability for 
eEVAR was determined by two blinded independent reviewers. Outcomes evaluated 
were mortality (intra-operative, 30-day, and 6-month), morbidity, complications 
requiring re-intervention, and length of hospital stay.  
Results 
A total of 107 consecutive patients presented with a rAAA and underwent pre-operative 
CTA scanning. In 25 patient eEVAR was performed. In the 82 patients who underwent 
open repair CTA showed an EVAR suitable rAAA in 33 patients (40.2%) and a non EVAR 
suitable rAAA in 49 patients. Thirty-day and 6-month mortality rate was 15/33 (45.5%; 
95% CI 28.1-63.7) and 18/33 (54.5%; 95% CI 36.4–71.9) in the EVAR suitable group versus 
24/49 (49.0%; 95% CI 34.4-63.7) (P=0.75) and 29/49 (59.2%; 95% CI 44.2-73.0) (P=0.68) 
in the non EVAR suitable group, respectively.  
Conclusions 
The present study suggests that anatomical suitability for EVAR is not associated with 
lower early and midterm mortality in patients treated with open ruptured AAA repair. 
Therefore, the reported reduction in mortality between eEVAR and open repair is 
unlikely due to selection bias based on anatomical AAA configuration. 
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Introduction 
Since 1994 emergency endovascular aneurysm repair (eEVAR) has successfully 
been used in suitable patients to treat ruptured abdominal aortic aneurysms 
(rAAA).1 Several comparative studies showed a reduction in early mortality from 
34-46% with open surgery to 18-24% with eEVAR.2-7 However, due to lack of 
randomization and the potential for selection bias it is uncertain whether this 
mortality benefit is due to the less invasive treatment or to patient 
characteristics such as hemodynamic condition or anatomic considerations.8  
Hemodynamical condition is reported to be associated with early mortality after 
open repair in several prediction models. Loss of consciousness, presence of 
shock and preoperative systolic blood pressure are independent predictors for 
mortality after rAAA repair in the Hardman Index9, Glasgow Aneurysm Score10 
and the Edinburgh Ruptured Aneurysm Score11, respectively. In a systematic 
review of Visser et al. approximately 24% of the patients underwent open 
ruptured AAA repair instead of eEVAR due to hemodynamic instability.7 
Therefore, comparison was biased due to an over-representation of hemo-
dynamic unstable patients in the open repair group. 
Approximately half of the patients with a rAAA are suitable for eEVAR based on 
anatomic considerations.7,12 Patients who are anatomically unsuitable for EVAR 
are treated with open repair. There is a theoretical possibility that anatomical 
suitability for EVAR as assessed on a preoperative computed tomography 
angiography (CTA) scan is independently associated with improved early and 
midterm mortality. However, no clear evidence supporting this assumption is 
available. 
In the present study, we compared mortality in EVAR suitable versus non EVAR 
suitable patients with a ruptured AAA, who all underwent preoperative CTA 
imaging and who were all treated with conventional open repair. 
Materials and Methods 
Patients 
All consecutive patients with a suspected rAAA, as confirmed by preoperative 
CTA scan and treated with open repair in a non-academic large teaching 
hospital between April 2002 and April 2008, were included. Hypotension in 
patients was accepted with minimal resuscitation to a systolic blood pressure of 
>70 mmHg to maintain consciousness and to prevent further bleeding 
(permissive hypotension). At baseline, gender, age, Body Mass Index (BMI), 
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blood pressure, renal function, Hardman index,9 AAA diameter, and co-
morbidity were recorded.  
Baseline co-morbidity was classified in cardiovascular, pulmonary, and diabetes 
mellitus (DM). Cardiovascular co-morbidity was defined as a history of ischemic 
heart disease, cerebrovascular accident (CVA) or transient ischemic attack (TIA), 
hypertension, cardiac failure, coronary arterial bypass graft, percutaneous 
transluminal coronary angioplasty, valvular disease, rhythm disorders or history 
of aortic operation. Pulmonary co-morbidity included presence of at least one 
of the following: asthma, chronic obstructive pulmonary disease (COPD), 
emphysema, or lung carcinoma. DM was defined as receiving either oral 
medication and/or insulin therapy. 
Definitions 
Rupture was defined as extravasation of blood or hematoma outside the AAA 
on CT examination, confirmed at open repair. Shock was defined as a systolic 
pressure lower than 100 mmHg. Suitability for endovascular repair, based on 
CTA, was evaluated according to guidelines for elective EVAR including proximal 
neck length of at least 15 mm, neck diameter less than 32 mm with less than 
90° angulation and less than 50% of circumferential thrombus and calcification. 
A conical shaped neck towards the aneurysm was considered to be unfavorable 
for endovascular repair, but was addressed in the view of other anatomical 
contraindications. Furthermore, access vessels had to be larger than 6 mm 
without severe iliac tortuosity to accommodate the introducer sheaths. 
Methods 
In the study hospital (Atrium medical center), three vascular surgeons were 
experienced in open rAAA repair, one of them (eEVAR-vs) performed both open 
repair as well as eEVAR. All patients presenting with a suspected rAAA 
underwent CTA scanning. Conventional open surgery was performed when the 
eEVAR-vs was not on call or when the rAAA was not EVAR suitable. This 
strategy, instigated for logistical reasons, resulted in a number of CTA scans of 
patients that underwent open repair with EVAR suitable anatomy. 
Retrospectively, two independent experienced reviewers, blinded for earlier 
evaluation, intervention, and outcome, assessed all preoperative CTA scans on 
suitability for EVAR. In case of disagreement between the reviewers, consensus 
was found in collaboration with an arbiter. Group 1 consists of patients treated 
with open repair who were considered suitable for eEVAR according to both 
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reviewers. Group 2 consists of patients treated with open repair who were 
considered unsuitable for eEVAR by the reviewers. 
Follow-up after open repair was performed at 2 weeks, 3 months and 1 year 
after hospital discharge. 
Clinical outcomes 
The outcomes evaluated were intra-operative, 30-day and 6-month mortality, 
morbidity during follow-up, complications requiring re-intervention during 
follow-up (as delineated by the reporting standards published by the Society for 
Vascular Surgery/American Association for Vascular Surgery)13, and length of 
hospital stay.  
Data analysis 
Data was collected prospectively and statistical analyses were performed with 
the SPSS statistical software package for Windows (Microsoft, Redmond, Wash), 
version 15.0 (SPSS inc, Chicago, Ill). Patients characteristics, clinical outcomes 
and follow-up were compared in rAAA patients treated with open repair who 
were EVAR suitable versus non EVAR suitable using the chi-square test, Fisher’s 
exact test, Student’s t-test, and Mann Whitney U-test (two-sided; α=0.05). 
Categorical variables are presented as frequency with percentages. Nominal 
variables are expressed as mean ± standard deviation (SD) for a normal 
distribution and for a skewed distribution in terms of median and inter-quartile-
range (IQR). Values of P<0.05 were considered statistically significant. Analyses 
were by intention to treat. 
Results 
Patients 
Between April 2002 and April 2008, 135 consecutive patients presented with 
suspected rAAA. In 28 patients (21%) a pre-operative CTA scan was not 
performed (6 patients were deemed unfit for any treatment, in 7 cases the CTA 
scanner was not instantly available within 30 minutes after presentation, in 
1 case the rAAA was revealed during surgery since preoperative US did not 
show an AAA, and in the other 14 cases preoperative CTA scanning was not 
performed due to protocol violation by a non-eEVAR vascular surgeon, since 
CTA scanning did not influence treatment selection when a non-eEVAR vascular 
surgeon was on call). In 107 patients a pre-operative CTA was performed, 
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25 patient received eEVAR and 82 patients were treated with open repair. Of all 
82 patients treated with open repair, CTA showed an EVAR suitable rAAA in 
33 patients (40.2%) and a non EVAR suitable rAAA in 49 patients, according to 
both external reviewers.  
Baseline characteristics are listed in Table 4.1. Significantly more male patients 
were considered EVAR suitable on CTA. Other variables did not differ 
significantly at baseline. Although the mean AAA diameter was larger in 
patients unsuitable for eEVAR, the difference did not reach statistical 
significance. 
 
Table 4.1 Baseline characteristics. 
 EVAR suitable Non EVAR suitable P‐value 
 n=33 Missing 
values 
n=49 Missing 
values 
 
Male  32 (97.0%)   0  39 (79.6%)   0 0.043 
Mean age in years (SD)  74.3 (7.1)   0  73.5 (8.1)   0 0.664 
Mean AAA diameter in mm (SD)  70.4 (17.6)   0  76.2 (17.5)   0 0.147 
Mean blood creatinine level (SD)  123.1 (38.2)   0  135.3 (43.5)   1 0.197 
Mean SBP in mmHg (SD)  106.0 (34.7)   9  102.5 (30.6) 12 0.677 
Mean Hardman Index (SD)  2.4 (0.8) 10  2.5 (0.6) 15 0.589 
Cardiovascular co-morbidity  24 (72.7%)   0  35 (71.4%)   0 0.898 
Pulmonary co-morbidity  6 (18.2%)   0  12 (24.5%)   0 0.499 
Diabetes Mellitus  4 (12.1%)   0  4 (8.2%)   0 0.708 
BMI=body-mass index, mm=millimeter, SBP=systolic blood pressure, mmHg=millimeter Mercury. 
 
Mortality and admission 
Primary and secondary outcome results are listed in Table 4.2 and 4.3, 
respectively. Intra-operative, 30-day and 6-month mortality rates as well as 
postoperative days of hospital stay were comparable for both groups (Table 
4.2). Intra-operative mortality was 2/33 (6.1%; 95% CI 0.7–20.2) and 5/49 
(10.2%; 95% CI 3.4–22.2) in the EVAR suitable and the non EVAR suitable group, 
respectively (P=0.70). The difference in intra-operative mortality between the 
groups was 4.1% (95% CI 0.7–20.2%). Thirty-day and 6-month mortality rate 
was 15/33 (45.5%; 95% CI 28.1–63.7) and 18/33 (54.5%; 95% CI 36.4–71.9) in 
the EVAR suitable group versus 24/49 (49.0%; 95% CI 34.4–63.7) (P=0.75) and 
29/49 (59.2%; 95% CI 44.2–73.0) (P=0.68) in the non EVAR suitable group, 
respectively. The difference in mortality between the treatment groups was 
therefore 4.5% (95% CI -24.7–18.2%) and 4.7% (95% CI -25.9–16.6) after 30 days 
and 6 months, respectively.  
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Table 4.2 Mortality rates and admissions. 
 EVAR suitable 
n=33 
Non EVAR suitable 
n=49 
P–value 
Intra-operative mortality 2 (6.1%)   5 (10.2%) 0.696 
30-day mortality 15 (45.5%) 24 (49.0%) 0.754 
6-month mortality 18 (54.5%) 29 (59.2%) 0.677 
Median postoperative days in hospital (IQR) 17.0 (9.5-28.0) 15.0 (9.5-33.5) 0.981 
IQR=inter-quartile range. 
 
 
Table 4.3 Re-interventions and morbidity. 
 EVAR suitable 
n=33 
Non EVAR suitable 
n=49 
P–value 
Re-intervention rate   6 (18.2%) 12 (24.5%) 0.499 
Morbidity * 17 (51.5%) 17 (34.7%) 0.149 
Cardiac   5 (15.2%) 1 (2.0%)  
Pulmonary   5 (15.2%)   5 (10.2%)  
Renal insufficiency 1 (3.0%) 4 (8.2%)  
Bowel ischemia 3 (9.1%) 4 (8.2%)  
Sepsis 3 (9.1%) 3 (6.1%)  
Abdominal compartment syndrome 1 (3.0%) 1 (2.0%)  
Wound infection/hematoma  0 (0.0%) 1 (2.0%)  
Continued bleeding 3 (9.1%) 3 (6.1%)  
* = Number of patients with one or more morbidities. 
 
Morbidity and reintervention rates 
During follow-up, which varied from 6 months to 6 years, the re-intervention 
rate was 18.2% and 24.5% in EVAR suitable patients and EVAR unsuitable 
patients, respectively (P=0.50). Morbidity rate, mainly consisting of cardiac and 
pulmonary complications, was higher in EVAR suitable patients (51.5%) 
compared to EVAR unsuitable patients (34.7%), although not significantly 
(P=0.15). 
Discussion 
Selection bias is often mentioned as a limitation in observational studies 
comparing endovascular with open ruptured AAA repair. The present study 
shows that in patients who all underwent preoperative imaging, anatomical 
suitability for EVAR was not associated with a lower mortality after open rAAA 
repair. In addition, the lower limit of the confidence interval of the 30-day 
mortality (28%) in EVAR suitable patients who were treated with open repair 
indicates that a mortality rate of 18-24%, as reported for eEVAR,2-5,7 would be 
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unlikely. Hence, while hemodynamic stability to undergo preoperative imaging 
might favor mortality for eEVAR in observational studies, it is unlikely that the 
reported difference in mortality between eEVAR and open repair can (partially) 
be explained by treating patients with a favorable anatomic configuration with 
eEVAR. 
In a recent meta-analysis of Hoornweg et al., including 116 observational 
studies, the reported overall early mortality rate of 60,822 patients undergoing 
open ruptured aneurysm repair was 48.5% (95% CI: 48.1-48.9%).14 The mortality 
observed in the current study compared well. Especially considering the fact 
that only 6 patients did not receive any treatment, due to severe comorbidity in 
combination with a quick deterioration of hemodynamic condition and old age.  
A recent study of Perrott et al. showed that anatomical suitability for EVAR 
might beneficially affect outcome following open repair in patients with a 
ruptured AAA (30-day mortality rate 6.9% versus 30.4%, P=0.066).15 However, 
this retrospective study had limited sample size and only 41% of the patients 
treated with open repair received pre-operative CTA scanning. Therefore, 
patients included in the main analyses were presumably hemodynamically 
more stable, which might influence mortality results. On the other hand, in 
patients treated with eEVAR for both symptomatic and ruptured AAA, Richards 
et al. demonstrated that adverse anatomy was associated with significant 
increase in graft related mortality.16 Therefore, in the acute situation, 
anatomical and clinical guidelines are important to be obeyed. 
In the present study, all patients underwent preoperative imaging in order to 
assess EVAR suitability, irrespective of the patients’ hemodynamical condition 
and irrespective of the availability of the eEVAR-vs. Primary reason was the 
establishment of a uniform (logistic) protocol for the intake and diagnostics of 
patients with a ruptured AAA in the emergency setting. Furthermore, CTA in 
patients treated with open repair appeared to be valuable for the assessment 
of the vascular anatomy prior to operation. Preoperative CTA scanning and 
assessment for endovascular repair is often considered to delay treatment, as 
patients undergoing eEVAR tend to be more hemodynamically stable compared 
with open repair in several observational studies.5 However, in the only 
randomized trial available, Hinchliffe et al. concluded that preoperative CTA 
scanning does not delay treatment. Furthermore, they state that patients who 
were so unstable that the surgeon deemed CT scanning unethical did badly with 
open repair and might even be those who have most to gain from endovascular 
repair.17 Lloyd et al. investigated the interval between admission and death in 
patients with a ruptured AAA who did not undergo surgery because of 
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advanced age and/or comorbidities, showing a median interval of 10 hours 
45 minutes (range, 1 hour 1 minute to 143 hours 55 minutes).18 This indicates 
that most patients with a ruptured AAA who reach the hospital alive are 
sufficiently stable to undergo CTA and consideration for eEVAR, as confirmed by 
a systematic review of Sadat et al.5 
In a recent systematic review, 23 studies comparing eEVAR with open repair 
were identified, including only one randomized controlled trial.5 The 
randomized controlled trial of Hinchliffe et al. was a pilot study, including only 
32 patients and showing comparable mortality results for both treatment 
options.17 Therefore, 22 non-randomized, mostly larger observational studies, 
with earlier mentioned limitations, are available. These show reduced early 
mortality results of eEVAR compared to open repair.5 Despite the potential 
methodological inadequacies, there is evidence that observational studies in 
general do provide valid information. In a study of Benson et al.19 the estimates 
of the treatment effects from observational studies were compared with well 
conducted randomized controlled trials identifying 136 reports published 
between 1985 and 1998 about 19 diverse treatments. In 17 of the 19 analyses, 
the estimates of the treatment effects were similar. Therefore, though not 
adjusted for hemodynamic condition at presentation, it is likely that the 
observational studies comparing endovascular with open ruptured AAA repair 
provide a reasonable estimation of the treatment effect. Especially since the 
present study shows that suitability for EVAR might not be associated with 
lower mortality rates.  
In the present study, all patients underwent preoperative imaging making 
selection bias based on hemodynamic condition unlikely. This is substantiated 
by comparable systolic blood pressure rates at baseline for both treatment 
groups (Table 4.1). Furthermore, anatomical suitability for EVAR was assessed 
afterwards by two independent experts, blinded for earlier evaluation, 
intervention, and outcome. Both external experts work for Medtronic 
Endovascular since 1997 and advised vascular surgeons (throughout the world, 
but especially in the Netherlands for the last 5 years) about the most 
appropriate choice of endograft based on their sizing, in more than 2000 cases 
each. Documented sizing, as well as actual attendance, of more than 1000 
Talent EVAR cases is available for both experts. Mortality data was recorded 
prospectively. However, some aspects in the present study deserve a comment. 
At baseline, significantly more patients in the EVAR suitable group were male. 
Although it is well established that women receive less EVAR treatment than 
men,20,21 there are contradictory reports whether this is due to their anatomical 
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suitability.22,23 Since women with a ruptured AAA are reported to have an 
increased mortality risk after EVAR compared to men, the baseline gender 
difference might theoretically influence mortality results.24 Secondly, non EVAR 
suitable patients treated with open repair by all three participating vascular 
surgeons were compared to EVAR suitable patients, who were treated with 
open repair by the non eEVAR-vs. All three vascular surgeons are experienced in 
open rAAA repair. 
 
In conclusion, the present study suggests that anatomical suitability for EVAR, 
assessed on preoperative CTA scan, is not associated with lower early and 
midterm mortality in patients treated with open rAAA repair. Therefore, the 
reported reduction in mortality between eEVAR and open repair, as observed in 
the cohort observational studies, is unlikely due to selection bias based on 
anatomical AAA configuration. 
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Abstract 
Objective 
In patients with a symptomatic abdominal aortic aneurysm (sAAA), acute intervention 
theoretically reduces rupture risk prior to surgery whereas delayed intervention provides 
surgery under optimized conditions. In the present study we evaluated differences in 30-
day mortality in patients with a sAAA operated within 12 hours compared to patients 
who received treatment after 12 hours and who were optimized for surgery.  
Materials and Methods 
All patients with a sAAA who were treated within one week after presentation were 
included in the analyses. The 30-day mortality rates of patients operated within 12 hours 
were compared to those operated after 12 hours, adjusted for type of operation and for 
all potential confounders.  
Results 
Of the 89 included patients, 37 patients received surgery within 12 hours. In patients 
treated within 12 hours, 30-day mortality rate was 6 (16.2%) compared to 3 (5.8%) in 
patients treated after 12 hours (odds ratio 0.316; CI 0.074-1.358). When adjusted for 
type of operation and other confounders, odds ratios were 0.305 (CI 0.066-1.405) and 
0.270 (CI 0.015–4.836), respectively.  
Conclusion 
In a substantial amount of patients with an alleged symptomatic AAA, delayed surgery 
with patient optimization might be justified. However, specific criteria in order to select 
patients that might benefit from delayed surgery need further investigation. 
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Introduction 
It is widely accepted that a so-called symptomatic AAA (sAAA) represents 
imminent rupture.1 A sAAA is defined as the presence of an AAA with symptoms 
of back and/or abdominal pain in combination with pain at aneurysm palpation 
and no evidence of rupture on Computed Tomography Angiography (CTA) 
scan.2 In order to prevent rupture with associated poor prognosis, acute 
treatment of patients with a sAAA is generally performed.3 4 
Advocates of acute intervention claim that the risk of rupture prior to surgery 
might be reduced.3,4 However, in an acute setting there is little time for 
preoperative optimization of patients’ and operative condition. Therefore, 
patients are likely to suffer from a higher peri-operative risk compared to 
patients who are operated upon in an elective setting.3,5-9 Since there is 
uncertainty of the time interval between initiation of symptoms and rupture in 
patients with a sAAA,6,10 a strategy to postpone surgery in order to optimize 
patients’ and operative condition might be permitted. Hence, a balance is 
needed between the benefits of surgery under optimized conditions and the 
risk of rupture prior to surgery.  
The aim of this study was to evaluate 30-day mortality in patients with a sAAA 
treated within 12 hours after presentation compared to patients treated after 
12 hours. 
Materials and Methods 
Patients 
All consecutive patients, who presented with a sAAA between April 2002 and 
February 2009 at the emergency department or outpatient clinic at a tertiary 
vascular referral center, were eligible for the study. Patients who received an 
intervention more than one week after presentation were excluded from the 
analysis. Analyses were performed retrospectively on a prospective database. 
A sAAA was diagnosed based on the following criteria: the existence of an AAA 
with acute onset of abdominal and/or back pain in combination with pain at 
aneurysm palpation.2 Furthermore, no sign of rupture had to be present on 
preoperative CTA scan.  
Ethical approval was obtained from the Local Ethics Committee. The 
Institutional Review Board waived the requirement for informed consent 
because the analyzed patient data were documented as part of routine clinical 
care.  
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Treatment protocol  
In all patients, medical history was taken, a physical examination was 
performed and blood pressure was measured at the upper arm. In most 
patients with a suspected sAAA an abdominal ultra sound was made prior to 
CTA scanning in order to identify the presence of an AAA. 
The policy in our center is to perform a CTA scan in all patients presenting with 
a sAAA in order to assess suitability for EVAR and to rule out rupture. EVAR 
suitability was initially defined as a proximal neck length >15 mm with 
<60 degrees angulation and access vessels large enough to accommodate the 
introducer sheaths.11 As time went by, we began accepting patients for EVAR 
with more challenging anatomies, including proximal neck lengths as low as 
10 mm and more severe angulations of aortic neck and aneurysm.  
All patients with a sAAA who did not receive immediate intervention were 
admitted to a medium care unit with bed rest, close blood pressure monitoring, 
and optimization of patients’ operative conditions. Blood glucose was 
monitored and regulated in patients with Diabetes Mellitus. A cardiologist was 
consulted for active lowering of blood pressure and pre-operative cardiac 
optimization. A pulmonologist was consulted for pre-operative pulmonary 
optimization. In patients with chronic obstructive pulmonary disease, 
ipratropium bromide and albuterol sulphate inhalation was provided. In 
patients with renal insufficiency who were eligible for endovascular repair a 
pre-operative prehydration protocol was started in order to reduce the risk of 
contrast-induced nephropathy. Furthermore, in all patients carbasalate calcium 
and a statin were administered.  
Procedure 
The operating room (OR) is fully equipped for EVAR as well as open surgical 
repair. Patients who underwent open surgical repair received general 
anesthesia, whereas patients who underwent EVAR preferentially received local 
or regional (spinal) anesthesia. The OR staff is trained and experienced with 
EVAR, and angiography assistance was always available. The operation 
procedure and materials that were used have been described in detail in a 
previous report.12 
Methods 
For all included patients the time between presentation and operation was 
recorded. Patients who received intervention within 12 hours were compared 
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to patients who received AAA repair after 12 hours but within one week. The 
decision to postpone surgical treatment in order to optimize patients’ and 
operative conditions was based on the professional judgement of the surgical 
team. The primary outcome was 30-day mortality. Secondary outcomes were 
complications, re-interventions and length of hospital stay. Furthermore, 
present mortality results were added to previous results in literature in a forest 
plot.  
Data collection 
The detailed data collection is described in a previous report, with addition of 
10 more months of inclusion in the present study.12 Recorded baseline 
characteristics were time of arrival, cardiovascular and pulmonary comorbidity, 
renal dysfunction, diabetes mellitus, and AAA diameter. Cardiovascular 
comorbidity included history of ischemic heart disease, angina pectoris, 
hypertension, cardiac failure, coronary artery bypass graft, percutaneous 
transluminal coronary angioplasty, cerebrovascular accident or transient 
ischemic attack, valvular disease, rhythm disorders, or history of aortic 
operation. Pulmonary comorbidity included the presence of at least one of the 
following: asthma, chronic obstructive pulmonary disease, or lung carcinoma. 
Renal dysfunction was defined as a blood creatinine level higher than 140 
μmol/L. To be characterized as present diabetic, the patient had to be receiving 
oral medication and/or insulin therapy. 
Statistical analyses  
Statistical analyses were performed using SPSS 15.0.1 for Windows (SPSS INC., 
Chicago, IL, USA). A chi-square or Fisher’s exact test was used for categorical 
variables, presented as frequency with percentages. Nominal variables were 
presented as mean ± standard deviation (SD) for a normal distribution or as 
median and inter-quartile-range (IQR) for a skewed distribution. P-values of 
<0.05 were considered significant. Differences in mortality rate were expressed 
using the odds ratio. A multiple regression analysis was performed to adjust for 
type of operation (EVAR or open surgery) and subsequently for other potential 
confounders. Type of operation, time of arrival (within or outside regular 
working hours; 8.00h till 17.00h), gender, cardiovascular comorbidity, 
pulmonary comorbidity, history of CVA or TIA, Diabetes Mellitus, preoperative 
creatinine levels, and AAA diameter were considered as potential confounders.  
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A summary of the available evidence on mortality in patients with a sAAA was 
listed in a forest plot using review manager 4.2 for Windows developed by the 
Nordic Cochrane center. 
Results 
Patients 
Between April 2002 and February 2009, a total of 89 patients presented with 
suspected sAAA and were treated within one week after presentation. Of these 
patients, 37 were treated within 12 hours after presentation (mean age 72 ± 10 
years) and 52 patients were treated after 12 hours (mean age 71 ± 8 years). 
Baseline characteristics were comparable for both treatment groups and are 
listed in Table 5.1.  
 
Table 5.1 Baseline and treatment characteristics. 
 Operated within 12 
hours 
(n=37) 
Operated after 12 
hours 
(n=52) 
P‐value 
Baseline    
Mean age in years (SD) 71.6 ± 9.5 71.2 ±7.6 0.733 
Male 33 (89.2%) 38 (73.1%) 0.062 
Cardiovascular comorbidity 29 (78.4%) 39 (75.0%) 0.711 
Pulmonary comorbidity 10 (27.0%) 10 (19.2%) 0.385 
Renal dysfunction    
- Creatinine (umol/L) (SD) 120.6 ± 68.5 111.6 ± 68.1 0.541 
- Serum Creatinine >140mmol/l 7 (18.9%) 5 (9.6%) 0.225 
Diabetes 5 (13.5%) 4 (7.7%) 0.481 
Mean aneurysmal diameter in cm (SD) 6.7 ± 2.4 6.4 ± 1.4 0.386 
Symptoms    
- Abdominal pain 27 (73.0%) 36 (70.6%) 0.807 
- Back pain 22 (59.5%) 28 (54.9%) 0.670 
- Flank pain   5 (13.5%) 5 (9.8%) 0.736 
- Groin pain 1 (2.7%) 0 (0.0%) 0.420 
- Chest Pain 1 (2.7%) 1 (2.0%) 1.000 
Abdominal examination    
- Pulsatile mass   8 (21.6%)   7 (13.7%) 0.331 
- Pain at aneurysm palpation 16 (43.2%) 23 (45.1%) 0.863 
Treatment    
Open 29 (78.4%) 26 (50.0%) 
EVAR   8 (21.6%) 26 (50.0%) 
0.007 
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Procedures and clinical courses 
Time between presentation and surgery is depicted in Figure 5.1. Among the 
patients who were treated within 12 hours (median 3, IQR 2-5), 8 (21.6%) were 
treated with EVAR and 29 (78.4%) patients were treated with open surgical 
repair. In one patient a contained rupture was found during open surgical repair 
that was not identified on preoperative CTA scan.  
Among the 52 patients who received their intervention after 12 hours (median 
45, IQR 25-78), 26 (50.0%) were treated with EVAR and 26 (50.0%) patients 
were treated with open surgical repair. In this group, two patients became 
hemodynamically unstable during the admission period due to rupture of their 
sAAA while waiting for surgery at one and two days after presentation. In a 
third patient the aneurysm ruptured during open repair directly after opening 
the peritoneum. A fourth patient who was treated with open surgical repair 
appeared to have a contained rupture.  
All 55 patients who underwent open surgery had general anesthesia. Among 
the 34 patients who were operated with EVAR, 2 (6.1%) patients received local 
anesthesia, 3 (3.4%) general anesthesia, and 28 (84.8%) patients received spinal 
anesthesia.  
The distribution of the number of patients who were treated within and after 
12 hours after presentation during the study period is shown in Figure 5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Time between presentation and surgery. 
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Figure 5.2 Patients included during the study period. 
 
Mortality 
The 30-day mortality rates are listed in Table 5.2. In total, 9 of the 89 (10.1%) 
patients died within 30 days. In the group operated within 12 hours, 6 out of 37 
(16.2%) patients died due to: urosepsis in combination with severe comorbidity 
(n=1), renal failure after open surgical repair in combination with a pneumonia 
eventually leading to multi organ failure (n=1), acute myocardial infarction 
(n=3), and graft limb obstruction resulting in leg ischemia for which a surgical 
reintervention was not performed due to the patient’s irreversible poor 
condition (n=1). In the group operated after 12 hours, 3 out of 52 (5.8%) 
patients died due to: extensive retroperitoneal hemorrhage one day after open 
surgical repair with clinical deterioration for which a reintervention was 
performed (n=1), acute myocardial infarction (n=1), and one patient whose 
aneurysm ruptured during admission prior to intervention died within 30 days 
after surgery. The crude odds ratio for mortality was 0.316 (CI 0.074–1.358). 
When adjusted for type of surgery (open and EVAR) and other potential 
confounders, adjusted odds ratios were 0.305 (CI 0.066–1.405) and 0.270 (CI 
0.015–4.836), respectively.  
When we repeated our analyses using 24 hours as a cut-off point, crude odds 
ratio was 0.131 (CI 0.016-1.100), consistent with the analyses using 12 hours as 
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a cut-off point. When adjusted for type of operation and other potential 
confounders, adjusted odds ratios were 0.124 (CI 0.014-1.083) and 0.002 (CI 
0.000-88.505), respectively. 
Figure 5.3 shows the combined mortality results of multiple studies including 
the present study using a forest plot of the available evidence in patients with a 
sAAA. Combined odds ratio was 1.73 (CI 0.74-4.03) and therefore not 
significant. 
 
Table 5.2 30-day mortality. 
 Within 12 hours 
(n=37) 
After 12 hours 
(n=52) 
ODDS ratio 
(CI) 
Adj ODDS ratioa
(CI) 
Adj ODDS ratiob 
(CI) 
Mortality 6 (16.2%) 3 (5.8%) 0.316 
(0.074-1.358)
0.305 
(0.066-1.405) 
0.270 
(0.015-4.836) 
a Adjusted for type of operation; b Adjusted for all potential cofounders. 
 
 
 
 
 
 
 
 
 
Figure 5.3  Mortality results in literature. 
 
Complications, re-interventions and admissions 
All complications, re-interventions and the duration of hospital stay are listed in 
Table 5.3. Follow-up varied from 13 months to 6 years (mean 3.8 years). In 
patients operated within 12 hours, the overall complication rate was 56.8% 
(21/37) compared to 46.2% (24/52) of the patients who received surgery after 
12 hours.  
Five (13.5%) patients operated within 12 hours versus 18 patients (34.6%) 
operated after 12 hours needed a re-intervention (P=0.029). Re-interventions in 
patients operated within 12 hours were performed for postoperative 
hemorrhage (n=3), correction of a cicatricial hernia (n=1), and ileus (n=1). Re-
interventions for patients who received the intervention after 12 hours were 
performed for postoperative recurrent hemorrhage (n=5), correction of a 
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Table 5.3 Complications, re-interventions and admission. 
  Within 12 hours
(n=37) 
After 12 hours 
(n=52) 
P‐value 
Rupture 1 (2.7%)   4 (7.7%) 0.397 
Overall complication ratea 21 (56.8%)   24 (46.2%) 0.324 
 - Deployment/procedure related complicationsa   6 (16.2%)     9 (17.3%) 0.892 
   Extensive peroperative bleeding   4 (10.8%)   3 (5.8%) 0.443 
   Aortic dissection 0 (0.0%)   0 (0.0%) 1.000 
   Arterial perforation or rupture 0 (0.0%)   1 (1.9%) 1.000 
   Peripheral embolization 1 (2.7%)   2 (3.8%) 1.000 
   Access site hematoma 1 (2.7%)   0 (0.0%) 1.000 
   False aneurysm 0 (0.0%)   1 (1.9%) 1.000 
   Access site lymphocele/lymphorrhea/lymphedema 0 (0.0%)   0 (0.0%) 1.000 
   Access site infection 1 (2.7%)   1 (1.9%) 1.000 
   Fever of unknown origin (<6 days after surgery) 2 (5.4%)   5 (9.6%) 0.695 
 - Implant related complicationsa   6 (16.2%)   10 (19.2%) 0.715 
   Anastomotic aneurysm 0 (0.0%)   0 (0.0%) 1.000 
   Graft migration 1 (2.7%)   3 (5.8%) 0.638 
   Graft infection 0 (0.0%)   0 (0.0%) 1.000 
   Postoperative graft limb obstruction 1 (2.7%)   4 (7.7%) 0.397 
   Buttock/leg claudication/ischemia 1 (2.7%) 0 (.0%) 0.416 
   Leaking prosthesis   4 (10.8%)   5 (9.6%) 1.000 
 - Systemic complicationsa   8 (21.6%)     7 (13.5%) 0.311 
   Cardiac 0 (0.0%)   2 (3.8%) 0.509 
   Pulmonary   4 (10.8%)   2 (3.8%) 0.229 
   Renal insufficiency   4 (10.8%)   2 (3.8%) 0.229 
   Bowel ischemia 0 (0.0%)   1 (1.9%) 1.000 
   Sepsis 1 (2.7%)   0 (0.0%) 0.416 
   Abdominal compartment syndrome 1 (2.7%)   0 (0.0%) 0.416 
Complications requiring surgical re-intervention   5 (13.5%) 18 (34.6%) 0.029 
   Hemorrhage 3 (8.1%) 5 (9.6%) 1.000 
   Cicatricial hernia 1 (2.7%) 1 (1.9%) 1.000 
   Ileus  1 (2.7%) 0 (0.0%) 0.416 
   Stent graft occlusion 0 (0.0%) 4 (7.7%) 0.138 
   Endoleak type 1 0 (0.0%) 3 (5.8%) 0.263 
   Endoleak type 2 0 (0.0%) 3 (5.8%) 0.263 
   Endoleak type 3 0 (0.0%) 1 (1.9%) 1.000 
   Aortic rupture post EVAR 0 (0.0%) 1 (1.9%) 1.000 
Postoperative days in hospitalb 8 (6.5 – 16.0) 7 (2.0 -10.5) 0.065 
a Number of patients with one or more complications; b median (interquartile range) 
 
 
cicatricial hernia (n=1), occluded prosthesis (n=4), aneurysm rupture after EVAR 
(n=1), and endoleakage (n=7). 
The median postoperative days in hospital were 8.0 (IQR: 6.5–16.0) grouping 
patients treated within 12 hours and 7.0 (IQR: 2.0–10.75) for patients treated 
after 12 hours (P=0.065). 
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Discussion 
In the present study, 30-day mortality rates in patients with a sAAA were lower 
in patients operated more than 12 hours after presentation compared to 
patients treated within 12 hours, though not significantly (odds ratio 0.316; 
CI 0.074–1.358). Similar results were obtained after adjustment for type of 
operation and other potential confounders. These results suggest that delayed 
treatment in certain patients with a sAAA may be justified.  
Results of the present study have to be interpreted with caution due to 
methodological limitations. In order to gain results that were statistically 
significant, more patients had to be included in the analyses. Due to lack of 
statistical power only a trend could be seen towards a lower mortality rate in 
patients that were treated under optimized conditions more than 12 hours 
after presentation. Furthermore, analyses were performed retrospectively on a 
prospective database. Therefore, patients were not allocated to the treatment 
groups in a randomized way and selection bias, based on subjective criteria, is 
likely to have occurred. Postponing surgical treatment has occurred for several 
reasons including the assembling of an EVAR dedicated team in case of EVAR 
suitability, the need for optimization of patients’ and operative conditions in 
case of severe comorbidity, and logistical reasons. Despite potential selection 
bias, baseline characteristics were comparable in patients treated before and 
after 12 hours after the initial presentation.  
In the acute setting (treated within 12 hours), EVAR was performed in patients 
who were suitable for endovascular repair depending to the attending vascular 
surgeon (78.4% open repair versus 21.6% treated by EVAR), since not all 
vascular surgeons were capable of performing endovascular aneurysm repair in 
the acute setting. Therefore, intention to treat by eEVAR protocol was not part 
of the study design. In patients who underwent delayed treatment, the 
distribution between patients who received open repair versus endovascular 
repair corresponds with the EVAR suitability rate.13 On one hand, this difference 
in proportion treated by EVAR might emphasize heterogeneity. Furthermore, it 
might affect mortality results in favor of the delayed group since EVAR is 
potentially associated with decreased 30-day mortality rates compared to 
conventional open repair in sAAA patients.2,11  
On the other hand, it might underline a theoretical advantage for delayed 
treated patients who are more likely to receive endovascular repair in case of 
EVAR-suitability. Logistic regression analyses were performed with type of 
operation as well as other potential confounders as variables. These adjusted 
analyses showed similar results. Though, given the limited number of patients, 
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conclusions of these analyses have to be interpreted with caution. 
In the delayed group, rupture of the sAAA occurred in two patients while 
waiting for surgery. In another patient rupture occurred during open repair 
directly after opening the peritoneum, which was probably a free rupture of a 
contained retroperitoneal hematoma due to the effect of general anaesthesia 
with related loss of abdominal muscle tone. A contained rupture was found in a 
fourth patient during open surgical repair. Despite the occurrence of 
preoperative aneurysm rupture in the delayed surgery group, no increase in 
mortality was observed, which support the conclusion that delayed surgery with 
optimization of patients’ and operative conditions might be justified in selected 
patients with a sAAA. 
Optimization of patients’ and operative conditions was accomplished 
subjectively by best individual clinical care: admission to a medium care unit 
with close monitoring and optimization of patients’ operative pulmonary, 
cardiac, renal, and internal condition. There is no fixed protocol or data 
available in literature. We stuck to our own optimization protocol as described 
in the methods section. Nevertheless, risk of heterogeneity in terms of 
optimization methods used in the delayed treatment group seemed inevitable. 
A summary of the available evidence is listed in a forest plot (Figure 5.3). Three 
studies describing acute treatment (within 24 hours) and delayed treatment 
(after 24 hours) in patients with a sAAA are available.4,6,10 Two small studies by 
Johnson et al.6 and Cambria et al.10 showed similar mortality results to the 
current study in favor of delayed treatment. On the other hand, mortality 
results of Tambyraja et al.,4 who used a comparable sample size to our study, 
were in favor of acute treatment. Overall, in contrast with the general opinion, 
there seems to be a trend in the available literature including the present study 
towards lower early mortality rates in patients receiving delayed treatment, 
though not significantly (odds ratio 1.73; CI 0.74–4.03) (Figure 5.3). As distinct 
from earlier studies, the analyses in the present study were based on 
prospective data and 30-day mortality results were adjusted for all potential 
confounders. Furthermore, in our main analyses we used 12 hours as the 
cut-off point between acute and delayed treatment based on the distribution of 
time to operation (Figure 5.1), instead of 24 hours as used by Tambyraja et al.4 
Though, when we repeated our analyses using 24 hours as a cut-off point, 
results were consistent with the analyses using 12 hours as a cut-off point.  
There is a wide variation of definitions employed for sAAA. Kapma et al. defined 
sAAA as any AAA requiring treatment within 24 hours and not classified as a 
ruptured AAA.11 In the present study sAAA was defined as the existence of an 
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AAA with acute onset of abdominal and/or back pain combined with pain at 
aneurysm palpation, as described by Peppelenbosch et al.2 However, abdominal 
pain and pain at aneurysm palpation might have causes other than an aneurysm 
in a state of pending rupture indicating potential false positive diagnoses. 
So far, studies comparing acute with delayed treatment in patients with a sAAA 
are flawed by methodological inadequacies such as lack of randomization and 
potential selection bias. As stated, despite the adjustments for multiple 
potential confounders in the present study, results have to be interpreted with 
caution. Although delayed treatment seems to be justified according to the 
results of the present study, a large prospective controlled trial in which 
patients are allocated to the acute or delayed treatment group in a randomized 
study setting is required to confirm the results of the present study. If this 
randomized controlled trial shows similar results to the present study, the 
contemporary assumption to treat patients with a sAAA in an acute setting in 
order to prevent rupture might be adjusted. Preoperative optimization of 
patients’ and operative condition could improve prognosis in selected patients 
with a sAAA. However, given the relatively small number of patients with a 
sAAA, a randomized controlled trial might be difficult to perform. 
Conclusions  
In conclusion, delayed surgical treatment in order to optimize patients’ and 
operative conditions does not result in higher mortality rates in a substantial 
amount of patients presenting with a symptomatic AAA. A trend towards a 
lower 30-day mortality rate was found for sAAA patients treated after 12 hours 
after presentation compared to patients treated within 12 hours. However, the 
present study was underpowered and results have to be interpreted with 
caution due to methodological limitations such as selection bias. Specific 
criteria in order to select patients that might benefit from delayed surgery need 
further investigation. Therefore, a large well-conducted randomized controlled 
trial is needed. 
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Abstract 
Objective 
Anastomotic pseudoaneurysms and true paraanastomotic aneurysms after initial open 
abdominal aortic prosthetic reconstruction often need reintervention because they are 
at risk for rupture. However, open surgical reinterventions are technically challenging 
procedures with high mortality and morbidity rates. In the present multicenter study, we 
describe the long-term clinical course in an expanded number of patients who 
underwent endovascular repair of paraanastomotic aneurysms after previous open 
reconstruction.  
Materials and Methods 
The study included all patients who were treated with an endovascular stent graft 
between July 1999 and July 2009 for an aortoiliac anastomotic pseudoaneurysm or a 
true paraanastomotic aneurysm after previous aortic prosthetic reconstruction for 
aneurysmal or occlusive disease in one of the four participating centers. Main outcomes 
were long-term complications, reinterventions and conversion rate, mortality, and 
hospital length of stay. 
Results 
An endovascular stent graft was used to treat 58 patients (53 [91%] men; mean age 
71±9 years) with 80 aortic or iliac pseudo or true paraanastomotic aneurysms, or both. 
Bifurcated stent grafts were used in 32 patients, endovascular tube grafts in 8, 
aortouniiliac stent grafts in 7, and iliac extension grafts in 11. Stent graft deployment was 
successful in 55 patients, for a technical success rate of 95%. Median hospital admission 
was 3 days (range, 1-122 days). The 30-day and in-hospital mortality rates were 3.4% 
(n=2) and 6.9% (n=4), respectively. The 30-day clinical success rate was 91% (n=53). 
Median follow-up was 41 months (range, 0-106 months). The cumulative and 
procedural-related mortality during follow-up was 19% (n=11) and 10% (n=6), 
respectively. During follow-up, computed tomography angiography revealed nine 
endoleaks (3 type I and 6 type II endoleaks) in eight patients and endotension in two 
patients. The overall reintervention and conversion rate during follow-up was 26.9% 
(n=15) and 6.9% (n=4), respectively. Life-table analysis showed reduced freedom from 
reintervention for aortouniiliac and tube stent grafts. Type I endoleaks were observed in 
25% of patients with endovascular aortic tube grafts for proximal anastomotic 
aneurysms. 
Conclusions 
The present study demonstrates that in patients with an appropriate anatomy, 
endovascular repair of paraanastomotic aortic and iliac aneurysms after initial prosthetic 
aortic surgery is safe and durable. On the long-term, fewer complications occurred after 
procedures with bifurcated stent grafts compared with procedures with tube grafts, 
aortouniiliac or iliac extension stent grafts. 
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Introduction 
Conventional aortic prosthetic reconstruction for repairs of abdominal aortic 
aneurysm (AAA) or aortoiliac obstructive disease is considered to be a durable 
procedure and is still widely performed. A typical complication after 
conventional aortic prosthetic reconstruction is paraanastomotic aneurysm 
formation. Paraanastomotic aneurysms after previous open reconstruction may 
present as continuing dilatation of the aortoiliac arteries adjacent to the 
anastomosis (true paraanastomotic aneurysms) or as disruption of the 
anastomosis leading to pseudoaneurysm formation (false paraanastomotic 
aneurysms).1 The reported incidence varies widely. In a retrospective 15-year 
follow-up study of 208 patients, proximal and distal aortic paraanastomotic 
aneurysms occurred in 6 (2.9%) and 18 patients (8.7%), respectively.2  
Most open reinterventions after initial abdominal aortic prosthetic 
reconstruction are for repairs of anastomotic pseudoaneurysms and true 
paraanastomotic aneurysms because they are at risk for rupture.2,3 However, 
these open surgical reinterventions are technically challenging, with mortality 
rates varying from 8% to 70% and morbidity rates of 70% to 83%, which are 
considerably higher than those associated with primary prosthetic 
reconstructions.4-8  
Endovascular paraanastomotic aneurysm repair (EVPAR) allows for local or 
regional anesthesia without requiring dissection through the scars of previous 
operations and might be preferred instead of renewed open repair.9 Except for 
case reports, a few small case series have suggested that endovascular 
exclusion of noninfected paraanastomotic aneurysms after previous abdominal 
aortoiliac surgery is feasible, with low perioperative mortality and morbidity.9-15 
Earlier, we showed that endovascular paraanastomotic aneurysm repair is 
effective with bifurcated stent grafts.9 However, larger series with longer-term 
follow-up are necessary to confirm the long-term effectiveness of this 
approach.9,10,12 
In the present multicenter study, we describe the long-term clinical course in an 
expanded number of patients who underwent EVPAR after previous open 
reconstruction. 
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Materials and Methods 
Patients 
Four Dutch centers participated in the study (AmcP, UMCU, St AHN, CHE). The 
study included all patients who were treated with an endovascular stent graft 
between July 1999 and July 2009 for an aortic or iliac false paraanastomotic or 
true paraanastomotic aneurysm after previous aortic prosthetic reconstruction 
for aneurysmal or occlusive disease. The short-term follow-up of 14 patients 
included in the current study has been described previously.9 
Variables analyzed included age, gender, comorbidities, initial aortic pathology, 
graft configuration at the initial open reconstruction, time between initial open 
prosthetic reconstruction and endovascular repair, paraanastomotic aneurysm 
characteristics, stent graft configuration at endovascular repair, hospital 
admissions, survival, complications, reinterventions (freedom from reinter-
ventions), and conversion rate during follow-up. 
Diagnostics and operative technique 
All patients underwent a preoperative contrast enhanced spiral computed 
tomography angiography (CTA) scan with a slice thickness of 1.5 to 3 mm or 
digital subtraction angiography (DSA), or both, to confirm the presence of a 
paraanastomotic aneurysm and to evaluate its anatomic characteristics. Criteria 
for intervention of paraanastomotic aneurysms were 1.5 times the diameter of 
the nondiseased aorta or iliac artery at that segment, symptoms of acute onset 
of abdominal or back pain combined with pain at aneurysm palpation 
(symptomatic paraanastomotic aneurysm), and signs of (contained) rupture on 
preoperative CTA or DSA.16  
 
Criteria for endovascular repair were proximal aortic neck length of ≥10 mm 
between the lowest renal artery and the beginning of the aneurysm, proximal 
aortic neck or iliac artery angulation <90°, lack of circumferential calcification or 
thrombus of the aortic neck or iliac arteries, and adequate iliac-femoral access 
to the paraanastomotic aneurysm. During the entire study period, endovascular 
repair was preferentially performed in anatomically suitable paraanastomotic 
aneurysms. The exclusion criterion for endovascular repair was anatomic 
unsuitability for endovascular repair.  
 
General, regional, or local anesthesia was used. Groin incisions with open 
femoral arteriotomy were performed to gain access to the common femoral 
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artery. Endovascular devices used were AneuRx (Medtronic, Sunnyvale, CA), 
Endurant (Medtronic, Sunnyvale, CA), Excluder (Gore, Arizona, US), Quantum 
LP/Fortron (Cordis Corp., Warren, NJ), Relay (Bolton Medical, Sunrise, FL), 
Talent (Medtronic, Sunnyvale, CA), Valiant (Medtronic, Sunnyvale, CA) and 
Zenith (Cook Vascular, Bloomington, IN). Tube grafts, aortouniiliac stent grafts, 
and bifurcated stent grafts were used. The device type was chosen according to 
anatomic suitability, preferences of the vascular surgeon, availability of the type 
of stent graft of suitable caliber at the time of the procedure in each 
participating center, and paraanastomotic aneurysm location and configuration, 
including aortic neck diameter and length, as well as the presence of iliac 
stenosis or occlusion.  
Tube grafts were used exclusively for proximal paraanastomotic aneurysms, 
whereas bifurcated or aortouniiliac stent grafts were used to treat patients with 
proximal or distal paraanastomotic aneurysms, or both. Aortouniiliac stent 
grafting was combined with a femorofemoral crossover bypass to restore blood 
flow to the contralateral leg and with an occluder in the contralateral common 
iliac artery to prevent backbleeding into the aneurysm sac. In patients with a 
single paraanastomotic iliac aneurysm and a proximal iliac sealing zone of at 
least 0.5 cm, exclusion was obtained by placement of an endovascular iliac 
extender graft. 
 
In patients with a proximal paraanastomotic aneurysm of the abdominal aorta, 
the (covered portion of the) endovascular device was proximally anchored just 
below the lowest renal artery for optimal sealing in the native aortic neck above 
the lesion. In case of an endovascular tube graft, the distal fixation was in the 
previous graft, with overlap of the endovascular device and the previous graft 
of at least two stent rings. For a bifurcated or aortouniiliac stent graft, the 
common iliac artery was used as distal landing zone in most patients. In patients 
with a paraanastomotic aneurysm near the hypogastric artery, the stent graft 
was extended in the external iliac artery after embolization of the hypogastric 
artery. According to the instructions for use all stent grafts were oversized at 
least 10% to 20%. 
Surveillance protocol 
Postoperatively, all electively treated patients went to a regular ward or 
medium care unit where they were fed a normal diet and started ambulating on 
the first postoperative day. Some patients who were endovascularly treated for 
a ruptured paraanastomotic aneurysm initially went to an intensive care unit 
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for close monitoring. Postdischarge surveillance after EVPAR included basic 
laboratory testing for renal function, physical examination, and triple-phase 
(nonenhanced, arterial, and delayed phase) CTA scans before discharge or 
within 3 months, at 12 months, and yearly thereafter. In patients with 
significant renal insufficiency (GFR<40 ml/min), a renal protection protocol 
consisting of prehydration and administration of acetylcysteine was used before 
and after CTA. Otherwise, non-contrast CT scanning combined with contrast-
enhanced ultrasonography was performed at the discretion of the vascular 
surgeon and scheduled at the same time intervals as the regular EVAR protocol.  
Statistical analyses 
Data were collected and analyzed using SPSS 15.0 software (SPSS Inc, Chicago, 
IL). Categoric variables are presented as frequency and percentages. Continuous 
variables are presented as mean ± standard deviation for a normal distribution, 
or as median and range for a skewed distribution. Survival and freedom from 
reintervention after endovascular repair of anastomotic aneurysms was 
evaluated using Kaplan-Meier curves, log-rank tests, and annual risk with 
related standard error (SE). 
Results 
Patients 
From July 1999 to July 2009, 58 patients (53 men [91%]; mean age of 71±9 
years) with 80 aortic or iliac pseudo or true paraanastomotic aneurysms, or 
both, were treated with an endovascular stent graft. Of these, 54 patients (93%) 
were initially treated for aneurysmal disease and 4 (7%) for occlusive aortoiliac 
disease (two of them had end-to-end and two end-to-side anastomosis). 
Twenty-eight patients were conventionally treated with a tube graft to exclude 
an AAA and 30 with a previous bifurcated prosthesis or bifurcated bypass. 
Baseline characteristics and clinical details of these patients are described in 
Table 6.1. In patients with a previous tube graft, 42 paraanastomotic aneurysms 
were present, including pseudoaneurysms at the proximal (n=9) or distal (n=7) 
anastomosis, and true iliac aneurysms at one (n=6) or both sides (n=10) (Figure 
6.1). In patients initially treated with a conventional bifurcated prosthesis, 38 
paraanastomotic aneurysms were present, including pseudoaneurysms at the 
proximal aortic anastomosis (n=10), at one (n=19) or both (n=3) distal iliac 
anastomosis, and unilateral (n=1) or bilateral (n=1) true iliac aneurysms. 
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Diameters of the aneurysms ranged from 3.4 to 11.0 cm for aortic 
pseudoaneurysms, from 1.5 to 8.3 cm for iliac pseudoaneurysms, and from 2.1 
to 7.5 cm for true iliac aneurysms. 
In 40 patients, the paraanastomotic aneurysms were detected by a routine 
surveillance protocol that included ultrasound imaging 1 year after open aortic 
surgery and every 3 or 5 years thereafter. In five patients, the paraanastomotic 
aneurysms were incidentally detected by diagnostic imaging that was 
performed for purposes other than surveillance after open AAA repair. Eight 
patients presented with a symptomatic paraanastomotic aneurysm, and five 
presented with a ruptured paraanastomotic aneurysm. None of the patients in 
this series had symptoms or signs at CT suggesting graft infection.  
 
Through preoperative risk assessment of pre-existent disease, 17 patients were 
classified as American Society of Anesthesiologists (ASA) II, 22 patients as ASA 
III, and 19 patients as ASA IV. At baseline, cardiovascular and pulmonary 
comorbidity was present in 50 (86%) and 21 (36%) patients, respectively. 
 
Table 6.1 Baseline characteristics and clinical details after initial open conventional tube and 
bifurcated graft. Data are presented as number (%) or as median (IQR). 
Variables Tube graft Bifurcated graft All 
 (n=28) (n=30) (n=58) 
Baseline characteristics 
  Age  68 (62-78)  74 (65-78)  73 (63-78) 
  Male  26 (93%)  27 (90%)  53 (91%) 
  Comorbidity  25 (89%)  26 (87%)  51 (88%) 
   Cardiovasculara  25 (89%)  25 (83%)  50 (86%) 
   Pulmonary  8 (29%)  12 (40%)  20 (35%) 
   Renal  5 (18%)  6 (20%)  11 (19%) 
  Serum creatinine level (µmol/L)  95 (91-115)  116 (98-165)  115 (95-161) 
  ASA class  3 (2-4)  3 (2-4)  3 (2-4) 
   I  0 (0%)  0 (0%)  0 (0%) 
   II  9 (32%)  8 (27%)  17 (29%) 
   III  12 (43%)  10 (33%)  22 (38%) 
   IV  7 (25%)  12 (40%)  19 (33%) 
  Latency time, yearsb  7 (4-11)  16 (12-21)  13 (6-18) 
Clinical details 
  Number of PAA 42 38 80 
  Proximal pseudo PAA   9 10 19 
  Proximal true PAA   0   0   0 
  Distal pseudo PAA   7 25 32 
  Distal true PAA 26   3 29 
ASA = American Society of Anesthesiologists; PAA = paraanastomotic aneurysm. 
a Other than previous aneurysmal or occlusive aortic disease; b Time between initial open prosthetic 
surgery and endovascular paraanastomotic aneurysm repair. 
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Figure 6.1 Flowchart showing the types of stent graft (grey) used for different localizations of 
anastomotic and true paraanastomotic aneurysms after previous open tube or 
bifurcated graft (dark grey). 
 
Endovascular intervention 
The median interval between the initial open reconstruction and EVPAR was 
12.5 years (range, 1-25 years). Endovascular repair was performed under 
general anesthesia in 38 patients, spinal anesthesia in 17, and under local 
anesthesia in 3. An endovascular tube graft was used in 8 patients, a bifurcated 
stent graft in 32, an aortouniiliac stent graft in 7, and an iliac extension graft in 
11 (Figure 6.1). Devices that were used are listed in Table 6.2. Median 
procedure time was 120 minutes (range, 45-355 minutes) and median blood 
loss was 250 ml (range, 30-1900 ml). The median radiation time was 23 minutes 
(range, 3-66 minutes), and median contrast dose administration was 87 ml 
(range, 20-150 ml). 
None of the patients died during the EVPAR procedure. Stent graft deployment 
was successful in 55 patients (technical success rate, 95%). One patient needed 
an adjunctive surgical procedure. In this patient, access to the retroperitoneum 
was gained to ligate the contralateral limb of the previous open bifurcated graft 
after successful aortouniiliac endoprosthesis placement for a ruptured proximal 
paraanastomotic aneurysm. In three patients (5%), primary stent graft 
deployment was unsuccessful, of whom one needed an additional laparotomy. 
In this patient, the short contralateral leg of the bifurcated stent graft was 
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deployed accidentally in the ipsilateral limb of the primary existing bifurcated 
graft. The bifurcated stent graft was then converted into an aortouniiliac stent 
graft by extending the graft to the right external iliac artery. Subsequently, a 
suitable endovascular occluder was not available, so a laparotomy was 
performed for ligation of the right hypogastric artery and the left common iliac 
artery to prevent back bleeding into the aneurysm sac. A femorofemoral 
crossover bypass was placed to restore blood flow in the left leg.  
 
Table 6.2 Types of endovascular stent grafts that were used. 
Device Tube graft Bifurcated graft Aortouniiliac graft Extension 
AneuRx 1   8 0   1 
Talent 3 19 7   6 
Endurant 0   1 0   0 
Valiant 1   0 0   0 
Zenith 1   1 0   1 
Quantum LP 0   1 0   0 
Gore excluder 1   2 0   3 
Relay 1   0 0   0 
Total 8 32 7 11 
 
 
The secondary technical success rate was 97%. In the two other patients with 
unsuccessful stent graft deployment, one (n=1) or both (n=1) renal arteries 
were inadvertently overstented during stent graft deployment by a tube and 
bifurcated stent graft, respectively. No type I or III endoleaks were observed at 
completion angiography. 
There were no statistically significant differences in primary (P=1.000) or 
secondary success rate (P=1.000) between patients included in the first or final 
5 years of the study period. 
 
Other events during EVPAR were type II endoleaks at angiography at the end of 
the procedure in four patients, of which one type II endoleak was still present 
on predischarge CTA. Furthermore, the left hypogastric artery in one patient 
was inadvertently covered by the stent graft. 
Hospital stay 
Median hospital stay was 3 days (range, 1-122 days). The in-hospital and 30-day 
mortality rates were 6.9% (n=4) and 3.4% (n=2), respectively, all in patients with 
successful stent graft deployment. Two of these four patients were treated for a 
ruptured paraanastomotic aneurysm. Causes of death were pulmonary 
insufficiency (day 8), progressive cardiac failure (day 8), pulmonary insufficiency 
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combined with a sepsis (day 55), and sepsis after repetitive infections and 
occlusion of a femorofemoral crossover bypass (day 122). This last patient 
underwent several reinterventions for critical limb ischemia.  
 
The 30-day clinical success rate was 91% (n=53). In five patients, 30-day clinical 
success was not achieved due to death (n=2), overstenting of both renal 
arteries causing progressive renal insufficiency (n=1), distal type I endoleak 
present on predischarge CTA (n=1) for which close observation was initiated, 
and hemodynamic shock (n=1) due to rupture of the left external iliac artery 
after paraanastomotic aneurysm repair for which an extension cuff was placed 
successfully. An abdominal compartment syndrome developed in this last 
patient due to a retroperitoneal hematoma and abdominal decompression was 
required the next day.  
Follow‐up 
Median follow-up was 41 months (range, 0-106 months). No patients were lost 
to follow-up. The cumulative mortality during hospital stay and follow-up was 
19% (n=11). Overall, median follow-up until death was 13 months (range, 
0-106 months). Patient survival is illustrated using a Kaplan-Meier curve (Figure 
6.2), which shows the annual risk of mortality was 4.0%. Two of seven deaths 
during follow-up were procedure-related. In one patient, slight aneurysm 
expansion (3 mm) without signs of an endoleak was observed on CTA at 
12 months after endovascular treatment for a proximal paraanastomotic 
pseudoaneurysm using a tube stent graft. A wait-and-see policy was followed, 
but this resulted in acute aneurysm rupture at 18 months needing acute 
reintervention including explantation of the endovascular graft and placement 
of an open bifurcated prosthesis. The patient died the next day due to bowel 
ischemia. The other patient, whose renal artery was overstented during the 
endovascular procedure, suffered from postoperative progressive hemodialysis-
dependent renal insufficiency. At 51 months, successful conversion to open 
repair was performed for a type Ia endoleak. However, this patient decided to 
stop undergoing hemodialysis and died at 106 months of follow-up.  
The overall complication rate during follow-up after discharge was 22% (n=13). 
Two patients died due to procedure-related complications, as described above. 
Hydronephrosis occurred in one patient as the result of external ureter 
compression by a paraanastomotic aneurysm in the iliac artery. In the other 10 
patients (17%), reinterventions were performed for stent graft occlusion in 4 
patients that needed thrombectomy or thrombolysis, followed by percutaneous 
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transluminal angioplasty (PTA) in 3 patients and replacement with a synthetic 
prosthesis in 1 patient; infection of a femorofemoral crossover bypass that was 
replaced by a venous bypass in 1, access site infection and bleeding of a patch 
in the groin in 2, type B dissection for which an aortouniiliac stent graft was 
placed in 1, distal type I endoleak (which was already detected on predischarge 
CTA as described previously) of a bifurcated stent graft for which an iliac 
extension graft was placed in 1, and endotension for which the stent graft was 
converted to a bifurcated prosthesis in 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Kaplan-Meier curve showing survival after endovascular paraanastomotic aneurysm 
repair. The dashed line indicates when the standard error exceeds 10%. 
 
 
During total follow-up, including hospital stay, reintervention was performed in 
15 patients (25.9%) at a median of 11 months (range, 0-80 months). Figure 6.3 
shows the Kaplan-Meier curve for freedom of reintervention after endovascular 
paraanastomotic aneurysm repair. The overall annual risk of reintervention was 
5.8% (SE, 0.088). The log-rank test for equality of reintervention distributions 
between differences in original presentation of paraanastomotic aneurysms is 
visualized in Figure 6.4A, showing no significant differences in freedom from 
reintervention curves during follow-up (P=0.131). In Figure 6.4B, freedom from 
reintervention during follow-up is presented for different stent graft 
configurations, showing a significantly larger proportion of tube and 
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aortouniiliac stent grafts needing reintervention during follow-up using the log-
rank test (P<0.001). The annual reintervention risk was 3.2% (SE, 0.098%) for 
bifurcated stent grafts, 16.6% (SE, 0.239%) for tube grafts, 66.4% (SE, <0.001%) 
for aortouniiliac stent grafts, and 19.1% (SE, 0.152%) for distal iliac extension 
grafts.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Kaplan-Meier curve showing freedom from reintervention after EVPAR for all stent 
grafts that were used. The dashed line shows when the standard error exceeded 10%. 
 
 
Furthermore, the reintervention rate in patients who were treated with 
endovascular repair during the first 5 years of the study period (30%) was 
comparable with patients treated during the final 5 years (23%), (P=0.560). 
 
Four patients (6.9%) required conversion to open repair at a median follow-up 
of 16 months (range, 4-51 months). Two patients needed conversion for 
endotension, which caused an aneurysm rupture in one patient. In one patient, 
an endovascular tube graft was replaced by an open tube graft at 51 months 
after EVPAR for persistent type Ia endoleak. Finally, an axillobifemoral 
prosthesis was placed in one patient for occlusion of a bifurcated stent graft at 
4 months after placement for bilateral true iliac paraanastomotic aneurysms. 
Mortality was 50% (2 of 4) in patients who underwent conversion to open 
aneurysm repair vs 0% (0 of 5) in patients who underwent an endovascular 
reintervention (P=0.167).  
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Figure 6.4 Kaplan-Meier curve showing freedom from reintervention after EVPAR for (A) 
different locations of paraanastomotic aneurysm formation and (B) the different types 
of stent grafts that were used. 
 
 
During follow-up, CTA revealed nine endoleaks (1 type Ia, 2 type Ib, and six 
secondary type II endoleaks) in eight patients. In one patient, type Ia endoleak 
was observed after migration of the previously described bifurcated stent graft, 
which was converted to an aortouniiliac stent graft during EVPAR. Type Ib 
endoleak was observed in two patients at the distal fixation side of the 
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endovascular tube graft, resulting in replacement of the stent graft by an open 
tube graft in one patient, as described above. Of the six secondary type II 
endoleaks, two disappeared spontaneously during follow-up, and the other four 
received close observation. None of these patients needed reintervention and 
AAA did not grow. Furthermore, endotension was observed in two patients 
treated with an endovascular tube graft for a proximal paraanastomotic aortic 
aneurysm, resulting in conversion to open surgical repair in one patient and 
acute aneurysm rupture in the other patient, as described previously. 
Discussion 
The reported incidence of paraanastomotic aneurysms after previous 
conventional aortic reconstruction varies widely, from 0.5 to 15%.17,18 This is 
probably an underestimation, because most patients who undergo open aortic 
repair do not receive regular imaging surveillance follow-up. Paraanastomotic 
aneurysms are associated with high rupture rates. The reported rupture rate 
ranges from 15% to 55% in patients who did not undergo revision surgery.8,19,20 
Pseudoaneurysms might be even more unpredictable in terms of rupture risk 
compared with true paraanastomotic aneurysms,1 with a mortality rate of 61% 
in the absence of an intervention.5 
 
EVPAR allows for local or regional anesthesia without requiring dissection 
through the scars of previous operative sites.9 However, EVPAR has some 
drawbacks, including inadequate proximal or distal fixation zones21, showing 
the importance of accurate pre-operative sizing and planning, and potential 
stent graft deformation in patients with previous end-to-side anastomoses.  
 
Several case series describing endovascular management of paraanastomotic 
aortic and iliac aneurysms have considered this treatment as feasible and 
safe.9-15,22,23 However, the available series describing endovascular repair 
included a small number of patients, and follow-up time is relatively short. The 
report by Sachdev et al. included 53 patients with paraanastomotic aneurysms 
treated with endovascular repair at a mean follow-up of 18.1 months, excluding 
patients who were lost to follow-up.16 However, they studied a mixture of 
thoracic and abdominal paraanastomotic aneurysms.  
Reported mortality rates of open paraanastomotic aneurysm reconstruction 
vary widely from 8% to 70% with morbidity rates of 70% to 83% reported for 
open paraanastomotic aneurysm reconstruction.4-8 One report compared 16 
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open repairs with 10 EVPAR procedures in patients who were candidates for 
endovascular repair, showing higher morbidity and complication rates after 
open repair than with endovascular repair.24 Furthermore, blood loss, 
procedural time, and hospital length of stay were significantly reduced for 
endovascular repair. The results of the present study focus on durability of 
endovascular repair with different types of stent grafts for paraanastomotic 
aneurysms, with extended follow-up time and more patients.  
 
The present study, with a follow-up up to 106 months, showed endovascular 
management of paraanastomotic aortic and iliac aneurysms is a feasible and 
durable alternative to open reconstruction. In 95% of patients treated with 
EVPAR after previous open aortic reconstruction, stent graft deployment was 
successful (primary technical success rate). Perioperative mortality and 
morbidity rates in patients (70% with ASA class ≥III) were acceptable, with an 
intraoperative mortality of 0%, 30-day mortality of 3.4%, and in-hospital 
mortality of 6.9%. Exclusion was successfully maintained during follow-up, 
without signs of endoleak, in 86% of the paraanastomotic aneurysms. 
Furthermore, in patients who needed conversion to open repair after EVPAR, 
there was a clear trend towards a higher mortality rate compared with patients 
who underwent an endovascular reintervention.  
The technical success rates and effective aneurysm exclusion rates reported in 
the present study are notable since 13 patients with either symptomatic or 
ruptured paraanastomotic aneurysms were included in this experience. This 
observation suggests that while careful adherence to stringent selection criteria 
for endovascular repair is important, this approach can be applied in more 
urgent settings where preoperative planning may be less thorough. 
 
Several patients in the present study who had paraanastomotic aortoiliac 
aneurysms with relatively small diameters were treated with endovascular 
repair. Indications for treatment in these patients were symptoms or rupture of 
the aneurysm, or aneurysm growth during routine follow-up after primary open 
prosthetic reconstruction. 
 
In the present study, there were no statistical significant differences in 
durability between endovascular repair in proximal aortic anastomotic, distal 
aortic anastomotic, distal iliac anastomotic and true distal paraanastomotic 
aneurysms after previous open aortic reconstruction (Figure 6.4A). However, 
the studied numbers were low for subgroup analysis and Figure 6.4A gives the 
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impression of a slight non-significant trend towards better durability in terms of 
freedom from reintervention after endovascular repair of anastomotic distal 
aortic aneurysms (after previous open tube graft placement) and anastomotic 
distal iliac aneurysms.  
When comparing different types of stent grafts in all included patients, as 
represented in Figure 6.4B, the endovascular reconstruction was less durable in 
patients treated with aortouniiliac and tube stent grafts for proximal 
paraanastomotic aortic aneurysms. The main causes for reintervention in 
aortouniiliac stent grafts were infections of the femorofemoral crossover 
bypass and stent graft occlusion. In patients treated with an endovascular tube 
graft, the main cause of reintervention was endoleak type I, caused by insecure 
distal anchoring of the endovascular stent graft in the previous polyester graft, 
or endotension. Therefore, when endovascular tube grafts are used for 
proximal anastomotic aneurysms, the distal fixation site has to be long enough 
for secure distal anchoring of the tube graft in the previous polyester 
prosthesis. Or when the proximal anchoring site is short, efforts have to be 
done to implant a bifurcated stent graft. Follow-up showed the proximal 
fixation site of the aortouniiliac or bifurcated stent grafts in the previous 
polyester graft was secure, probably due to the longitudinal columnar support 
in these types of stent grafts. Stent grafts that were fixated proximally and 
distally in the native aorta or iliac vessels were all secure. 
Although original anatomical presentation of paraanastomotic aneurysms did 
not influence long-term durability results significantly (Figure 6.4A), results from 
different types of stent grafts that were used (Figure 6.4B) have to be 
interpreted with caution due to the limited numbers of cases and anatomical 
variation influencing stent graft selection. Stent graft selection for endovascular 
paraanastomotic aneurysm repair should not merely be based on the reported 
differences in outcome between various types of stent grafts as demonstrated 
in the present study, but rather be an individualized approach in which these 
results are addressed in the view of anatomical considerations.   
Conclusions 
The present multi-center study confirms that EVPAR after initial prosthetic 
aortic surgery is a feasible and safe alternative to open reconstruction with 
relatively low perioperative mortality and morbidity in selected cases. At long-
term follow-up, treatment with bifurcated stent grafts showed to be durable 
with low reintervention rates. Aortouniiliac stent grafts and endovascular tube 
grafts appeared less durable, requiring more reinterventions. Based on the 
 The durability of endovascular repair of paraanastomotic aneurysms 
 105 
long-term results of EVPAR in this series of 58 patients, endovascular exclusion 
of anatomically suitable paraanastomotic aneurysms with bifurcated stent 
grafts can be considered as the first-choice treatment option. Though, EVPAR 
requires an individualized approach taking anatomical considerations into 
account. 
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Introduction 
Open surgical repair has been the established treatment option in the 
prevention of rupture in patients with an abdominal aortic aneurysm (AAA). In 
1991, Parodi et al. introduced a less invasive alternative to conventional open 
surgical repair in selected patients with an AAA, endovascular aneurysm repair 
(EVAR).1 By means of a catheter based system a synthetic stent graft is 
introduced from the groin up to the AAA neck. When positioned correctly just 
below the renal arteries, the stent graft is unfolded, excluding the aneurysm sac 
from systemic blood pressure, but leaving the aneurysm sac in situ. Gradually 
decreasing AAA diameter after endovascular repair is presumed to reflect 
successful treatment and low rupture risk,2,3 whereas increasing AAA diameters 
at follow-up indicates incomplete exclusion and therefore continued rupture 
risk.4 Stent graft related complications might cause re-establishment of 
pressure in the aneurysm sac resulting in aneurysm expansion and ongoing 
rupture risk.5 Therefore, long term surveillance is required for detection of 
these stent graft related complications, including migration, kinking, and 
endoleakage. Surveillance could be in the form of an imaging modality or a 
systemic blood marker. 
According to the practical guidelines of the Society of Interventional Radiology, 
three parameters should be included for imaging surveillance: diameter 
measurements of the aortic aneurysm, detection of morphologic details of the 
stent grafts, and detection and classification of endoleaks.6 In order to follow-
up aneurysm size, aneurysm diameter as well as volume measurements can be 
used. Currently, maximal anterior-posterior diameter is the most widely used 
parameter for aneurysm size measurements. Aortic lumen volume and 
thrombus volume might be more appropriate to discriminate successful from 
failed exclusion.7 However, their association with the presence of an endoleak 
does not appear to be substantially stronger according to Wolf et al.8 
Furthermore, changes in volume seem to be parallel with changes in maximal 
aneurysm diameter.8 Bley et al. showed that volumetric increase on 
nonenhanced CT serves as an adequate screening test for endoleak.9  
Alteration of stent grafts morphology, including migration, kinking and fracture, 
are the result of hemodynamic stress, aortic morphologic changes and/or 
device inadequacy. These stent graft deformations may cause endoleakage, 
continued rupture risk or obstruction of blood flow through the device.  
Endoleak formation, defined as a blood flow outside the stent graft and inside 
the aneurysm sac,3,10,11 is the most common complication of EVAR with a 
reported incidence varying from 2 to 45%.12-15 Persistent endoleak is often 
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considered a procedural failure because it may cause enlargement and eventual 
rupture of the aneurysm. It represents the main indication for late surgical 
conversion.16 Endoleak can be organized into four categories, based on the 
origin of the leak, as described by Veith et al.3 The reported incidence of type I 
and II endoleak after EVAR is 8.2-18.0% and 7.8-23.4%, respectively.17-20 Due to 
stent graft improvements, type III and IV endoleaks are currently fairly unusual 
with reported incidence of 0.7-3.8%.17-20 Endotension is defined as persistent or 
recurrent increased intrasac pressure after endovascular aneurysm repair 
without evidence of endoleak.3,21 Endotension remains an important yet 
controversial concept, since its etiology and clinical consequences are not fully 
understood.22 
Since endoleakage may cause aneurysm expansion and ongoing rupture risk, 
modalities in order to identify them are essential in the post-EVAR surveillance. 
Among various imaging modalities, computed tomography angiography (CTA) is 
the most widely used technique for post-EVAR surveillance.13 However, 
magnetic resonance angiography, (contrast enhanced) ultrasonography, digital 
subtraction angiography, plain abdominal X-ray, and possibly also biomarkers 
might all have a role in endoleak detection. 
This review will discuss the strategies for endoleak detection in the follow-up 
after EVAR in terms of imaging techniques and biochemical assays. 
Strategies for surveillance 
CT Angiography 
Contrast-enhanced helical CTA is generally considered the gold standard in the 
follow-up of patients after stent graft implantation.14,16 Improvements in 
contrast injection methods and timing have resulted in superior aortic 
enhancement.23,24 Furthermore, the introduction of multidetector scanners has 
allowed CTA to be performed with a substantial reduction of contrast medium 
dose and scanning duration, and with higher longitudinal spatial resolution.25,26 
Currently, the widespread availability, rapid acquisition, reproducibility, and 
high spatial and contrast resolution of CTA have made this the imaging modality 
of choice for post-EVAR follow-up.27 CTA allows for correct detection and 
classification of endoleaks with higher sensitivity for endoleak detection than 
conventional angiography (92% versus 63%).14,28-30 However, repetitive CTA has 
several important drawbacks, including cumulative radiation dose, nephrotoxic 
contrast load, and high cost.31,32 Furthermore, CTA is inadequate in determining 
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the direction of blood flow in the vessel feeding the endoleak, thereby limiting 
the role for this modality in endoleak classification.27 
Since endoleaks occur at variable flow rates, detection is possible at variable 
times after the administration of contrast. Therefore, multiphasic CTA imaging 
is performed routinely in most institutions. In addition to arterial phase 
acquisition (imaging just after contrast administration), an unenhanced (prior to 
contrast administration) and delayed (post contrast) phase acquisition can be 
acquired. Non-enhanced acquisitions might be useful for differentiation of 
endoleaks from calcifications or the metallic portion of a stent graft.33 Arterial-
phase imaging can be helpful to determine the access site for endoleak 
intervention.27 Delayed CT acquisitions enable the detection of additional 
endoleaks who were not depicted on arterial phase imaging, especially low-flow 
endoleaks.13,28,33,34 However, the optimal timing for detection of low-flow 
endoleaks is unknown since this is (endoleak) flow-rate dependent. Although a 
minimum delay of 1 minute is recommended, the reported delays in literature 
varies widely from 60 to 300 seconds.6 The specific role of nonenhanced, 
arterial and delayed phase acquisition in the detection of endoleaks is 
uncertain. Therefore, the optimal CT image acquisition protocol is still a subject 
of debate.27 Golzarian et al. concluded that the diagnostic value of biphasic 
helical CT (nonenhanced and arterial phase acquisition) is superior to arterial 
phase acquisition alone for follow-up after EVAR.13 In a study of Rozenblit et al. 
the combination of an unenhanced acquisition with either an arterial phase and 
delayed phase acquisition contributed to accurate diagnosis of endoleaks.33 
Iezzie et al. found that the delayed enhanced imaging phase did not significantly 
increase sensitivity for detection of endoleaks, but it did depict low-flow 
endoleaks not seen at the arterial phase.34 Macari et al. on the other hand, 
indicated that the arterial enhanced imaging phase may not be necessary for 
the routine detection of endoleaks and therefore be eliminated from the 
protocol, saving 36.5% of the effective radiation dose delivered.35  
Modern CT techniques, such as the recently introduced dual-energy dual-source 
CT system consisting of two x-ray tubes operating at different tube voltages and 
two corresponding detectors, make it possible to reconstruct virtual 
nonenhanced images from contrast-enhanced dual-energy CT data.36 
Consequently, nonenhanced imaging is made unnecessary, which reduces 
radiation dose. Stolzmann et al. have assessed the diagnostic performance of 
dual-energy dual-source CT for the detection of endoleaks after EVAR and 
found a high accuracy with considerably lower radiation dose.37 Additionally, a 
phantom study of Szucs-Farkas et al. suggests that reduced radiation exposure 
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without increased risk of missing significant endoleaks can also be achieved 
with lower tube-voltage CTA.38 
Not only the optimal CT image acquisition protocol is still controversial, but also 
the ideal frequency of CT(A) follow-up is debatable. The intensive imaging 
follow-up provides a great amount of information, but the relevance of the 
information acquired has not been evaluated in relation to improving results 
obtained with successive generations of stent grafts.39,40 In two recent studies, 
it is suggested that less-frequent CT follow-up is sufficient in the majority of 
patients.41,42 Contrast-enhanced CT scans continue to be critical when re-
interventions are planned.42  
(Contrast‐Enhanced) Color Duplex Ultrasound 
Color duplex ultrasound (US) imaging is convenient, noninvasive, inexpensive, 
widely available, and involves no exposure to radiation. A number of studies 
have indicated that color duplex ultrasound may be used for post-EVAR 
surveillance.43-48 Aneurysm sac size differences over time as assessed with US 
correlate well with CT.43,47,49-51 However, poor agreement in absolute AAA 
diameter was observed.52 When compared to orthogonal CT, US measurements 
agrees better than axial CT measurements, since US measurements are not 
affected by angulation.53,54 Therefore, overall US measurements are reported to 
be slightly smaller than those with axial CT,51,52,55 and might even be a better 
approximation of true perpendicular AAA diameter as determined by 
orthogonal CT compared to axial CT.53,54  
For the detection of endoleaks, color duplex US has reported low sensitivity 
and low positive predictive value compared to conventional CT angio-
graphy.46,50-52,56,57 Reported sensitivity and specificity of US in the detection of 
endoleak varies considerably, from 43% to 97% and 25% to 96%, 
respectively.46,51,52,58 A review of Ashoke et al. showed a pooled sensitivity and 
specificity of 69% and 91%, respectively.56 Manning et al., Raman et al., and 
Sato et al. found low positive and high negative predictive values of 45-66% and 
94-98%, respectively.46,51,58 Despite its low sensitivity and positive predicting 
values, frequent US monitoring might identify an unstable aneurysm that 
requires further intervention.57  
Sonographic contrast agents enhance the capability of color duplex to detect 
endoleaks.45,48,59-63 Iezzi et al. assessed the diagnostic accuracy of real-time 
contrast-enhanced US imaging (CEUS) in the detection of endoleaks compared 
with non-enhanced US imaging in 84 patients. CEUS imaging significantly 
improved the diagnostic accuracy in the detection of endoleaks compared to 
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non-enhanced US studies, in terms of sensitivity (98% vs. 63%), specificity (82% 
vs. 64%), and negative predictive value (97% vs. 65%).45 In a systematic review 
of Sun et al. containing 21 studies, sensitivity in the detection of endoleak was 
significantly improved with contrast material-enhanced color duplex US 
compared with non-enhanced color duplex US.63 However, no significant 
difference was found regarding the specificity, positive predictive value, 
negative predictive value, and accuracy between unenhanced and enhanced 
color duplex US. With recent improvements, such as newly developed contrast 
agents and tissue harmonic imaging,64 diagnostic results will improve and 
contrast-enhanced US might even depict endoleaks when depiction fails in 
other imaging modalities.48,62,65  
Through the use of spectral Doppler analysis, intrasac Doppler velocities and 
Doppler scan waveform patterns can be used to predict whether a type II 
endoleak will spontaneously seal.66,67 Another great advantage of US is that, in 
contrast with CTA, no adverse events, such as nephropathy, have been reported 
for ultrasound contrast agents so far. Limitations for clinical applicability of US 
investigation may be operator-dependent variability, as demonstrated by the 
considerable variation in sensitivity and specificity results. However, a recent 
report showed low inter-operator variability for AAA size measurements.65 
Second, inadequate aneurysm sac visualization is seen in 1.7% of patients, 
predominantly due to patient physical habitus such as obesity.46 In the study of 
Elkouri et al. only 74% of US imaging was considered technically adequate.52,68 
Although US is highly dependent on well trained operators and is subject to 
inter-operator variability, improving diagnostic results of CEUS are promising. 
Magnetic Resonance Angiography 
For aortic diameter measurements magnetic resonance (MR) imaging has 
comparable reliability with CT.69 Nowadays, MR angiography (MRA) with 
intravenous administration of paramagnetic contrast agent is a commonly 
accepted MR technique to evaluate abdominal aorta and its main branches.68 
Several studies comparing CTA with MRA for the detection of endoleaks 
showed that MRA is more sensitive than,69-73 or at least as sensitive as CTA,74-76 
particularly in patients with Type II endoleaks. This might be due to the relative 
higher signal generation from lower concentrations of contrast as present in 
endoleaks. One case report describes a patient with a persistent growing 
aneurysm sac without signs of an endoleak (i.e. endotension) detected by CTA 
follow-up, where additional MRA revealed a type II endoleak which was treated 
percutaneously.77  
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Classification of endoleaks by MRA is better when based on three-dimensional 
contrast-enhanced dynamic and delayed gradient-echo sequences compared to 
nondynamic scans.78 In 1996, the first description of contrast enhanced time-
resolved MRA (TR-MRA) was published, allowing visualization of changes in the 
direction of blood flow over time during an MR examination, analogous to a 
conventional angiogram.79 Lookstein et al.80 and recently Cohen et al.81 
described the initial use of TR-MRA in the characterization of endoleaks and 
compared these results with conventional digital subtraction angiography 
(DSA). Both studies found that TR-MRA allows for a noninvasive and effective 
diagnostic tool for classification of endoleaks following EVAR when compared to 
DSA. Recently, a new non-enhanced sequence has been introduced in clinical 
practice: the true-fast imaging with steady-state precession (true-FISP). This is a 
hybrid high speed T2/T1-weighted acquisition in which anatomy and 
morphology of organs and vessels are imaged with high detail.82 Iozzelli et al. 
demonstrated that true-FISP is a fast (non-breath-hold) and powerful sequence 
for improvements in diagnostic information with good details of abdominal 
arteries when added to a standard MRA.83 Therefore, this imaging technique 
might have a future role in follow-up after EVAR, but further investigation is 
required. Other potential improvements of MRA could be found in the use of 
contrast agents. So far, most studies relied on gadolinium or iodine enhanced 
MR imaging, but excretion and redistribution of these contrast agents into the 
extracellular fluid compartments degrade delayed images restraining low flow 
endoleaks. Ferumoxyto, a blood pool contrast agent, might be a promising 
method for better detection and characterization of small and low flow 
endoleaks, due to permission of acquisition of delayed MR images without 
degradation.70  
Advantages of MR(A) imaging includes the lack of exposure to ionizing radiation 
and low nephrotoxicity of MR contrast medium. However, in a study of Broome 
et al. the development of nephrogenic systemic fibrosis (NSF), a multisystemic 
fibrosing disorder that principally affects the skin but may affect other organs of 
patients with renal insufficiency, was associated with gadolinium administration 
in the setting of dialysis-dependent chronic renal insufficiency and acute 
hepatorenal syndrome.84 However, NFS has never been reported in patients 
with adequate renal function. Furthermore, gadolinium-containing contrast 
agents have different properties that affect their behavior in the body. Contrast 
agents such as Omniscan and OptiMARK that carry no molecular charge and are 
arranged in a linear structure with excess chelate seem to be more likely to 
release free gadolinium ions (Gd3+) into the body. Those that carry a molecular 
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charge and have a linear structure (eg, Magnevist, MultiHance, Primovist, and 
Vasovist), and those that carry no molecular charge and have a cyclical 
structure (eg, Gadovist and ProHance), seem to be less likely to release free 
Gd3+ into the body. Dotarem has a molecular charge and a cyclical structure, 
and is least likely to release free Gd3+ into the body. The exact mechanism by 
which free gadolinium ions that might be deposited in tissues and organs can 
stimulate NSF is unknown, but is thought to trigger fibrosis (formation of fibrous 
tissues). There are a few other limitations of using MR angiography for 
detection and classification of endoleaks after EVAR. Stainless steel devices, 
pacemakers, or coils placed during prior embolization procedures cause 
significant metallic artifacts and risk of malfunctioning, moving and heating of 
the device during MR angiography imaging, whereas stent grafts composed of 
nitinol are generally more suitable for MR imaging.74 However, new 
technologies may enable scanning of pacemaker and ICD patients with reduced 
concerns regarding the short- and long-term effects of MR imaging.85 Other 
limitations are prolonged procedure time compared to CT (angiography), poor 
visualization of vascular calcification and device integrity, and the spatial 
resolution of MR angiography may not be adequate to permit accurate 
classification.81 Other general disadvantages are limited availability, high costs, 
and claustrophobia.  
So far, MRA has both advantages and disadvantages compared to CT-
angiography without exposure to ionizing radiation and with low nephrotoxicity 
of MR contrast medium. Despite limited availability and high costs, MR might 
have a future role in the follow-up after EVAR. 
Plain abdominal X‐ray 
Plain radiographs are considered to be a useful adjunct to CT for detecting 
structural changes in the stent graft, like migration, kinking/deformity, limb 
dislocation, hook and stent fracture, anchor stent separation, and progressive 
dilatation of native vessels.86,87 Graft migration might potentially lead to limb 
kinking as well as proximal Type I endoleaks88 and can be accurately assessed by 
plain abdominal X-ray if a standardized protocol in taking and comparing images 
over time is used as described in the “Liverpool protocol”.89,90 However, plain 
abdominal X-ray cannot be used as a stand-alone imaging modality, as it clearly 
does not assess for changes in the size of the excluded aneurysm sac or for 
presence of endoleak, and therefore does not meet guideline criteria outlined 
by the Society of Interventional Radiology.6 Furthermore, three-dimensional 
postprocessed CTA images can provide equal information,86 in addition to 
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detecting endoleak formation and changes in aneurysm size. Advances in three-
dimensional visualization tools may render plain radiographs redundant, and its 
traditional role as an adjunct examination to CTA should be carefully re-
evaluated.  
Circulating biomarkers 
Several circulating biomarkers have been related to AAA presence, expansion 
and eventual rupture.91-93 These biomarkers represent the pathological changes 
of the aortic wall.94,95 Matrix metalloproteinases (MMP) represent extracellular 
matrix degeneration of the aortic wall and increased circulating levels of MMP 
have been demonstrated in patients with AAA.91 Increased circulating levels of 
MMP-2, -9 and tissue inhibitor of the MMP type-1 (TIMP-1) are associated with 
presence and size of AAA.94 The concept of EVAR is the exclusion of the 
aneurysm sac from the systemic circulation, eventually leading to aneurysm sac 
reduction. Endoleak is associated with continuous sac pressurization, aneurysm 
growth, and increased risk of rupture, i.e. normal AAA natural history. These 
facts have lead to the idea that a postoperative decrease in the levels of 
biomarkers, such as MMP, could represent a simple marker of successful EVAR. 
Conversely, elevations of circulating biomarkers, could serve as a marker of 
persistent sac pressurization or endoleak. Reports on significant decrease in 
circulating levels of MMP-9 after surgical exclusion of AAA,96-99 suggest that 
circulating MMP-9 may provide a biologically relevant marker of successful 
aneurysm repair. In 2001 Sangiorgi et al. were the first to report on the 
usefulness of biomarkers for assessment of the response to EVAR.99 Their well-
designed study resulted in four major findings. First, they found that the 
circulating plasma levels of MMP-3 and -9 were significantly elevated in AAA 
patients compared to healthy controls. Second, they demonstrated a 
continuous decrease in both MMP-3 and -9 after successful EVAR up to 6 
months of follow-up. This decrease was to a similar level to that after surgical 
treatment. Third, they showed that an increase in circulating MMP levels after 
EVAR represents a reliable marker of endoleak. Fourth, after endoleak 
treatment, circulating MMP levels decreased significantly compared with 
6-month pre-treatment values, suggesting a complete AAA exclusion at this 
time. These observations were confirmed by others,97,100 and Monaco et al. 
have shown comparable results in EVAR for thoracic abdominal aneurysms.98 
However, none of these studies reported on diagnostic value of these 
biochemical assays (sensitivity and specificity). Our research group did report 
diagnostic values,101 but a large randomized clinical trial is necessary to 
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ascertain the true diagnostic value of these assays. Hence, to date none of 
these assays are clinically applied.  
Now we can only speculate on the clinical implications of a simple and readily 
available assay. Such an assay would provide evidence of successful EVAR only 
regarding aneurysm sac exclusion. Migration, kinking or other complications not 
(yet) leading to aneurysm sac pressurization would not be detected by this 
assay. This suggests that the assay should be supplemented by a type of 
imaging that provides information on stent graft integrity and location.  
Two studies have reported on the additional effects of pharmacotherapeutical 
agents on levels of circulating biomarkers after EVAR. A randomized, placebo 
controlled, trial of Hackmann et al. showed that doxycycline (a MMP inhibitor) 
significantly decreased plasma levels of MMP-9 in the treatment group at 
6 months.100 Nakamura et al. compared plasma levels of MMP-9 at 1 and 
3 months after EVAR between patients receiving Azelnidipine (a calcium 
channel blocker) and controls.102 Patients with endoleak showed no significant 
decrease in plasma levels of MMP-9 at 1 and 3 months follow-up. In patients 
without endoleak Azelnidipine treatment after EVAR was associated with a 
significant decrease in mean plasma MMP-9. 
Necessity of surveillance for endoleaks 
Sternbergh et al. reported that absence of endoleak at short-term follow-up 
greatly predicts the future development of an endoleak.103 Based on this early 
outcome they have recommended a new EVAR follow-up regimen that 
modulates the intensity and frequency of postoperative imaging. In patients 
without early endoleak, the 6-month surveillance is eliminated, and aortic US is 
suggested for long-term surveillance >1 year. They suggest that in most 
patients, this reduced follow-up regimen would be appropriate and could 
improve patient safety by reducing the cumulative deleterious effects of 
intravenous contrast and radiation exposure while also reducing health care 
costs. 
In addition, Houbballah et al. reported that significant sac retraction after EVAR 
was accurately predictive of durable success with better survival, decreased 
frequency of endoleaks, and lower secondary reintervention rates.2 Therefore, 
less intensive follow-up seems to be safe in these patients. Contrary, Schlösser 
et al. recently identified 270 ruptures detailed in the literature with a mean 
time to rupture of 24±18 months.104 In 35 patients imaging surveillance showed 
no prior abnormalities in terms of history of endoleak, migration or sac 
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enlargement during follow-up. These findings showed that even benign findings 
do not nullify the possibility of late rupture and emphasize the importance of 
close patient follow-up. However, data used in their study was collected from 
various reports without re-evaluation of CTA scans by an independent reviewer. 
Type I and III endoleaks are significantly related to a high risk of aneurysmal 
rupture, and it is therefore a general consensus that these should be treated 
when discovered.19,105  
Type II endoleaks are the most common endoleak and occur in 20% to 30% of 
patients following EVAR.106,107 The presence of a type II endoleak during EVAR 
significantly increases the likelihood of a postoperative endoleak and should 
prompt a high degree of suspicion during follow-up.108 However, long-term 
significance of type II endoleaks is still subject to debate, since contrary results 
have been published. In a report of Silverberg et al. approximately 75% of type 
II endoleaks sealed spontaneously within a 5-year period.109 Most investigators 
advocate a more conservative approach, due to both very low incidence of 
aneurysm rupture associated with type II endoleaks and lower costs of 
sequential radiographic follow-up compared to early reintervention.3,26,110 
Adversely, Jones et al. reported that persistent type II endoleak is associated 
with an increased incidence of adverse outcomes, including aneurysm sac 
growth, the need for conversion to open repair, reintervention rate, and 
rupture.106 
The optimal follow-up regimens and techniques have not yet been defined. 
Current lifelong surveillance after EVAR is not only due to potential aneurysm-
related complications but also lack of data on long-term endograft durability. 
Discussion 
EVAR has reduced perioperative mortality compared with open repair, but is 
associated with a higher rate of subsequent reinterventions.111-113 
Consequently, long-term follow-up after EVAR is considered mandatory to 
identify patients requiring reintervention. However, the reported reintervention 
rate is lower in contemporary EVAR series,103, 114 reflecting the improvements in 
stent graft design and the adoption of a more conservative approach to type II 
endoleaks.  
In order to minimize the need for early secondary reinterventions following 
EVAR, introduction of intraoperative imaging modalities allowing for immediate 
treatment of significant stent-related complications might have a future role. 
Kopp et al. showed that intraoperative CEUS-assisted EVAR represents a new 
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intraoperative visualization option for proximal or distal fixation zones and 
identified more endoleaks in comparison to conventional EVAR using 
intraoperative iodine-based contrast angiography. In one symptomatic patient, 
proximal stent graft extension was required based on a type Ia endoleak that 
was only identified by intraoperative CEUS.115 Intraoperative CTA (DynaCT) is 
able to generate CT like images from rotational angiographic acquisitions and is 
feasible of imaging the aortic aneurysm during elective EVAR successfully.116 
The clinical application for DynaCT in detecting intraoperative device-related 
anomalies is reported by Biasi et al. by detecting and immediately treating a 
type Ia endoleak which was not seen on completion angiography.117 Future 
studies will clarify the role of these intraoperative imaging modalities and 
whether perioperative incidence of secondary reinterventions will be reduced. 
The present report discusses the strategies for endoleak detection in the follow-
up after EVAR in terms of imaging techniques and biochemical assays. CTA 
follow-up after EVAR is considered the gold standard, with high sensitivity for 
endoleak detection combined with widespread availability, rapid acquisition 
and reproducibility.27 However, cumulative radiation dose and nephrotoxic 
contrast agent underline the importance of upcoming alternative imaging 
modalities. Although operator- and patient-dependent, CEUS is excellent for 
monitoring the evolution of the aneurysm sac during follow-up without 
disadvantages of radiation dose and the use of nephrotoxic contrast agent. It 
captures a significant majority of endoleaks and this sensitivity is likely 
underestimated by comparing it against CT as the reference standard. Some 
true endoleaks depicted by CEUS will be categorized as “false positives” 
because they were not visualized by CT.65,118 MR imaging in the follow-up after 
EVAR has its limitations such as unsuitability in a number of patients, limited 
availability, and high costs. However, with increasing availability and improving 
technologies for i.e. pacemaker suitability, MR access is expanding.85 Evolving 
MR techniques are able to detect and classify endoleaks with increasing 
sensitivity and specificity, reserving a potential prominent role in future post-
EVAR follow-up. Plain abdominal X-ray is considered to be a useful adjunct to CT 
for detecting structural stent changes, but it does not assess for aneurysm sac 
size changes or for presence of endoleak.6 In 2001 Sangiorgi et al. reported on 
the usefulness of biomarkers for assessment of the response to EVAR.119 They 
found decreased circulating plasma levels of MMP-3 and -9 after successful 
EVAR and increased levels after endoleak presence. Plasma MMP-9 levels 
appear to discriminate between patient with and without an endoleak with 
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both high sensitivity and specificity.101 However, a large randomized clinical trial 
is necessary to ascertain the true diagnostic value of these assays. 
 
In conclusion, US and MR imaging are promising modalities for detection and 
classification of endoleaks after EVAR without radiation exposure and 
nephrotoxic contrast load. Based on present studies, true recommendations for 
ideal follow-up after EVAR cannot be made. Continuing technical improvements 
and future prospective comparative research might eventually lead to an 
imaging modality other than CTA as the gold standard in the follow-up of 
patients after stent graft implantation. Furthermore, a prospective clinical trial 
is necessary to validate the clinical applicability of circulating biomarkers in 
selecting patients for imaging. 
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Abstract 
Objective 
The aim of this study was to compare the diagnostic accuracy between contrast-
enhanced ultrasound and computed tomographic angiography (CTA) to detect changes 
in abdominal aortic aneurysm (AAA) size and endoleaks during follow-up after 
endovascular aneurysm repair (EVAR). 
Materials and Methods 
Between May 2006 and December 2008, 83 patients were consecutively enrolled for 
contrast-enhanced ultrasound and CTA imaging during surveillance after EVAR, yielding 
127 paired examinations. Comparative analysis was performed for the anteroposterior 
and transverse maximal diameters of the aneurysm sac, and for the presence or absence 
of endoleak, as determined by ultrasound and CTA.   
Results 
Contrast-enhanced ultrasound demonstrated significantly more endoleaks, pre-
dominantly type II, as compared with CTA (53% vs. 22% of cases). The number of 
observed agreements was 77/127 (61%), indicating a low level of agreement (κ = 0.237). 
Ultrasound was as accurate as CTA in the assessment of maximal aneurysm sac 
diameters, as shown by Bland-Altman analyses and low coefficients of variation (8.0% 
and 8.6% respectively). The interobserver variability for AAA size measurement by 
ultrasound was low, given the interclass correlation coefficients of 0.99 and 0.98 for 
anteroposterior and transverse maximal diameters, respectively. 
Conclusion 
This study shows that contrast-enhanced ultrasound may be an alternative to CTA in the 
follow-up of patients after EVAR. Since ultrasound reduces exposure to the biological 
hazards associated with lifelong annual CTA, including cumulative radiation dose and 
nephrotoxic contrast load, contrast-enhanced ultrasound might be considered as a 
substitute to CTA in the surveillance of patients after EVAR. 
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Introduction 
Endovascular aortic aneurysm repair (EVAR) is a less invasive alternative to 
open surgical repair in selected patients with abdominal aortic aneurysms 
(AAA). As elegantly demonstrated, EVAR has an initial postoperative benefit 
over open AAA repair due to decreased early morbidity and mortality.1-3 
However, as is shown in the EVAR trial 1, stent graft related complications are 
observed in approximately 40% of patients by 4 years after EVAR, resulting in a 
20% reintervention rate to reduce the ongoing rupture risk.1 Long-term imaging 
surveillance of patients is required to detect stent graft related complications, 
including aneurysm growth, endoleak, migration, and kinking after EVAR.4 
Among various imaging modalities, computed tomographic angiography (CTA) is 
the most widely used technique for post-EVAR surveillance.5 However, 
repetitive CTA has several important drawbacks, including cumulative radiation 
dose, nephrotoxic contrast load, and high cost.6  
A number of studies have indicated that color Duplex ultrasound may be used 
for post-EVAR surveillance.7-10 Noncontrast-enhanced ultrasound correlates 
with CTA in determining change in AAA sac size over time, but has low 
sensitivity and positive predictive value in endoleak detection compared to 
conventional CTA.9,11-13 Sonographic contrast agents enhance the capability of 
color duplex to detect endoleaks.14-18 Second-generation sonographic contrast 
agents consist of stabilized microbubbles of sulphur hexafluoride gas, which is 
eliminated through the respiratory system, surrounded by a phospholipid-shell. 
These microbubbles improve blood flow echogenicity by resonating with low-
intensity ultrasound, which enhances backscatter and thereby increases the 
detected signal.19 Bubble destruction during imaging is minimized, allowing 
real-time scanning for several minutes.17,20 No adverse events, such as 
nephropathy, have been reported for ultrasound contrast agents. The clinical 
applicability of ultrasound investigation may be limited by operator-dependent 
variability as well as by patient-related limitations such as obesity. The aim of 
the present study was to investigate the accuracy of contrast-enhanced 
ultrasound as an alternative to CTA in the follow-up of patients after EVAR with 
regard to detection of endoleaks and changes in AAA dimensions. 
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Materials and Methods 
Patients 
Patients who underwent endovascular repair for infrarenal AAA after April 2001 
were consecutively enrolled for dual modality post-EVAR imaging surveillance 
between May 2006 and December 2008 in a non-academic teaching hospital. 
All patients were treated in the department of vascular surgery with a 
commercially available endovascular graft (Talent, Medtronic, Minneapolis, MN, 
USA). The routine surveillance regimen consisted of an intravenous contrast-
enhanced CT scan at 3 and 12 months post-procedure and yearly thereafter. 
During the study period, contrast-enhanced ultrasound examinations were 
added to this regimen. Data were prospectively collected in this consecutive 
series of participants. Patients who could not undergo CTA due to severe 
iodinated contrast allergy or severe renal insufficiency were excluded from 
participation. There were no exclusion criteria for contrast-enhanced 
ultrasound examination. The study was approved by the institutional ethics 
committee and informed consent was obtained prior to enrollment.  
CTA 
Triple-phase (unenhanced, and contrast-enhanced in arterial and delayed 
phases) CT angiography was performed from the diaphragm to the common 
femoral arteries after continuous intravenous administration of iodinated 
contrast agent (Xenetix® 300, Guerbet, Cedex, France). Diluted contrast solution 
was obtained by mixing 120 ml contrast with 30 ml saline, and was 
administered with a flow rate of 4 ml/s. A multidetector 16 slice spiral CT 
scanner (Somaton sensation; Siemens, Forccheim, Germany) was used with the 
following parameters: high-speed mode capability, rotation time 0.5 seconds, 
table speed 24 mm per rotation, collimation 1.5 mm, and a slice thickness of 
3 mm. Images were acquired in both the arterial phase, triggered by contrast 
passing the aorta, and the delayed phase 70 seconds after intravenous contrast 
medium injection. Patients with mild iodinated contrast allergy or renal 
insufficiency were prepared for CTA according to the guidelines of the Dutch 
Institute for Healthcare Improvement.21 Patients with a history of iodinated 
contrast allergy received oral corticosteroids and antihistamines prior to CTA. 
Preparation for patients with renal insufficiency consisted of intravenous 
hydration and oral acetylcysteine before and after the CTA.   
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Contrast‐enhanced ultrasound  
Ultrasound investigation was performed with an abdominal 3.5 MHz curved 
array transducer (Biomedic, Aloka SSD-5000). The examinations were 
performed by three well-trained vascular technicians dedicated to ultrasound 
imaging, who were blinded to the results of each other as well as to CTA. 
Patients were instructed to fast in the morning of the contrast-enhanced 
ultrasound investigation. The abdominal aorta was scanned from the diaphragm 
to below the iliac limb attachment sites in long-axis and cross-sectional views in 
supine position through an anterior approach. First, standard noncontrast-
enhanced B-mode ultrasound investigation with grey-scale and color Duplex 
were performed for measurement of aneurysm sac diameter. Next, diluted 
sonographic contrast solution was administered by continuous intravenous 
infusion (240 ml/h) for a period of 15 minutes. Sonographic contrast solution 
was obtained by mixing 5 ml SonoVue® (Bracco, Milan, Italy) containing 8 µl 
sulfur hexafluoride microbubbles per mL with 55 ml saline. Continuous real-
time tissue harmonic imaging for endoleak detection was performed for 
15 minutes during sonographic contrast agent infusion at a mechanical index of 
0.4-0.5 and at low acoustic power.  
Parameters 
Both imaging techniques were used to determine anteroposterior maximal 
diameter and transverse maximal diameter of the aneurysm sac, as well as to 
assess the presence or absence of an endoleak. All diameters were measured 
outer wall to outer wall on both CTA and contrast-enhanced ultrasound. 
Endoleak was defined as the presence of persistent intrasac flow outside the 
graft.22 An endoleak on CTA was defined as contrast enhancement outside the 
endograft within the aneurysm sac in the arterial and/or venous phase. An 
endoleak was identified on contrast-enhanced ultrasound by flow and spectral 
signals within the aneurysm sac during infusion of sonographic contrast agent. 
Endoleaks were classified as type IA/B, II, III, or IV.23,24 AAA diameter 
measurements and endoleak assessment on CTA were performed by the two 
principal investigators (J.T.B., E.R.), blinded to the results of contrast-enhanced 
ultrasound and to each other. As for contrast-enhanced ultrasound, each of the 
three vascular technicians independently measured AAA sac diameters and 
reported the presence or absence of endoleak at the end of each contrast-
enhanced ultrasound examination, blinded to the results of CTA. AAA 
dimensions on contrast-enhanced ultrasound were recorded as the means of 
the three 3 measurements. 
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Statistics  
Comparisons of aneurysm size measurements between CTA and contrast-
enhanced ultrasound were performed by Bland-Altman plots25 and by 
calculating the coefficients of variation. The coefficient of variation, expressed 
as a percentage, was determined by dividing the standard deviation of the 
differences between the two measurements by the mean of the averages for 
the study population. Interobserver variability for AAA size measurement by 
contrast-enhanced ultrasound was determined by calculating the interclass 
correlation coefficient for absolute agreement. To determine the level of 
agreement between CTA and contrast-enhanced ultrasound for identifying 
endoleaks, kappa was calculated. A McNemar chi square test was performed to 
identify differential endoleak detection by the two imaging modalities. 
Continuous data were reported as mean and 95% confidence interval (CI), 
unless stated otherwise, whereas categorical data were reported as frequencies 
or percentages. Statistical significance was defined as P<0.05. Statistical analysis 
was performed with SPSS version 15.0 for Windows. 
Results 
Between May 2006 and December 2008, a total number of 113 patients 
presented at the outpatient clinic of our non-academic teaching hospital for 
imaging surveillance after EVAR. Seven of these patients were excluded from 
participation in the study because of severe iodinated contrast allergy (n=3) or 
severe renal insufficiency (n=4), which precluded CTA. The remaining 106 
patients who were eligible for the study were prospectively enrolled for dual 
modality imaging after consent. Overall, 62 out of 189 potential paired 
examinations were excluded from comparative analysis for one of the following 
reasons: time interval between CTA and ultrasound examinations exceeding 30 
days as a consequence of logistic problems (n=53), failure to perform 
ultrasound due to obesity (n=2) or bowel gas (n=1), failure to receive CTA due 
to study protocol violation (n=6). Overall, 127 out of 189 potential paired 
examinations in 83 patients were available for comparative analysis. Mean age 
at the time of EVAR was 71±9 (SD) years; 92% of patients were male (n=76). 
Devices used for EVAR were 16 aorto-uni-iliac endografts and 67 bifurcated 
endografts. The median number of follow-up evaluations was 1 (interquartile 
range 1-2) with a maximum of 3 over a period ranging from 1 to 77 months 
after EVAR (mean 19 months). The median interval between examinations was 
0 days (interquartile range 0-2).  
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Diameter 
The agreement between anteroposterior and transverse maximal diameter 
measurements by CTA and contrast-enhanced ultrasound was visualized in 
Bland-Altman plots (Figures 8.1A and 8.1B). These plots depict the difference 
between the CTA and contrast-enhanced ultrasound diameter measurements in 
relation to the average diameter as determined by the two imaging modalities. 
As shown by the Bland-Altman plots there was good correspondence in both 
anteroposterior and transverse maximal diameters as determined by the two 
imaging modalities. The mean difference in AAA sac diameters as measured by 
CTA and contrast-enhanced ultrasound was 3.2 mm (95% CI –5.8–12.3) for 
anteroposterior and 4.1 mm (95% CI -6.4–14.6) for transverse maximal 
diameters, both in favor of CTA. The good agreement between the two 
methods was confirmed by a coefficient of variation of 8.0% and 8.6% for 
anteroposterior and transverse maximal diameters, respectively. The interclass 
correlation coefficient for absolute agreement with respect to AAA size 
measurement using contrast-enhanced ultrasound was 0.993 (95% CI 0.989-
0.996) for the anteroposterior and 0.984 (95% CI 0.974-0.991) for the 
transverse maximal diameter, indicating low interobserver variability between 
the three vascular technicians.  
Endoleak 
Comparison of endoleak detection between CTA and contrast-enhanced 
ultrasound is displayed in Table 8.1. Endoleak was detected by CTA in 22% 
(27/127) and by contrast-enhanced ultrasound in 53% (67/127) of successful 
cases. The number of observed agreements was 77/127 (61%) with a number of 
agreements expected by chance of 61 (48%). The strength of agreement was 
considered to be low (kappa=0.237, 95% CI 0.072-0.402). In 45 cases an 
endoleak was visualized by ultrasound but not by CTA, whereas in 5 cases an 
endoleak was detected by CTA but not by ultrasound. The differential detection 
of endoleaks by the two imaging modalities was confirmed by the McNemar chi 
square value (P<0.001).  
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Figure 8.1 A. Bland-Altman plot of the anteroposterior maximal diameter. B. Bland-Altman plot 
of the transverse maximal diameter. Note that 2 data points are outside the axis 
limits. 
 CEUS=contrast-enhanced ultrasound. 
 
 
Table 8.1 Endoleak detection by contrast-enhanced ultrasound (CEUS) and CTA. Data are 
presented as number of cases. 
CTA  
CEUS Yes No Total 
Yes 22   45   67 
No   5   55   60 
Total 27 100 127 
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Detection of different types of endoleaks by contrast-enhanced ultrasound and 
CTA is listed in Table 8.2. The majority of the endoleaks were type II (Figure 8.2), 
however, contrast-enhanced ultrasound also detected two additional type I 
endoleaks. No type III or IV were detected in this study population by either CTA 
or contrast-enhanced ultrasound. 
 
Table 8.2 Classification of endoleaks as detected by contrast-enhanced ultrasound and CTA. 
Data are presented as number of cases. 
Endoleak Contrast‐enhanced ultrasound CTA 
No 60 100 
Yes 67   27 
Type I   3     1 
Type II 64   26 
Type III   0     0 
Type IV   0     0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Clear type II endoleak (arrow) in arterial phase of CTA. 
 
 
To exclude a potential bias in favor of contrast-enhanced ultrasound due to 
repetitive yearly examinations in the same patient, statistical analysis was 
subsequently performed for the first paired examination in all 83 patients. This 
analysis revealed a similar endoleak detection rate of 20% (17/83) by CTA and 
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of 47% (39/83) by contrast-enhanced ultrasound. The number of observed 
agreements was 51/83 (61%) with a number of agreements expected by chance 
of 43 (52%). The strength of agreement in these 83 paired examinations was 
comparable to that of the complete group of 127 paired examinations 
(kappa=0.200, 95% CI -0.017-0.418). These results indicate that there is no 
potential bias in favor of contrast-enhanced ultrasound due to repetitive 
examinations. 
Discussion 
Contrast-enhanced CT is generally considered the gold standard in the follow-
up of patients after stent graft implantation.26 However, the lifelong 
requirement for patient surveillance accentuates certain drawbacks of CTA, 
including ionizing radiation burden and nephrotoxic contrast load. Contrast-
enhanced Duplex ultrasound requires neither ionizing radiation nor nephrotoxic 
contrast. The present study suggests that contrast-enhanced Duplex ultrasound 
may be a diagnostic alternative to CTA in the follow-up of patients after 
endovascular aneurysm repair. The criteria developed by the Standards for 
Reporting of Diagnostic Accuracy (STARD) steering group were used to report 
this study of diagnostic accuracy.27  
Accurate measurement of AAA dimensions in the follow-up after EVAR is 
essential in order to identify either shrinkage or growth of the aneurysm sac 
and assists in defining the success or failure, respectively, of aneurysm 
exclusion. In the present study, Bland-Altman analyses of aneurysm sac 
diameters demonstrated good agreement between ultrasound and CTA. In 
support of this, the coefficients of variation for the anteroposterior and 
transverse diameters of the aneurysm sac as measured by the two imaging 
modalities were less than 10%, which is generally regarded as acceptable 
accuracy for diagnostic tests.  
The present study shows a large discrepancy between CTA and contrast-
enhanced ultrasound with regard to detection of endoleaks. In 20% of cases an 
endoleak was detected with CTA in our study, which corresponds to previous 
reported rates of CT-detected endoleakage.16 The significantly higher rate of 
endoleak detection with contrast-enhanced ultrasound may be explained by the 
continuous dynamical real-time contrast-enhanced scanning for 15 minutes in 
contrast with CTA showing two (arterial and delayed phase) static temporal 
angiographic images.28  
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The majority of additional endoleaks identified by contrast-enhanced 
ultrasound were type II, the importance of which is still subject of debate.29 
However, ultrasound also revealed two extra type I endoleaks. The detection of 
an endoleak by contrast-enhanced ultrasound that was not visualized by CTA 
resulted in an intervention in 2 out of 45 cases, including coiling of the internal 
iliac artery in one patient and aortic banding of the proximal aneurysm neck in 
the other. In the latter case, CTA showed a significant increase in aneurysm sac 
size of >5 mm, in spite of the absence of a demonstrable endoleak. Although 
this is traditionally classified as a type V endoleak, or endotension, an endoleak 
was clearly depicted on contrast-enhanced ultrasound (Figure 8.3). Thus, 
endotension may not necessarily be a separate entity, but the mere effect of 
inadequate imaging, which may be improved by contrast-enhanced 
ultrasound.17  
Only in 5 cases, ultrasound did not reveal an endoleak that was detected by 
CTA, which might be classified as false-negative ultrasound results. In these 
cases no aneurysm sac growth was observed and no interventions were 
needed. Given the lack of a gold standard, is it not possible to compare 
sensitivities and specificities for endoleak detection between contrast-
enhanced ultrasound and CTA. We suggest that endoleaks detected by one or 
the other imaging modality should be considered as real endoleaks. Based on 
this assumption, the number of endoleaks detected by contrast-enhanced 
ultrasound greatly outweighs CTA.  
The use of ultrasound as the preferred imaging modality in the follow-up of 
patients can reduce the biological hazards associated with CTA.19 First, the EVAR 
procedure and lifelong annual CT follow-up carry a substantial ionizing radiation 
burden. Patients receive a total effective dose of about 60 mSv within the first 
year of EVAR, taking into account both procedure-related fluoroscopy and 
follow-up CT angiographies.30 The mean effective dose of CTA for EVAR follow-
up results is approximately 15 mSv. The stochastic risk of a fatal radiation-
induced tumor is estimated to be 5%/Sv radiation. Thus, the risk of cancer 
induction of one CTA is about 1 in 1500,31 indicating the relevance of reliable 
alternatives to annual CTA for post-EVAR follow-up, particularly in younger 
patients. Second, CTA requires the administration of iodinated contrast agents, 
which are associated with nephrotoxic effects.32 Renal dysfunction is a 
comorbidity found in 80% of aneurysm patients, and is the most important risk 
factor for contrast-induced nephrotoxicity.32,33 Since no major side effects, 
including nephrotoxic effects, have been reported for ultrasound contrast 
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agents, this favors the use of contrast-enhanced ultrasound for post-EVAR 
follow-up.  
In general, ultrasound examinations may carry a number of well-known 
limitations. First, operator dependency might limit reproducibility of the results. 
It is clearly true that assessment of a CT scan is less operator dependent. 
However, as indicated by the interobserver analysis in the present study, 
variability in AAA sac dimensions as measured by contrast-enhanced ultrasound 
was low when performed by well-trained vascular technicians. Unfortunately, 
interobserver variability for endoleak detection by contrast-enhanced 
ultrasound could not be assessed since this would require repetitive 
sonographic contrast agent infusions. Second, patient habitus may interfere 
with ultrasound imaging. However, in the present study contrast-enhanced 
ultrasound was unsuccessful in only 3 out of 130 cases (2%), due to patients’ 
obesity (n=2) or bowel gas (n=1). A potential drawback of contrast-enhanced 
ultrasound is the inability to detect kinking and migration of the stent graft. 
Plain abdominal radiography may be used for the detection of graft migration 
and structural failure.34,35 In addition, sonographic contrast agents are not 
worldwide available yet, which may limit the applicability of contrast-enhanced 
ultrasound techniques. 
The long-term outcome of endovascular repair is yet unknown. A recent 
retrospective analysis of AAA ruptures following EVAR showed that most 
ruptures occur within the first 3 year after the procedure, with a mortality rate 
of 60%.36 Although AAA rupture occurred even if no predisposing abnormalities 
were present, the majority of these ruptures were preceded by endoleaks. 
Strikingly, in only 35% of the patients endoleaks were detected before rupture, 
i.e. during regular follow-up. These findings underline the importance of a 
sensitive and reliable post-EVAR follow-up regimen to reduce the AAA rupture 
rate. 
In line with recent reports,7-10 the results of the current study support the 
notion that contrast-enhanced ultrasound may be equivalent to CTA for the 
assessment of aneurysm sac dimensions and the detection of endoleaks. Since 
ultrasound precludes the risks of contrast-induced nephropathy and ionizing 
radiation load, contrast-enhanced ultrasound might be considered as a 
substitute to CTA as the primary imaging modality in the surveillance of patients 
after EVAR in those patients who are suitable for abdominal/pelvic US and 
when highly trained ultrasound operators are available. 
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Figure 8.3 Contrast-enhanced ultrasound demonstrating two type II endoleaks (arrows), which 
were not detected by CTA. 
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Abstract 
Objective  
Identification of endoleakage by a blood test with high sensitivity could spare 
endovascular aortic aneurysm repair (EVAR) patients to undergo repetitive computed 
tomography angiography (CTA). Our objective was to evaluate the value of plasma levels 
of matrix metalloproteinase (MMP)-2, -9, and tissue inhibitor of MMP-1 (TIMP-1) as a 
diagnostic tool to discriminate between patients with and without endoleak. 
Materials and Methods  
Consecutive patients (n=17) who visited the outpatients clinics of two Dutch medical 
centers and who had an endoleak present on post-EVAR CTA surveillance between 
January and July 2008 were prospectively enrolled in the study. Controls (n=20) were 
EVAR patients without endoleak on CTA, frequency matched for age and gender. Plasma 
levels of MMP- 2, -9 and TIMP-1 were determined in duplicate. Main outcome measures 
were sensitivity and specificity for different biomarker plasma concentration cut-off 
points. 
Results  
Increased levels of MMP-9 were observed in patients with an endoleak (P<0.001) 
compared to patients without endoleak. The ROC curve of plasma MMP-9 levels showed 
that a cut-off value of 55.18 ng/ml resulted in 100% sensitivity and 96% specificity. The 
AUC was 0.988 (P<0.001). 
Conclusions  
The present study shows that plasma levels of MMP-9 can accurately discriminate 
between patients with and without an endoleak with both high sensitivity and 
specificity. 
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Introduction 
Endovascular aortic aneurysm repair (EVAR) is a safe and effective method to 
treat patients with suitable abdominal aortic aneurysm (AAA).1 Compared to 
conventional open aortic aneurysm repair, EVAR has decreased early mortality 
and length of hospital stay.2,3 However, during 4 years of follow up stent graft 
related complications have been observed in approximately 40% of patients, 
resulting in a 20% reintervention rate.4 Therefore, long term imaging 
surveillance is required for detection of stent graft related complications, 
including migration, kinking, and endoleakage.  
EVAR excludes the AAA from the circulation but the AAA sac is left in situ. A 
minority of cases show persistent flow in the aneurysm sac due to endoleak.5 
Endoleak is the most common complication of EVAR with a reported incidence 
varying from 2 to 45%.1,6-9 Endoleak is clinically important since it may cause 
enlargement with eventually rupture of the aneurysm sac. Hence, 
reinterventions are frequently required. Computed tomography angiography 
(CTA) is considered the gold standard for detection of these graft related 
complications in the follow-up of patients after EVAR.9,10 The European 
Collaborators on Stent/Graft Techniques for Aortic Aneurysm Repair 
(EUROSTAR) Registry recommends a CTA surveillance regime scheduled at 3, 6 
and 12 months and subsequently yearly thereafter.11 However, repetitive CTA 
has known disadvantages such as cumulative radiation dose, nephrotoxic 
contrast agent and high costs.12 Therefore, a less harmful and less costly 
alternative for follow-up after EVAR is desirable. Previous investigations have 
focused on biochemical assays and alternative imaging modalities such as 
(contrast-enhanced) ultrasonography ((CE)US) and magnetic resonance 
angiography (MRA).13-15 Increased circulating plasma levels of matrix 
metalloproteinase (MMP)-2, -9 and tissue inhibitor of MMP-1 (TIMP-1) are 
associated with presence and size of AAA.16-18 Sangiorgi et al. were the first to 
report that a decrease of plasma MMP-3 and MMP-9 during post EVAR 
surveillance indicates successful EVAR and that an increase in MMP 
concentration after EVAR may help to identify patients with aneurysm sac 
growth and/or endoleakage.19 These observations were confirmed by 
others.20,21 However, none of these studies reported on diagnostic value of 
these biochemical assays (sensitivity and specificity). Hence, to date none of 
these assays are clinically applied. The objective of this study was to evaluate 
the potential clinical applicability of MMP-2, -9, and TIMP-1 as a diagnostic tool 
for presence of endoleakage. 
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Materials and Methods 
Patients 
At the Maastricht University Medical Center (Maastricht, the Netherlands) and 
the Atrium Medical Center (Heerlen, the Netherlands) surveillance after 
endovascular AAA repair consisted of CTA scheduled at 1 month, 6 months, and 
yearly thereafter. All consecutive patients who visited the vascular outpatients 
clinic of the participating centers between January 1st and July 1st 2008 with 
endoleak present on CTA were prospectively enrolled in the study. Controls 
were EVAR patients without endoleak on CTA, frequency matched for age and 
gender. EVAR procedures were performed between May 1st 2006 and August 1st 
2008. Mean follow-up time was 15 months. After patients provided written 
informed consent, blood samples for assessment of biochemical assays were 
collected within a week after CTA imaging. Cardiovascular risk factors as well as 
smoking history and drug use were recorded. The study was approved by both 
institutional ethics committees and the patients gave informed consent. 
Blood collection 
Venous blood was drawn via an antecubital vein puncture and collected in EDTA 
buffered (K2E 7.2 mg) vacutainer® for plasma. Exactly thirty minutes after 
collection, blood was centrifuged (15 minutes, 3000g, 4°C) and multiple aliquots 
were stored at -80°C pending analysis. As demonstrated by others, 
concentration and activity of MMP is stable during long term storage at –80°C.22 
Assays 
Plasma levels of MMP- 2, -9 and TIMP-1 were determined by means of a 
commercially available enzyme linked immunosorbent assay (GE Health-
care/lifesciences, Upssala, Sweden) according to the manufacturer’s guidelines 
and were determined in duplicate. Duplicates with less than 10% within assay 
variation in concentration were accepted and means were determined for 
further analysis.  
The between-assay variation (7% for MMP-2, 10% for both MMP-9 and TIMP-1) 
was determined by the manufacturer. 
Imaging 
During follow-up after EVAR, CTA was performed by a multidetector 16 slice 
helical CT scanner. CT scanning was performed with an in-plane resolution of 
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512x512 pixels and a slice-thickness of either 1 or 3 mm, due to the use of 
different protocols in the two hospitals. Scanning occurred from the diaphragm 
to the common femoral arteries after continuous intravenous administration of 
iodinated contrast agent (Xenetix® 300, Guerbet, Cedex, France). Images were 
either acquired as a native CT scan followed by an a arterial phase scan, 
triggered by contrast passing the aorta, or by arterial phase followed by a 
delayed phase after 30 seconds. Maximal anterior-posterior diameter (Dmax) of 
the aneurysm sac was determined and presence of endoleak, migration, and 
component separation was assessed.  
Statistical analysis 
Statistical analyses were performed by means of SPSS 15.0 software. The 
characteristics of patients with or without endoleak were compared with 
Pearson Chi-Squared or Fisher’s Exact test for nominal variables and Mann-
Whitney U test for continuous variables. The ability of plasma MMP-2, -9, and 
TIMP-1 to distinguish patients with an endoleak from patients without endoleak 
was investigated using receiver operating characteristic (ROC) curve and area 
under the curve (AUC). In a ROC curve the true positive rate (sensitivity) is 
plotted in function of the false positive rate (100-specificity) for different cut-off 
points.23 Our objective was to identify a cut-off value related to high sensitivity 
in order to reduce the risk of false negative results. 
Results 
Patients 
Thirty-seven patients were included in the study. Seventeen patients had an 
endoleak as detected on CTA, which included 4 type I, 12 type II and 1 type III 
endoleaks. Four of the patients’ endoleaks were primary and were present at 
the completion angiography of the original EVAR operation. The demographic 
and clinical characteristics of patients with and without endoleak are listed in 
Table 9.1. The maximal AAA diameter was higher among patients who 
presented with an endoleak. 
Assays 
Mean plasma levels of MMP-2, -9, and TIMP-1 are listed in Table 9.2. Plasma 
levels of MMP-2 and TIMP-1 did not differ significantly for patients with 
endoleak compared to patients without endoleak. On the other hand, an 
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increased concentration of MMP-9 was observed in patients with an endoleak 
(P<0.001) (Figure 9.1), as compared to patients without endoleak.  
 
Table 9.1 Patient and aneurysm characteristics. 
 Endoleak – 
(n=20) 
Endoleak + 
(n=17) 
P‐value 
Male gender (%)  19 (95)  16 (94) ns 
Age - years (mean (SD))  74 (9.5)  73 (7.0) ns 
Smoking history (%)   20 (100)   17 (100) ns 
      Current smokers (%)    5 (25)  4 (24)  
      Ex smokers (%)  15 (75)  13 (76)  
Statin use (%)    7 (35)  11 (65) ns 
Months between EVAR and CTA (mean (SD))  18 (15)  21 (15) ns 
Maximal AP AAA diameter – mm (mean (SD))  57 (17)  72 (19) 0.038 
Right introduction of main device (%)  18 (90)   17 (100) ns 
Neck diameter – mm (mean (SD))   24 (4.2)  24 (3.7) ns 
Neck length – mm (mean (SD))  35 (14)  37 (16) ns 
Unfavorable angulation of neck (%)  3 (15)   2 (12) ns 
Diameter ipsilateral CIA – mm (mean (SD))  17 (6.1)  15 (3.2) ns 
Diameter contralateral CIA – mm (mean (SD))  18 (7.3)  17 (4.5) ns 
Tortuosity of iliac axis   3 (15)  4 (24) ns 
Patent IMA (%)   5 (25)  4 (24) ns 
AP=Anterior-posterior, mm=millimeter, SD=standard deviation, CIA=common iliac artery, 
IMA=inferior mesenteric artery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1 Plasma MMP-9 levels of patients without and with endoleak. 
 * Indicates a statistically significant difference (P<0.001) of MMP-9 plasma levels 
observed in patients with an endoleak as compared to patients without endoleak. The 
open dot represents the only patient without endoleak on CTA that overlapped with 
the values of those with endoleak on CTA. 
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The ROC curve of plasma MMP-9 levels for the discrimination of patients with 
and without an endoleak is shown in Figure 9.2. A cut-off value of MMP-9 
plasma concentration of 55.18 resulted in a sensitivity of 100% (95% CI 80.5-
100%) and a specificity of 96% (95% CI 75.1-99.9%). The AUC was 0.988 
(P<0.001). However, differentiation between different types of endoleaks could 
not be made based on plasma MMP-9 levels (Figure 9.3). 
 
 
Table 9.2 Mean (SD) Plasma levels of candidate biomarkers. 
Biomarkers Endoleak – (SD) Endoleak + (SD) P‐value 
MMP-2 (pg/ml)  1006.58 (285.76)  1110.37 (370.23) ns 
MMP-9 (pg/ml)  25.02 (13.40)  89.54 (26.46) 0.000 
TIMP-1 (pg/ml)L  138.14 (69.08)  142.51 (63.29) ns 
MMP-2 = matrix metalloproteinase -2, MMP-9 = matrix metalloproteinase -9, TIMP-1 = tissue 
inhibitor of matrix metalloproteinase type 1. 
 
 
Mean Dmax of the endoleak group was significantly larger than the group with 
endoleak (72 mm vs. 57 mm). Figure 9.4 and 9.5 show that the plasma levels of 
MMP-9 were dependent on presence of endoleak and not Dmax or intraluminal 
thrombus (ILT) volume. Furthermore, no statistical differences in aneurysm 
characteristics between the endoleak and the control group were present 
(Table 9.1). 
Blood samples of two patients that underwent intervention to eliminate type II 
endoleak showed significant decrease in plasma levels of MMP-9 at one month 
post intervention (102.95 to 16.23 ng/ml and 121.97 to 20.28 ng/ml). 
Furthermore we determined MMP-9 levels in fluid aspirated from the aneurysm 
sac of these patients. These showed greatly increased levels of MMP-9, 386.34 
and 343.78 ng/ml, respectively. 
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Figure 9.2 ROC curve for plasma MMP-9 levels. 
 At a cut-off value of MMP-9 plasma concentration of 55.18 a sensitivity of 100% (95% 
CI 80.5-100%) and a specificity of 96% (95% CI 75.1-99.9%) were found. The AUC was 
0.988 (P<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.3 Plasma MMP-9 levels of patients with different types of endoleak. 
 Differences in MMP-9 plasma levels between different types of endoleak were not 
statistically significant. 
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Figure 9.4 Plasma MMP-9 levels of patients with and without endoleak and Dmax.  
 Blue dots represent patients without endoleak and green dots represent patients with 
endoleak. MMP-9 levels were dependent on the presence of an endoleak and not on 
Dmax. Patients with large Dmax and without endoleak displayed low levels of MMP-9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.5 Plasma MMP-9 levels of patients with and without endoleak and ILT volume. 
 Blue dots represent patients without endoleak and green dots represent patients with 
endoleak. MMP-9 levels were dependent on the presence of an endoleak and not on 
ILT volume. Patients with large ILT volume and without endoleak displayed low levels 
of MMP-9. 
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Discussion 
The present study showed that plasma levels of MMP-9 could accurately 
discriminate between patients with and without an endoleak with both high 
sensitivity and specificity. The ROC and the AUC demonstrated that plasma 
MMP-9 is an excellent test for the determination of endoleak presence. The 
implication of a clinical applicable blood test for differentiation between 
patients with and without endoleak is of major clinical importance. Patients 
without an endoleak could be spared to undergo CTA with the aforementioned 
additional hazards and cost. Reports on short and medium term outcome of 
EVAR show incidences of endoleak up to 10%.1,6 When patients with an 
endoleak can be identified by a simple blood test with high sensitivity (eg 
MMP-9), a potential 90% of follow up CT scans can be spared. Besides individual 
benefits, like less exposure to cumulative radiation doses and nephrotoxic 
contrast loads, health care costs are vastly reduced. Over 100.000 EVAR 
procedures are performed in Europe and the United States each year and the 
number is rising. Most of these patients are submitted to a follow-up 
surveillance regime of long term annual CTA, as recommended by the 
EUROSTAR Registry.11 This regime imposes a major contribution to the overall 
costs of EVAR treatment and strain on the medical system. Subject of debate is 
whether the costs of EVAR, including the long term costs for endoleak 
surveillance, could outweigh the benefits of this treatment strategy as 
compared to conventional open surgical repair.24 Therefore, it seems that cost 
reduction of post EVAR surveillance is of vital importance for the future of 
EVAR. Recently, the necessity of surveillance after EVAR has been questioned as 
reports show that interventions after EVAR were initiated by symptoms rather 
than by surveillance imaging.25,26 Black et al. suggest a follow-up regime of CTA 
at three months, followed by routine ultrasonography therafter.25 From a cost-
effectiveness perspective they even argued that long-term surveillance is not 
justified at all. Karthikesalingam et al. suggested to curtail surveillance to 
patients at high risk of reintervention after EVAR.26 MMP-9 plasma levels could 
be suitable for differentiation of patients with low and high risk of re-
intervention.  
Plasma MMP levels decrease within the first 3 months after EVAR.20 Sangiorgi et 
al. and Lorelli et al. previously reported on plasma MMP-9 levels for the 
evaluation of the successfulness of EVAR procedures and showed proof of 
concept.19,20 Monaco et al. have shown the potential of MMP-3, -9 and TIMP-1 
in the differentiation between successful thoracic EVAR (TEVAR) and endoleak 
after TEVAR.21 The current study is the first to report on the diagnostic value of 
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the MMP-9 assay for post EVAR surveillance. We also showed that MMP-9 
levels were dependent on the presence of endoleak and not on Dmax. Although 
this case control study has a limited number of patients, sensitivity and 
specificity rates are impressive and the confidence intervals are reassuring. 
Nevertheless, an adequately powered prospective clinical trial is necessary to 
validate the applicability of plasma MMP-9 levels for the differentiation of 
patients with and without endoleak in clinical practice and the potential role of 
plasma MMP-9 levels in the selection of EVAR patients that need CTA. 
Furthermore, standardization of the assay (e.g. monoclonal antibody and 
calibrators) will be necessary for the application of one standard cut-off value.  
Endoleak is a derivative or sign of failed EVAR with circulation in the aneurysm 
sac, thus pressurization of the aneurysm sac. Since we only report on the 
diagnostic value of the MMP-9 assay for the discrimination of the presence or 
absence of endoleak, additional diagnostics will be necessary in order to detect 
other potential complications of EVAR, such as migration and kinking. A widely 
accepted imaging modality for detection of these mechanical stent graft related 
complications is plain abdominal X-ray, which imposes far less radiation and 
costs than CTA.27,28 Hypothetically, complications of EVAR can be detected by 
combination of MMP-9 plasma levels and plain abdominal X-ray, but the most 
important derivative of EVAR complication, aneurysm sac expansion, can not be 
assessed. For detection of AAA growth after EVAR additional ultrasound 
measurement of Dmax could be added. Besides the evaluation of Dmax, 
ultrasound can be used to access the presence of endoleak, although regular 
ultrasound and color duplex has poor sensitivity for detection of endoleak. 
However, contrast-enhanced ultrasound imaging (CEUS) has significantly 
improved the diagnostic accuracy in the detection of endoleaks.29 CEUS has 
been reported as the preferred test on which to base an intervention for 
endoleak.30 Drawback of endoleak detection by means of duplex or CEUS is the 
requirement of a dedicated vascular laboratory, which is not widespread 
available. Plasma levels of MMP-9 are not observer-dependent and lower in 
cost. Future studies most evaluate EVAR follow-up by means of one and 6 
month CTA followed by yearly combination of plain abdominal X-ray, ultrasound 
and MMP-9 plasma levels. 
In conclusion, the present study shows that plasma levels of MMP-9 can 
accurately discriminate between patients with and without an endoleak with 
both high sensitivity and specificity. A prospective clinical trial in order to 
validate the clinical applicability of this assay is in progress. 
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General discussion 
Technical advancements in treatment as well as follow-up of patients with 
abdominal aortic aneurysms (AAA) affect daily clinical practice. Increasing 
numbers of patients are treated with minimally invasive endovascular aneurysm 
repair (EVAR). In patients with an acute AAA or paraanastomotic aneurysm after 
previous open reconstruction, perioperative mortality rates after open repair 
are known to be high. In section one of this thesis, the general objective was to 
assess potential early and midterm mortality reduction of EVAR compared with 
open surgical repair in patients with an acute AAA or paraanastomotic 
aneurysm after previous open reconstruction.  
Once EVAR (acute and elective) has been performed, it has its own specific 
complications, which include migration, kinking, and endoleakage. Endoleak 
formation is the most common complication of EVAR. Computed tomography 
angiography (CTA) is the gold standard in detecting these endoleaks, but 
important drawbacks are its cumulative radiation dose and the use of 
nephrotoxic contrast agents. Technical advancements in follow-up of patients 
after EVAR have lead to multiple alternative imaging modalities and biochemical 
assays. The objective in section two of this thesis was to assess potential 
alternatives to CTA in post-EVAR surveillance.  
In this chapter we describe the main findings of the studies presented in this 
thesis including methodological considerations, implications for clinical practice, 
and suggestions for future research. Finally, the overall conclusions are 
presented. 
Main findings 
An acute abdominal aortic aneurysm (aAAA) can either present as a 
symptomatic (nonruptured) AAA or as a ruptured AAA. Despite progression in 
surgical techniques, anesthetic management, vascular prostheses and 
perioperative care over the past decades, the mortality rate in patients with an 
aAAA treated with conventional open surgery remains high.1-3 In 1991, Parodi et 
al. introduced a new minimally invasive technique for elective AAA repair, 
EVAR. In the elective setting, EVAR has proved its short and midterm 
effectiveness in terms of mortality risk reduction.45 Since 1994, emergency 
EVAR (eEVAR) has become an accepted treatment option, which is increasingly 
being performed to treat aAAA. However, the potential reduction in peri-
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operative mortality of eEVAR compared to conventional open repair in patients 
with an aAAA is still open to debate.  
In an era where endovascular repair is increasingly performed, the indications 
have been extended. A few small case series have been published regarding 
endovascular repair for paraanastomotic aneurysms after previous open 
prosthetic reconstruction, without requiring dissection through previous 
scarred operative sites.6-9 
The studies described in section one of this thesis focus on the role of 
endovascular repair in patients with an aAAA (symptomatic and ruptured) and 
in patients with a paraanastomotic aneurysm after previous open prosthetic 
reconstruction. 
PART ONE – ACUTE AND PARAANASTOMOTIC ABDOMINAL AORTIC 
ANEURYSMS, EVAR OR OPEN SURGERY? 
So far, studies comparing eEVAR with conventional open surgery in patients 
with a ruptured AAA are flawed by methodological inadequacies such as 
selection bias and lack of randomization.10 Selection bias is created by selecting 
patients for eEVAR constituting a lower-risk category, presumably because they 
need to be hemodynamically more stable for preoperative imaging and have a 
more favorable (EVAR suitable) anatomic configuration. In chapter 2 we 
compared eEVAR with conventional open surgery in patients with a ruptured 
AAA who all underwent the same preoperative imaging protocol (CT 
angiography) and who were all judged suitable for endovascular repair by an 
independent external blinded group of experts. A 30-day mortality reduction of 
25.5% in favor of eEVAR was found. This advantage maintained at 6 months of 
follow-up, with comparable complication and reintervention rates. 
Furthermore, a reduced length of hospital stay was observed after eEVAR. 
Therefore, we conclude that eEVAR is a valuable treatment option for EVAR 
suitable patients with a ruptured AAA. 
Chapter 3 describes early and midterm (up to one year of follow-up) outcomes 
for eEVAR versus open repair of both symptomatic and ruptured AAA, in a large 
cohort of 246 patients (111 symptomatic and 129 ruptured AAA). It shows 
reduced early as well as midterm all cause mortality rates of eEVAR compared 
with open surgery in patients with a ruptured AAA, while comparable mortality 
results are observed in patients with a symptomatic AAA. Late aneurysm related 
mortality occurred only in the eEVAR group, which might be due to a significant 
increase in the need for late surgical re-interventions after eEVAR owing to an 
ongoing rupture risk in case of endoleak or stent graft migration.  
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There is a theoretical possibility that anatomical suitability for EVAR is 
independently associated with improved mortality outcome as stated in 
Chapter 3. In chapter 4, we compared mortality results of open ruptured 
aneurysm repair in EVAR suitable patients versus patients that were not 
suitable for EVAR, as assessed on preoperative CTA. This study suggests that for 
all included patients who underwent preoperative CTA imaging, anatomical 
suitability for EVAR was not associated with a lower 30-day or 6-month 
mortality rate after open rAAA repair. It is remarkable that the lower limit of the 
95% confidence interval of the 30-day mortality (28%) in EVAR suitable patients 
who were treated with open repair is higher than the mortality rates of 18-24% 
as reported for eEVAR in chapter 2 and 3 of this thesis as well as in 
literature.11-15 Therefore, it is unlikely that the reported difference in mortality 
between eEVAR and open repair can be explained by treating patients with a 
favorable anatomic configuration with eEVAR.  
A symptomatic AAA generally represents imminent rupture,16 and therefore 
acute treatment is generally performed in order to prevent rupture with 
associated poor prognosis, as readily described in the previous chapters.17,18 
However, since there is uncertainty of the time interval between initiation of 
symptoms and rupture in these patients, postponing surgery in order to 
optimize patients’ and operative conditions might be permitted. Chapter 5 
describes acute symptomatic AAA repair compared to delayed surgery after 
patient optimization. Aneurysm rupture occurred in 1 patient in the acute 
group (2.7%) versus 4 patients in the delayed treatment group (7.7%), which 
was not statistically significantly different. A trend was seen toward lower early 
mortality rates in patients who received delayed surgery. Consequently, chapter 
5 shows that postponed surgical treatment in order to optimize patients’ and 
operative conditions does not result in higher mortality rates in a substantial 
amount of patients presenting with a symptomatic AAA and might therefore be 
justified. 
There are several theoretical advantages of EndoVascular Paraanastomotic 
Aneurysm Repair after previous open reconstruction (EVPAR). It allows for local 
or regional anesthesia without requiring dissection through the scar tissue of 
previous operative sites.8 Chapter 6 describes the long-term clinical course in a 
relatively large number of patients (n=58) who underwent EVPAR. This chapter 
confirms that EVPAR is a feasible and durable alternative to open 
reconstruction, with a high primary technical success rate of 95%, acceptable 
perioperative mortality and morbidity rates, and good long-term exclusion 
rates. Especially bifurcated stent grafts showed to be durable with low 
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reintervention rates compared to aorto-uni-iliac stent grafts and endovascular 
tube grafts.  
PART TWO – FOLLOW‐UP AFTER ENDOVASCULAR ANEURYSM REPAIR, 
DEPICTING STENT GRAFT RELATED COMPLICATIONS 
Endovascular repair for AAA is increasingly performed in both acute and 
elective situations. When a stent graft is positioned correctly, the aneurysm sac 
is excluded from systemic blood pressure. Stent graft related complications 
might cause re-establishment of pressure in the aneurysm sac, thereby 
resulting in aneurysm expansion and ongoing rupture risk.4 Therefore, long-
term surveillance is required for detection of alterations in stent graft 
morphology, including migration, kinking (with subsequent limb occlusion), and 
endoleakage. Endoleak formation, defined as blood flow outside the stent graft 
and inside the aneurysm sac,21-23 is the most common complication of EVAR.24-27 
It represents the main indication for late surgical conversion.28 Therefore, 
modalities for detection of endoleaks are essential in the post-EVAR 
surveillance.  
In chapter 7 various strategies for endoleak detection in the follow-up after 
EVAR in terms of imaging techniques and biochemical assays are discussed. CTA 
follow-up after EVAR is considered the gold standard, with high sensitivity, 
widespread availability, rapid acquisition, and reproducibility.29 However, 
drawbacks are the cumulative radiation dose and nephrotoxic contrast agent. 
Promising alternative modalities for endoleak detection without ionizing 
radiation burden and the use of nephrotoxic contrast load are contrast 
enhanced ultrasound, magnetic resonance (angiography) imaging, and 
circulating biomarkers.30-32 These evolving techniques are able to detect and 
often classify endoleaks with increasing sensitivity and specificity, reserving a 
potential, prominent role in future post-EVAR follow-up. However, based on 
available evidence, true recommendations for ideal follow-up after EVAR 
cannot be made at this moment.  
Sonographic contrast agents enhance the capability of color duplex to detect 
endoleaks.33-37 Chapter 8 compares the diagnostic accuracy between contrast-
enhanced ultrasound (CEUS) and computed tomographic angiography (CTA) in 
order to detect endoleaks and changes in AAA size during post-EVAR follow-up. 
Good agreement between the two imaging modalities was demonstrated for 
maximal aneurysm sac diameter measurements with low inter-observer 
variability for CEUS. Adversely, a significant discrepancy was observed with 
regard to detection of endoleaks. In 22% of cases CTA detected an endoleak, 
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which corresponds with results in the available literature,35 versus 53% with 
CEUS. The level of agreement was low (κ=0.237). The majority of additional 
endoleaks identified by contrast-enhanced ultrasound were type II, of which the 
clinical importance is still subject of debate.38 However, ultrasound also 
revealed two extra type I endoleaks. These results support the notion that 
contrast-enhanced ultrasound may be a substitute for CTA in the assessment of 
aneurysm sac dimensions and the detection of endoleaks, in suitable patients 
and when performed by highly trained ultrasound operators. 
Increased circulating levels of plasma matrix metalloproteinase (MMP)-2, -9 and 
tissue inhibitor of MMP-1 (TIMP-1) are known to be associated with both the 
presence as well as the size of AAA.39-41 Some data show that a decrease of 
MMP concentration during post EVAR surveillance might indicate successful 
EVAR.42-44 Chapter 9 evaluates the potential clinical applicability of MMP-2, -9, 
and TIMP-1 as a diagnostic tool for the presence of endoleakage. An increased 
concentration of MMP-9 was observed in patients with an endoleak, as 
compared to patients without endoleak. A cut-off value of 55.18 resulted in a 
sensitivity of 100% and a specificity of 96%. However, differentiation between 
different types of endoleaks could not be made based on plasma MMP-9 levels. 
Nevertheless, this chapter shows that plasma levels of MMP-9 can accurately 
discriminate between patients with and without an endoleak with both high 
sensitivity and specificity.  
Methodological considerations 
PART ONE 
In the first part of this thesis we compare emergency EVAR with open repair in 
patients with an aAAA in terms of early and midterm mortality and morbidity. 
Well-conducted randomized controlled trails in an acute severe condition as 
aAAA are difficult to perform, as we can learn from Hinchcliffe et al. and the 
Amsterdam Acute Aneurysm Trial.45,46 Problems include obtaining informed 
consent in hemodynamically unstable patients, inclusion of patients unsuitable 
for either open surgery or EVAR, instant accessibility of a CT-scanner at all 
times, permanent availability of a vascular surgeon who is capable of 
performing emergency EVAR, permanent availability of a vascular team 
dedicated to EVAR, availability of an OR that is adequately equipped to perform 
EVAR, and availability of a variety ‘off-the-shelf’ stent-grafts.46-48 The only 
randomized controlled trail available, which showed identical 30-day mortality 
rates in both treatment groups, was underpowered and served as a pilot study 
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for future randomized studies.46 In a large prospective observational study with 
long-term follow-up, as described in chapter 3, the nonrandomized allocation of 
patients might result in differences in baseline characteristics (e.g. gender) and 
in selection bias. Selection bias is based on the allocation of patients to the 
EVAR group who are hemodynamically stable enough to undergo preoperative 
imaging and who have a potentially more favorable anatomic (EVAR suitable) 
configuration. In chapter 2 we took advantage of the fact that one vascular 
surgeon performed EVAR in the acute setting. eEVAR was performed in EVAR-
suitable cases when the eEVAR vascular surgeon was on call and open surgery 
was performed when the eEVAR vascular surgeon was not on call, making the 
previously described selection bias unlikely and providing a better comparison. 
However, similar results were obtained in both chapters, namely reduced early 
and midterm mortality rates of eEVAR compared to open surgery in patients 
with a ruptured aAAA. Therefore, we could ask ourselves whether selection bias 
really affects mortality results and prevents a proper comparison. A recent 
small retrospective study of Perrott et al. showed that anatomical suitability for 
EVAR might beneficially affect outcome following open repair in patients with a 
ruptured AAA.49 However, chapter 4 shows that the reported reduction in 
mortality between eEVAR and open repair, as observed in observational 
studies, is unlikely, due to selection bias based on anatomical AAA 
configuration. In this study, all patients underwent preoperative imaging, 
making selection bias based on hemodynamic conditions unlikely. Furthermore, 
anatomical suitability for EVAR was assessed afterwards by two independent 
experts, blinded for earlier evaluation, intervention, and outcome. Though, 
results of chapter 4 should be treated with some caution. At baseline, 
significantly more patients in the EVAR suitable group were male. This might 
theoretically influence mortality results, since women with a ruptured AAA are 
reported to have an increased mortality risk after EVAR compared to men.50 
Secondly, patients who were anatomically unsuitable for EVAR were treated 
with open repair by all three participating vascular surgeons whether EVAR 
suitable patients were only treated with open repair by the vascular surgeon 
who was experienced in performing emergency EVAR.  
Chapter 5 is based on the question why treatment of symptomatic non 
ruptured AAA is accompanied with higher mortality rates when compared to 
elective surgery.20,51,52 Potentially, these patients might suffer from a higher 
perioperative risk, due to the generally performed acute treatment with little 
time for preoperative optimization of patients’ and operative conditions. In an 
ideal situation, patients would benefit from surgery under optimized conditions, 
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with an acceptable risk of rupture prior to surgery. In chapter 5, the 30-day 
mortality rates in patients with a sAAA are lower in patients who were operated 
on more than 12 hours after presentation compared with patient who received 
acute treatment within 12 hours, though these results were not significant. Our 
conclusion that delayed treatment in certain patients with a sAAA in order to 
optimize conditions may be justified is mild due to several methodological 
limitations. First, there is lack of statistical power, which might be due to lower 
mortality rates in sAAA patients, approaching those of elective aneurysm repair, 
needing more patients in order to reach statistical significance. Secondly, since 
analyses were performed retrospectively on a prospective database and since 
an intention to treat by eEVAR protocol was not part of the study design, 
selection bias is likely to have occurred and heterogeneity might be present. In 
order to adjust for confounders, a logistic regression analyses was performed 
with type of operation as well as other potential confounders as variables, 
which showed similar results. Thirdly, since there is no fixed protocol available 
in literature for preoperative optimization of patients’ and operative conditions 
in case of a sAAA, this was tailor-made by best individual clinical care. Finally, a 
sAAA was defined as the existence of an AAA with acute onset of abdominal 
and/or back pain combined with pain at aneurysm palpation, as described by 
Peppelenbosch et al.53 However, abdominal pain and pain at aneurysm 
palpation might have other causes than an aneurysm in a state of pending 
rupture indicating potential false positive diagnoses.  
Besides acute AAA repair, EVAR might theoretically be the preferred treatment 
option for paraanastomotic aneurysm repair after previous open 
reconstruction, since it allows for local or regional anesthesia without requiring 
dissection through the scars of previous operations.8 In chapter 6 we describe 
the long-term clinical course in patients who underwent EVPAR after previous 
open reconstruction. In comparison to available studies and given the fact that 
paraanastomotic aneurysms are rather uncommon, a relatively large cohort of 
patients is included in this multicenter study. Though, the studied numbers are 
too low for subgroup analysis on aneurysm site. Also the results from different 
types of stent grafts that were used have to be interpreted with caution due to 
the limited numbers of cases and anatomical variation influencing stent graft 
selection. 
PART TWO 
Chapter 7 gives an overview of the available studies on strategies for endoleak 
detection in the follow up after EVAR in terms of imaging techniques and 
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biochemical assays. CTA follow-up after EVAR is considered the gold standard. 
Therefore, in comparative clinical studies, other imaging techniques are 
compared against the results of CT as the reference standard. A methodological 
problem is that some true endoleaks depicted by any imaging modality will be 
categorized as “false positives” because CTA did not visualize them.54,55 
Therefore, results of the index test in comparative studies might be flawed by 
potential invalid results of the reference test.  
The aim of chapter 8 was to investigate the accuracy of contrast-enhanced 
ultrasound as an alternative to CTA in the follow-up of patients after EVAR with 
regard to the detection of endoleaks and changes in AAA dimensions. Given the 
lack of a proper reference test, we did not report on sensitivity and specificity 
results for endoleak detection with contrast-enhanced ultrasound compared to 
CTA. We suggest that endoleaks detected by one or the other imaging modality 
should be considered as real endoleaks. Based on this assumption, the level of 
agreement between CTA and contrast-enhanced ultrasound for identifying 
endoleaks was calculated using kappa. A McNemar chi square test was 
performed to identify differential endoleak detection by the two imaging 
modalities. Methodological considerations in this chapter mainly consists of 
limitations in performing ultrasound examinations, such as operator 
dependency, which might limit reproducibility, and patient habitus, which may 
interfere with ultrasound imaging.  
Other than contrast-enhanced ultrasound, several biochemical assays might 
have an additional role as a diagnostic tool for presence of endoleakage. In 
chapter 9, the potential clinical applicability of MMP-2, -9, and TIMP-1 was 
assessed using a receiver operating characteristic curve and area under the 
curve. Our objective was to identify a cut-off value related to high sensitivity in 
order to reduce the risk of false negative results, and we found a cut-off value 
of MMP-9 plasma concentration resulting in both high sensitivity and specificity 
with an almost maximal area under the curve. We are aware that this is a case 
control study with a limited number of patients, though sensitivity and 
specificity rates are impressive and the confidence intervals are reassuring. 
However, in the absence of a standardized assay protocol, widespread 
application might not yet be achievable.  
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Implications for clinical practice 
PART ONE 
The proportion of patients with a rAAA treated by eEVAR increased significantly 
over the last decade. Together with the improvement of new generation 
devices, skills of the physicians improved, as well as their enthusiasm for the 
procedure. eEVAR offers many theoretical advantages over open repair. It is 
less invasive, eliminates damage to peri-aortic and abdominal structures, 
decreases bleeding from surgical dissection, minimizes hypothermia, and 
lessens the requirement for deep anesthesia. Several retrospective series 
demonstrate a potential survival advantage with mortality rates of 8-40%.56-59 
Prospective trials had also shown this potential benefit before, but are limited 
by sample size.60-63 Only one randomized trial is available, demonstrating 
equivalent results and therefore challenging the benefit of EVAR in patients 
with a rAAA. However, this study showed lack of statistical power due to the 
small sample size. More than two-thirds of patients were excluded from the 
study because of hemodynamic instability or staff unavailability. Furthermore, 
there were 13 patients in the eEVAR group and only 11 completed eEVAR, due 
to open surgical repair crossover or preoperative death.46 
The most complete and recent review included data from 13 selected centers 
that were committed to treat all rAAA patients who were anatomically suitable 
with eEVAR, irrespective of patients’ hemodynamic or risk status.58 For this 
update a total of 1443 patients were included of which 680 received eEVAR 
(47%) and 763 underwent open repair (53%). In these centers, the 30-day 
mortality rate for eEVAR was 19.7%, compared to 36.3% for open repair 
(P<0.001). The percentage of rAAA patients who were treated by eEVAR was 
high, with a mean of 49.1% ± 12.9% (±SD). However, the reported wide 
variability in 30-day eEVAR mortality might reflect case-mix and differences in 
risk stratification as well as treatment details in the various centers. Also 
potential selection bias might be a factor preventing a proper comparison.  
In our own series, described in chapter 2, we found similar results in favor of 
eEVAR. Based on the design of the logistics that constituted our series, although 
not randomized, selection bias for anatomical or hemodynamic criteria was 
highly unlikely. Despite mounting level 2 evidence for survival advantage in 
patients undergoing eEVAR for rAAA, the vascular world is looking forward to 
the results of the first multicenter randomized controlled trial on this subject. 
During the 34th International Charing Cross Symposium 2012 in London the 
preliminary results of the AJAX trial were presented.64 During the AJAX trial, in 
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an area covering 1.2 million inhabitants, 520 patients with a rAAA were enrolled 
between April 2004 and February 2011. The preferred eEVAR technique was the 
use of an aorto-uni-iliac graft with contralateral occluder and femoro-femoral 
crossover bypass. A total of 116 patients were randomized: 57 to eEVAR and 59 
to open repair. The primary endpoint was the combined and severe 
complications rate at 30 days which was 42% (24/57) in the eEVAR group and 
47% (28/59) in the open group [ARR 5.4% (95%CI -13 to +23)]. With regard to 
the secondary endpoints, ICU stay was 28 hours following eEVAR and 48 hours 
after open repair (P=0.14); hospital stay was nine days following eEVAR and 13 
days after open repair (P=0.57); 39 patients had to use a mechanical ventilator 
following eEVAR while 52 did so after open repair (P=0.002); blood loss was 500 
ml following eEVAR and 3500 ml after open repair (P<0.001). Finally, the 
mortality rate associated with eEVAR was 21% (12/57) versus 25% following 
open repair (15/59).  
These preliminary results of the AJAX trial show no clear advantage for eEVAR in 
patients with a rAAA, although a significant reduction in blood loss and the 
need for mechanical ventilation in the eEVAR group can be seen as major 
advantages. Nevertheless, the AJAX trial raises, in some respect, more 
questions than answers. The eEVAR results were relatively consistent with 
current literature, but how come the results in the open repair group were, 
compared with the rest of the world, exceptionally favorable? Secondly, 
exclusion rates were high, since only 24.9% of patients were randomized (116 
patients of the 466 patients that were initially enrolled in one of three trial 
centers). Reasons given for this high exclusion rate were lack of preoperative 
CTA scanning (n=71), unfavorable anatomic configuration for EVAR (n=240), 
unfitness for open surgery (n=16), logistical reasons (n=11), hemodynamic 
instability (n=7), and patients refusing surgery (n=5). Furthermore, 240 patients 
(61% of the patients who underwent preoperative CTA scanning) were deemed 
anatomically unfavorable for EVAR, which is high compared to the <50% as 
reported in literature.56,65 Together with the 15% of patients who did not 
receive a preoperative CTA scan, results in a group of 311 patients need to be 
clarified in the awaited publication, to put these preliminary results in a clear 
perspective and, moreover, to make sure that there was no selection prior to 
randomization.  
Despite the on-going debate regarding the need for randomized controlled 
trials of eEVAR versus open repair, the issue of one treatment being superior to 
another may be less relevant than the evaluation of the impact on mortality of 
a service combining both open and endovascular operations compared to a 
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service supplying open treatment alone. Data from the Nationwide Inpatient 
Sample (NIS) demonstrate reduced overall mortality after rAAA repair since 
EVAR was introduced in de United States.66 Also Hoornweg et al. showed in a 
meta-analysis, that the impact of the introduction of an endovascular program 
for rAAA has a positive effect on operative mortality with an Odds Ratio of 0.37 
(95% CI 0.22 to 0.63).67 
This accumulation of superior results after the introduction of eEVAR, supports 
the increasing trend of centers adopting an eEVAR-first approach.48,68,69 
Especially since the reported reduction in mortality in cohort observational 
studies is unlikely due to selection bias based on anatomical AAA configuration, 
as described in chapter 4 of this thesis. However, an eEVAR-first approach has 
great implications for clinical practice, since it requires instant and permanent 
accessibility of a CT-scanner, continual availability of an endovascular specialist 
capable of performing emergency EVAR, constant availability of a vascular team 
dedicated to eEVAR, availability of an OR that is adequately equipped to 
perform eEVAR, and the availability of a variety ‘off-the-shelf’ stent-grafts.46-48 
The indications for performing endovascular repair are expanding. Patients with 
a paraanastomotic aneurysm after previous open AAA or aAAA prosthetic 
reconstruction might also gain from an EVAR first approach. In chapter 6, so 
called EVPAR is confirmed to be a feasible, durable, and safe alternative to open 
reconstruction, especially when using bifurcated stent grafts. However, in these 
patients stent graft selection should not merely be based on the reported 
differences in outcome between various types of stent grafts, but should rather 
be individualized in the view of anatomical considerations.  
On a larger scale, an EVAR-first approach for acute and paraanastomotic 
aneurysms might indicate centralization of AAA care. Centralization of complex 
surgical procedures has the potential to improve patient outcomes and 
particularly reduce mortality.70,71 Surgeon experience, support staff, 
infrastructure and recognition of complications may all be important factors in 
this regard.69,72,73 Vascular surgery is a specialty where centralization could be 
beneficial due to its complex procedures and multi-disciplinary requirements, 
especially with regard to interventional procedures such as eEVAR.58,74 
Next to type and quality of surgery, timing of surgery might also be clinically 
relevant in acute AAA care. In patients with a symptomatic AAA, the 
contemporary assumption to treat patients acutely in order to prevent rupture 
might have to be adjusted. Delayed surgical treatment with preoperative 
optimization of patients’ and operative condition could improve prognosis in 
selected patients with a symptomatic AAA. Admission to a medium care unit 
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with bed rest, close blood pressure monitoring, and optimization of patients’ 
operative conditions are indicated. 
PART TWO 
Chapter 7 showed that true recommendations for ideal post-EVAR surveillance 
cannot be made based on the current available evidence. Among various 
imaging modalities, computed tomography angiography (CTA) is the most 
widely used technique for follow-up after EVAR.25 However, the risk of cancer 
induction of one CTA is about 1 in 1500.75 Furthermore, renal dysfunction is a 
comorbidity found in 80% of aneurysm patients, and is the most important risk 
factor for contrast-induced nephrotoxicity.76,77 The cumulative radiation dose, 
nephrotoxic contrast load, and high costs indicate the relevance of reliable 
alternatives to annual CTA in daily clinical practice.78,79 Furthermore, a recent 
retrospective analysis of AAA ruptures following EVAR showed that most 
ruptures occur within the first 3 years after the procedure and rupture is mostly 
preceded by endoleaks.80 These findings underline the importance of a sensitive 
and reliable post-EVAR follow-up regimen to reduce the AAA rupture rate. 
Although ultrasound is dependent on well-trained operators and is subject to 
inter-operator variability, improving diagnostic results of CEUS are promising. 
Moreover, no major side effects have been reported for ultrasound contrast 
agents. In chapter 8, we showed that contrast-enhanced ultrasound might be 
equivalent to CTA for the assessment of aneurysm sac dimensions, while the 
number of endoleaks detected by contrast-enhanced ultrasound greatly 
outweighs those diagnosed on CTA. Therefore, contrast-enhanced ultrasound 
might be considered as a substitute to CTA as the primary imaging modality in 
the surveillance of patients after EVAR for those patients who are suitable for 
abdominal/pelvic ultrasound and when highly trained ultrasound operators are 
available. 
In chapter 9, we showed that plasma concentrations of MMP-9 can accurately 
discriminate between patients with and without an endoleak, with both high 
sensitivity and specificity. The availability of a clinical applicable blood test for 
differentiation between patients with and without endoleak has major clinical 
implications, since patients without an endoleak could be spared to undergo 
CTA with the aforementioned additional hazards. A potential 90% of follow-up 
CT scans could be spared when taking the 10% incidence of endoleaks into 
account.81,82 Besides individual benefits, health care costs might be greatly 
reduced. Increasing numbers of EVAR procedures are performed with over 
100.000 in Europe and the United States each year. When all these patients 
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would be submitted to the follow-up surveillance regime of long-term annual 
CTA, as recommended by the EUROSTAR Registry,28 a major contribution to the 
overall costs of EVAR treatment and a strain on the medical system is imposed.  
Implications for future research 
PART ONE 
Thus far, studies comparing emergency EVAR versus open surgery in patients 
with an acute AAA are flawed by methodological inadequacies such as selection 
bias.10 Based on these methodological limitations, results from a randomized 
controlled trial are needed. However, a pilot study showed that it is challenging 
to perform a randomized study in an acute condition like ruptured AAA.46  
Furthermore, since mortality results of rAAA repair as described in chapter 2 
and chapter 3 are comparable, and while the potential effect of selection bias 
on mortality is further flawed as explained in chapter 4, the next question might 
be: do we really need a randomized controlled trial in order to confirm these 
observational results? Especially considering the observation of Benson et al. in 
the New England Journal of Medicine, that observational studies and 
randomized controlled trials usually produce similar results.83 When taking this 
into account and given the accumulation of superior short term results of 
emergency EVAR compared with conventional open surgery in observational 
studies, there might even be a potential ethical issue associated with trials that 
randomize patients to these treatments.59 However, since EVAR is known for its 
ongoing mortality risk due to stent graft related complications, longer-term 
results of emergency EVAR for acute AAA and clinical results are required. 
Concerning paraanastomotic aneurysms after previous abdominal aorto-iliac 
surgery, only a few small case series have suggested that endovascular 
exclusion is feasible, with low perioperative mortality and morbidity.6-9.84-86 
Based on the long-term results as provided in chapter 6, endovascular exclusion 
of paraanastomotic aneurysms with bifurcated stent grafts can be considered 
as the first-choice of treatment when feasible. However, a proper conducted 
clinical trail is desirable in order to confirm these results of EVAR for patients 
with paraanastomotic aneurysms.  
PART TWO 
In an era where endovascular treatment is evolving due to improvements in 
devices, skills, and expanding suitability ranges, there is an overall shift towards 
Chapter 10  
 178 
endovascular repair in AAA patients. Subject of debate is whether the costs of 
EVAR, including the long term costs for endoleak surveillance, could outweigh 
the benefits of this treatment strategy as compared to conventional open 
surgical repair.87 Therefore, it seems that cost reduction of post EVAR 
surveillance is of vital importance for the future of EVAR. This incorporates 
potential alternative surveillance modalities as well as the ideal interval scheme 
and total duration of surveillance programs. These are important topics that 
cannot be answered based on present available reports and creates an 
important role for future research.  
CTA follow-up after EVAR is considered the gold standard, with high sensitivity 
for endoleak detection combined with widespread availability, rapid acquisition 
and reproducibility.29 However, high costs, cumulative radiation dose, and 
nephrotoxic contrast agent underline the importance of upcoming alternative 
imaging modalities. Continuing technical improvements and future prospective 
comparative research might eventually lead to an imaging modality other than 
CTA as the gold standard in the follow-up of patients after stent-graft 
implantation. 
To be more specific, in this thesis we showed that CEUS might be equivalent to 
CTA for the post EVAR assessment of aneurysm sac dimensions and the 
detection of endoleaks. However, results of CEUS are mainly based on patients 
with a type 2 endoleak, which are largely benign,88 in contrast to type 1 and 
type 3 endoleaks for which there is consensus that intervention is required.89,90 
As we can learn from Mirza et al., the relative sensitivity of CEUS for detecting 
the specific group of endoleaks requiring reintervention remains unknown.91 
Since the role of surveillance is to enable the treatment of stent graft-related 
complications that would otherwise lead to aneurysm-related death, there is a 
need for reappraisal of the diagnostic accuracy of CEUS, focusing on detection 
of clinically relevant types 1 and 3 endoleaks. 
We showed that plasma MMP-9 levels appear to discriminate between patient 
with and without an endoleak with both high sensitivity and specificity. 
However, despite reassuring confidence intervals, we are aware that this is a 
case control study with a limited number of patients. Therefore, an adequately 
powered prospective clinical trial is necessary to validate the applicability of 
plasma MMP-9 concentrations for the differentiation of patients with and 
without an endoleak in clinical practice and, moreover, to investigate the 
potential role of plasma MMP-9 concentrations in the selection of EVAR 
patients for imaging. Furthermore, standardization of the assay will be 
necessary for the application of one standard cut-off value in future clinical use. 
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Conclusions 
In conclusion, data presented in this thesis show that EVAR is a valuable 
treatment option for anatomically suitable patients with an acute (ruptured or 
symptomatic) or paraanastomotic AAA. Delayed treatment in certain patients 
with a symptomatic AAA might be justified in order to optimize conditions. In 
case endovascular repair is performed, contrast-enhanced ultrasound may be a 
substitute to CTA for the assessment of aneurysm sac dimensions and the 
detection of endoleaks in post-EVAR surveillance. Plasma levels of MMP-9 can 
accurately discriminate between patients with and without an endoleak and 
might have a future role in the selection of EVAR patients for imaging. 
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Summary 
Part one of this thesis is dedicated to evaluate the potential value of emergency 
endovascular aneurysm repair (eEVAR) in patients with an acute abdominal 
aortic aneurysm (AAA). It also addresses the potential value of EVAR treatment 
for paraanastomotic aneurysms. Additionally, in part two, alternatives to 
computed tomography angiography (CTA) in post-EVAR surveillance were 
explored.  
 
In chapter 1, the rationale for this research is presented. Currently, eEVAR has 
become an accepted treatment option, which is increasingly performed to treat 
acute AAA. Nonetheless, the potential reduction in peri-operative mortality of 
eEVAR compared with conventional open repair in patients with an acute AAA is 
still questionable. 
PART ONE – ACUTE AND PARAANASTOMOTIC ABDOMINAL AORTIC 
ANEURYSMS, EVAR OR OPEN SURGERY? 
The first decision in patients presenting with an acute or paraanastomotic AAA, 
is whether to offer treatment at all (i.e. selective treatment policy). When 
decided to perform an intervention, two treatment options are available: 
conventional “open” AAA repair or the minimally invasive emergency 
endovascular AAA repair (eEVAR). 
 
So far, observational studies comparing endovascular aneurysm repair with 
open surgery in patients with a ruptured AAA are flawed by methodological 
inadequacies. Selection bias occurs mainly by selecting patients with a lower-
risk profile to undergo eEVAR, presumably because these patients need to be 
hemodynamically stable in order to undergo preoperative imaging and have a 
more favorable (i.e. EVAR suitable) anatomic configuration. In order to minimize 
the effect of selection bias, chapter 2 describes a comparison of eEVAR with 
open surgery in patients with a ruptured AAA who all underwent the same 
preoperative imaging protocol and who were all defined anatomically suitable 
for EVAR by two independent experts. Main outcome parameters were 
mortality (intra-operative, 30-day, and 6-month) and length of hospital stay. In 
total, 25 patients underwent eEVAR and 33 EVAR-suitable patients underwent 
an open procedure. An absolute perioperative mortality reduction of 25.5% in 
patients undergoing eEVAR over open surgery was found (P=0.04), which was 
still present after 6 months of follow-up (P=0.04). The median length of hospital 
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stay was 9.5 days (interquartile range 5.0-20.5) after eEVAR and 17.0 days 
(interquartile range 9.5-28.0) after open surgery (P=0.03). These data suggest 
that eEVAR is a superior treatment option compared to open surgery for 
patients with a ruptured AAA that is anatomically suitable for EVAR. 
 
In chapter 3, early and midterm outcomes for eEVAR versus open surgery were 
prospectively described in patients with an acute AAA, both unruptured 
(symptomatic) and ruptured. A total of 240 patients were enrolled in this study, 
111 patients with an unruptured acute AAA and 129 patients with a ruptured 
AAA. Of the patients with an unruptured acute AAA, 47 (42%) underwent eEVAR 
and the all cause mortality as well as the aneurysm-related mortality did not 
differ significantly when compared to open surgical repair at 30-day, 6-, and 12-
month follow-up. Though, increasing aneurysm-related mortality results during 
follow-up were observed in the eEVAR group, whereas aneurysm-related 
mortality in the open repair group remained stable. In patients with a ruptured 
AAA, 25 (19%) underwent eEVAR and the intra-operative, 30-day, 6- and 12-
month mortality rates were 4%, 20%, 28%, and 36% versus 8% (P>0.999), 45% 
(P=0.021), 60% (P=0.004), and 63% (P=0.014) for patients treated with open 
surgery, respectively. Again, aneurysm-related mortality was observed only in 
the eEVAR group during follow-up, but significant differences in aneurysm-
related mortality remained. Furthermore, the length of hospital stay after 
eEVAR compared with length of stay following open surgery in patients with 
either an unruptured aAAA or a ruptured aAAA was significantly reduced by 
5 and 6.5 days, respectively. Based on these results we concluded that a 
reduced 30-day, 6- and 12-month mortality of eEVAR was observed compared 
with open surgery in all patients with an acute AAA, probably due to a lower 
mortality in the ruptured AAA group. Late aneurysm-related mortality occurred 
only in the eEVAR group. Nevertheless, results have to be interpreted with 
caution due to several limitations, including selection bias. 
 
The reported mortality reduction of eEVAR compared with open repair in 
patients with a ruptured AAA, as described in chapter 3, might be flawed by 
selection bias based on anatomical suitability for EVAR. In chapter 4 we 
compared mortality results in EVAR suitable versus non EVAR suitable patients 
with a ruptured AAA, who all underwent preoperative CTA imaging and who 
were all treated with conventional open repair. Anatomical suitability for EVAR 
was determined by two independent experienced reviewers who were blinded 
for earlier evaluation, intervention, and outcome. A total of 82 consecutive 
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patients with a ruptured AAA on pre-operative CTA received open repair and 
were therefore included in this study. CTA revealed an EVAR suitable ruptured 
AAA in 33 patients (40.2%) and a non EVAR suitable ruptured AAA in 
49 patients. At baseline, significantly more male patients were considered EVAR 
suitable on CTA. Intra-operative, 30-day, and 6-month mortality results as well 
as postoperative days of hospital stay were comparable for both groups. 
Therefore, anatomical suitability for EVAR seems not to be associated with 
lower early and midterm mortality in patients treated with open ruptured AAA 
repair. We concluded that the reported reduction in mortality after eEVAR 
compared to open repair is not likely due to selection bias based on anatomical 
AAA configuration. 
 
In chapter 5 we focused on the symptomatic AAA, defined as the existence of 
an AAA with acute onset of abdominal and/or back pain in combination with 
pain at aneurysm palpation and with no signs of rupture on a CTA scan. 
Traditionally this condition requires acute treatment, since it might represent 
imminent rupture. In this chapter, we compared acute symptomatic AAA repair 
with delayed surgery after optimization of patients’ operative conditions. We 
used 12 hours as a cut-off point and adjusted for type of operation and 
potential confounders. A total of 89 patients were included of which 37 patients 
received acute surgery. Although rupture occurred in 1 patient in the acute 
group (2.7%) versus 4 patients in the delayed treated group (7.7%), a trend was 
seen toward lower early mortality rates in patients who received delayed 
surgery. In the group operated within 12 hours, 30-day mortality rate was 
16.2% versus 5.8% in patients treated after 12 hours (odds ratio 0.316; CI 
0.074–1.358). When adjusted for type of surgery (open versus EVAR) and other 
potential confounders, the adjusted odds ratios were 0.305 (CI 0.066–1.405) 
and 0.270 (CI 0.015–4.836), respectively. When using 24 hours as a cut-off 
point, (adjusted) odds ratios were comparable. We concluded that in a 
substantial amount of patients with an alleged symptomatic AAA, delayed 
surgery with patient optimization might be justified. However, it is important to 
realize that the study described in chapter 5 was underpowered and that 
selection bias might have occurred. Further investigation is instigated in order 
to select patients who might benefit from delayed surgery based on specific 
criteria.  
 
Chapter 6 describes a multicenter study in which we described the long-term 
clinical course in an expanded number of patients who underwent endovascular 
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paraanastomotic aneurysms repair (EVPAR) after previous open reconstruction. 
Initial open reconstruction included a tube graft or a bifurcated prosthesis. A 
total of 58 patients with 80 aortic or iliac pseudo or true paraanastomotic 
aneurysms, or both, were treated with an endovascular stent graft. An 
endovascular tube graft was used in 8 patients, a bifurcated stent graft in 32, an 
aortouniiliac stent graft in 7, and an iliac extension graft in 11 patients. Stent 
graft deployment was successful in 55 patients (technical success rate: 95%). 
Median hospital stay was 3 days (range, 1-122 days) and the 30-day mortality 
rate was 3.4% (n=2). The median follow-up was 41 months (range, 0-106 
months). Exclusion was successfully maintained in 86% of the paraanastomotic 
aneurysms. Kaplan-Meier curves showed an annual risk of mortality of 4.0% 
during follow-up and an annual risk of reintervention of 5.8%. A log-rank test 
for equality of reintervention distributions between differences in original 
anatomical presentation of paraanastomotic aneurysms showed no significant 
differences (P=0.131). However, regarding different stent graft configurations, a 
significantly larger proportion of tube and aortouniiliac stent grafts needed 
reintervention during follow-up (P<0.001). The annual reintervention risk was 
3.2% (SE, 0.098%) for bifurcated stent grafts, 16.6% (SE, 0.239%) for tube grafts, 
66.4% (SE, <0.001%) for aortouniiliac stent grafts, and 19.1% (SE, 0.152%) for 
distal iliac extension grafts. We concluded that endovascular exclusion of 
anatomically suitable paraanastomotic aneurysms is feasible and durable. 
Especially patients who received bifurcated stent grafts had lower 
reintervention rates and might be considered as the first-choice treatment 
option. Care should be taken that EVPAR requires an individualized approach 
taking anatomical considerations into account. 
PART TWO – FOLLOW‐UP AFTER ENDOVASCULAR ANEURYSM REPAIR, 
DEPICTING STENT GRAFT RELATED COMPLICATIONS 
In an era where (emergency) EVAR is increasingly performed, shortcomings of 
this minimally invasive technique, such as the requirement of long-term 
imaging surveillance in order to detect stent graft related complications, are 
becoming more relevant. CTA is the most widely used technique for post-EVAR 
surveillance. However, repetitive CTA has several important drawbacks, 
including cumulative radiation dose, and nephrotoxic contrast load. Therefore, 
less harmful alternatives in the follow-up after EVAR in terms of imaging 
modalities or biochemical assays are desirable. 
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In chapter 7 various strategies for endoleak detection in terms of imaging 
techniques and biochemical assays in the follow up after EVAR were discussed. 
CTA follow-up after EVAR is considered the gold standard, with high sensitivity, 
widespread availability, rapid acquisition, and reproducibility. However, 
drawbacks are the cumulative radiation dose and nephrotoxic contrast agent. 
Furthermore, the optimal CT image acquisition protocol is still controversial. 
Promising alternative modalities for endoleak detection without ionizing 
radiation burden and the use of nephrotoxic contrast load are contrast 
enhanced ultrasound (CEUS), magnetic resonance (angiography) imaging 
(MRA), and circulating biomarkers (matrix metalloproteinase). These evolving 
techniques are able to detect and classify endoleaks with increasing sensitivity 
and specificity, reserving a potential prominent role in future post-EVAR follow-
up. However, based on present studies, true recommendations for ideal follow-
up after EVAR cannot be made. 
 
The accuracy of CEUS as an alternative to CTA in the follow-up of patients after 
EVAR with regard to changes in AAA dimensions and detection of endoleaks 
was described in Chapter 8. During EVAR surveillance, 83 patients were 
consecutively enrolled for both CEUS and CTA imaging, yielding 127 paired 
examinations. Good correspondence between the two imaging modalities was 
observed in both anteroposterior and transverse maximal diameters with a 
coefficient of variation of 8.0% and 8.6%, respectively. The interobserver 
variability was low with an interclass correlation coefficient of >0.98 in both 
dimensions. CEUS was able to detect significantly more endoleaks (38 additional 
type II and 2 type I endoleaks) when compared with CTA (53% versus 22%), 
resulting in an intervention in two patients. The number of observed 
agreements was 77/127 (61%), indicating a low level of agreement (κ=0.237). 
The results as reported in chapter 8 indicate that CEUS might be equivalent to 
CTA in post-EVAR surveillance without the risks of contrast-induced 
nephropathy and ionizing radiation load.  
 
In chapter 9 we focused on biochemical assays and the potential clinical 
applicability of MMP-2, -9, and TIMP-1 as a diagnostic tool for the presence of 
endoleakage. In 37 included patients, plasma levels of MMP-2, -9, and TIMP-1 
were determined using enzyme-linked immunosorbent assay. In 17 patients, an 
endoleak was detected on CTA (4 type I, 12 type II and 1 type III endoleak) and 
the other 20 patients were matched controls. In patients with an endoleak 
MMP-9 levels were significantly higher than in patients without an endoleak 
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(P<0.001). The ROC curve of plasma MMP-9 concentrations showed that a cut-
off value of 55.18 ng/ml resulted in a 100% sensitivity and a 96% specificity with 
an area under the curve of 0.988 (P<0.001). However, plasma MMP-9 levels 
could not differentiate between different types of endoleak. The study 
described in chapter 9 shows that plasma concentrations of MMP-9 can 
accurately discriminate between patients with and without an endoleak with 
both high sensitivity and specificity. A prospective clinical trial is needed in 
order to validate the clinical applicability of this assay. 
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Samenvatting 
Dit proefschrift behandelt de positie van de endovasculaire herstelmethode 
(EVAR – EndoVascular Aneurysm Repair) bij patiënten met een acuut 
(symptomatisch of geruptureerd) aneurysma van de abdominale aorta (AAA) of 
een paraanastomotisch aneurysma. Na EVAR is langdurige, misschien wel 
levenslange controle geïndiceerd. Verschillende alternatieven voor de 
gebruikelijke computed tomography angiography (CTA) scan in de follow-up na 
EVAR worden uiteengezet.  
 
In hoofdstuk 1 wordt het doel van dit proefschrift gepresenteerd. Momenteel is 
EVAR een geaccepteerde behandeloptie om het acute AAA te behandelen. Wel 
bestaat nog discussie over de potentiële reductie in perioperatieve mortaliteit 
wanneer deze wordt vergeleken met de conventionele open operatie bij 
patiënten met een acuut AAA.  
DEEL EEN – ACUTE EN PARA‐ANASTOMOTISCHE ANEURYSMA’S VAN DE 
ABDOMINALE AORTA: EVAR OF OPEN CHIRURGIE? 
Bij patiënten die zich presenteren met een acuut of paraanastomotisch AAA 
moet worden beslist of een behandeling al dan niet gewenst dan wel zinvol is. 
Wanneer besloten wordt een interventie te verrichten, bestaan twee 
behandelopties: de conventionele “open” operatie of de minimaal invasieve 
endovasculaire behandeling oftewel EVAR. Tot nu toe worden observationele 
studies die beide behandelmethoden bij patiënten met een geruptureerd AAA 
vergelijken afgezwakt door methodologische tekortkomingen waarbij 
selectiebias een grote rol speelt. Selectiebias kan enerzijds ontstaan door de 
veronderstelling dat patiënten die in aanmerking komen voor emergency EVAR 
(eEVAR) hemodynamisch stabieler dienen te zijn om de noodzakelijke 
preoperatieve beeldvorming te kunnen ondergaan. Anderzijds, doordat enkel 
patiënten met een minder gecompliceerde anatomie van het aneurysma in 
aanmerking komen voor eEVAR. Om de genoemde oorzaken van selectiebias te 
minimaliseren wordt in hoofdstuk 2 eEVAR vergeleken met de open procedure 
bij anatomisch vergelijkbare patiëntgroepen met een geruptureerd AAA. Alle 
patiënten hebben hetzelfde preoperatieve beeldvormingsprotocol doorlopen 
en werden retrospectief door onafhankelijke experts anatomisch geschikt 
bevonden voor eEVAR. Door de opzet van deze studie is tevens de kans op 
selectiebias aangaande hemodynamische instabiliteit of andere demografische 
patiëntkenmerken minimaal tot afwezig. De belangrijkste parameters zijn 
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mortaliteit (intra-operatieve, 30-dagen en 6-maanden mortaliteit) en 
opnameduur. Van de 58 anatomisch eEVAR-geschikte patiënten hebben 25 de 
eEVAR-procedure ondergaan en 33 de open procedure. De studie laat een 
absolute reductie van 25,5% in perioperatieve mortaliteit zien in de eEVAR-
groep vergeleken met de groep die de open procedure heeft ondergaan 
(P=0,04). Dit positieve effect van eEVAR blijkt na 6 maanden onveranderd 
aanwezig (P=0,04). De mediane opnameduur is 9,5 dagen (interkwartiel afstand 
5,0-20,5) na eEVAR en 17 dagen (interkwartiel afstand 9,5-28,0) na open 
chirurgie (P=0,03). Hieruit kunnen we concluderen dat eEVAR een superieure 
behandelmethode is in vergelijking met de open procedure bij patiënten met 
een geruptureerd AAA. 
 
In hoofdstuk 3 worden de vroege- en lange termijnresultaten van eEVAR bij 
zowel symptomatische als geruptureerde AAA’s afgezet tegen de open 
procedure. In totaal zijn 240 patiënten geïncludeerd, waarvan 111 patiënten 
met een symptomatisch AAA en 129 patiënten met een geruptureerd AAA. In 
de groep met een symptomatisch AAA hebben 47 patiënten een eEVAR 
ondergaan (42%) en 54 kregen een open procedure (48%). Op de drie follow-
up-momenten (30 dagen, 6 en 12 maanden) kan geen significant verschil 
worden aangetoond in algehele en AAA-gerelateerde mortaliteit tussen eEVAR 
en de open procedure. Wel wordt gedurende de follow-up een toename in 
aneurysma-gerelateerde mortaliteit gezien in de eEVAR-groep, terwijl deze in 
de groep met de open procedure stabiel blijft.  
In de groep met een geruptureerd AAA hebben 25 patiënten een eEVAR 
ondergaan (19%) en 104 kregen een open procedure (81%). De studie laat hier 
een intra-operatieve, 30 dagen, 6 maanden en 12 maanden mortaliteit zien van 
respectievelijk 4%, 20%, 28% en 36% na eEVAR versus respectievelijk 8% 
(P=1,000), 45% (P=0,021), 60% (P=0,004) en 63% (P=0,014) na een open 
procedure. Ook hier is enkel in de eEVAR-groep een toename in aneurysma-
gerelateerde mortaliteit aangetoond gedurende de follow-up, maar de 
verschillen in aneurysma-gerelateerde mortaliteit blijven significant. Verder 
blijkt de opnameduur na eEVAR significant korter dan na een open procedure 
voor zowel patiënten met een symptomatisch als met een geruptureerd AAA 
met respectievelijk 5 en 6,5 dagen. Op basis van bovenstaande resultaten kan 
worden geconcludeerd dat eEVAR als behandeling voor het geruptureerde AAA 
gepaard gaat met een reductie in 30 dagen, 6 maanden en 12 maanden 
mortaliteit ten opzichte van de open procedure. Deze resultaten komen 
overeen met een meerderheid van de vergelijkbare internationale studies. 
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Echter, het is aannemelijk dat selectiebias is opgetreden. Bovenstaande 
resultaten dienen dan ook met enige voorzichtigheid geïnterpreteerd te 
worden.  
 
De mogelijke invloed van selectie op basis van anatomische criteria op de 
gevonden reductie in mortaliteit ten gunste van eEVAR bij patiënten met een 
geruptureerd AAA (hoofdstuk 3), is het onderwerp van studie in hoofdstuk 4. 
Hierin vergelijken we de mortaliteit van eEVAR-geschikte versus eEVAR-
ongeschikte patiënten met een geruptureerd AAA. Alle patiënten zijn 
behandeld met een open procedure. eEVAR geschiktheid werd door twee 
onafhankelijke en ervaren beoordelaars bepaald aan de hand van een 
preoperatieve CTA. Beiden waren geblindeerd voor eerdere evaluatie, 
interventie en uitkomst. In totaal zijn 82 patiënten geïncludeerd. De 
preoperatieve CTA toont een eEVAR-geschikt geruptureerd AAA in 33 patiënten 
(40,2%) en een eEVAR-ongeschikt geruptureerd AAA in 49 patiënten (59,8%). 
De mortaliteit in beide groepen blijkt niet significant te verschillen met een 
verschil in intra-operatieve, 30 dagen en 6 maanden mortaliteit van 
respectievelijk 4,1% (95% BI: 0,7-20,2%), 3,5% (95% BI: -24,7-18,2%) en 4,7% 
(95% BI: -25,9-16,6). We concluderen dat in deze analyse anatomische 
geschiktheid voor eEVAR niet geassocieerd is met een vermindering in 
mortaliteit op vroege en middellange termijn bij patiënten die behandeld zijn 
met een open procedure voor een geruptureerd AAA. Hieruit kunnen we 
mogelijk extrapoleren dat de gerapporteerde reductie in mortaliteit na eEVAR 
vergeleken met de open procedure niet of nauwelijks het gevolg is van 
selectiebias op basis van anatomische AAA configuratie. 
 
In hoofdstuk 5 focussen we op het symptomatische AAA, gedefinieerd als de 
aanwezigheid van een AAA met acute aanvang van buik en/of rugklachten in 
combinatie met pijn bij palpatie van het aneurysma en zonder tekenen van 
ruptuur op CTA. Deze aandoening representeert mogelijk een dreigende 
ruptuur waarvoor een acute operatie geïndiceerd is. In dit hoofdstuk vergelijken 
we de acute behandeling van het symptomatische AAA met de uitgestelde 
behandeling na optimalisatie van de preoperatieve condities van de patiënt. We 
gebruiken hiervoor 12 uur als afkappunt en hebben gecorrigeerd voor type 
operatie en mogelijke confounders. In de studie zijn 89 patiënten geïncludeerd 
waarvan 37 patiënten een acute operatie hebben ondergaan. De andere 52 
patiënten zijn eerst geoptimaliseerd en daarna (uitgesteld) behandeld. In de 
acuut geopereerde groep is bij 1 patiënt een ruptuur opgetreden (2,7%) 
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vergeleken bij 4 patiënten in de uitgesteld geopereerde groep (7,7%). De 30 
dagen mortaliteit in de groep die binnen 12 uur is geopereerd betreft 16,2% 
versus 5,8% in de groep die na 12 uur is geopereerd (OR: 0,316; BI: 0,074-
1,358). Na correctie voor type operatie (open of eEVAR) en andere potentiële 
confounders zijn de gecorrigeerde odds ratio’s respectievelijk 0,305 (BI: 0,066-
1,405) en 0,270 (BI: 0,015-4,836). Wanneer men 24 uur als afkappunt kiest, 
blijven de (gecorrigeerde) odds ratio’s onveranderd. Hieruit hebben wij 
geconcludeerd dat het verantwoord lijkt patiënten met een symptomatisch AAA 
een uitgestelde behandeling te geven, indien de beschikbaar gekomen 
tijdspanne wordt aangewend ter optimalisatie van de patiënt. Vervolg-
onderzoek is aangewezen om patiënten te kunnen selecteren die op basis van 
specifieke criteria voordeel hebben van een uitgestelde operatie. 
 
Hoofdstuk 6 beschrijft de lange termijn resultaten van een multicenter-studie 
naar de uitkomsten van de endovasculaire behandeling van het para-
anastomotische aneurysma na een eerdere open reconstructie. Deze initiële 
open reconstructie kan zowel uit een aortabuis of een aorta-bifurcatie-prothese 
bestaan. In totaal zijn 58 patiënten met 80 pseudo- en/of ware aneurysmata 
van de aorta en/of iliacale arteriën endovasculair behandeld met een 
endoprothese. Een endovasculaire buisprothese is gebruikt bij 8 patiënten, een 
bifurcatie endoprothese bij 32 patiënten, een aorta-uni-iliacale-endoprothese 
bij 7 patiënten en een iliacale extensie bij 11 patiënten. Bij 55 patiënten is een 
succesvolle procedure verricht met een technisch succespercentage van 95%. 
De mediane opnameduur bedraagt 3 dagen (Range: 1-122 dagen) en de 30 
dagen mortaliteit bedraagt 3,4% (n=2). De mediane follow-up is 41 maanden 
met een range van 0-106 maanden. Tijdens de follow-up wordt een jaarlijks 
mortaliteitsrisico van 4,0% en een reïnterventierisico van 5,8% gezien. De 
preoperatieve anatomische presentatie van het para-anastomotische 
aneurysma lijkt geen invloed te hebben op het reïnterventierisico (P=0,131). 
Echter, voor wat betreft de verschillende configuraties van de gebruikte 
endoprotheses zien we wel een significant verschil in reïnterventies na plaatsing 
van een aortabuis of aorta-uni-iliacale endoprothese gedurende de follow-up 
(P<0,001). Het jaarlijkse risico op een reïnterventie is 3,2% (SE: 0,098%) voor de 
bifurcatie endoprothese, 16,6% (SE: 0,239%) voor een endovasculaire 
buisprothese, 66,4% (SE: <0,001%) voor aorta-uni-iliacale endoprotheses en 
19,1% (SE: 0,152%) voor distale iliacale extensies. We concluderen dat 
endovasculaire exclusie van anatomisch geschikte para-anastomotische 
aneurysmata uitvoerbaar en duurzaam is; met name de bifurcatie endo-
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prothese laat een stabiele follow-up zien en mag daarom beschouwd worden 
als eerste-keus-behandeling. Echter, de endovasculaire behandeling van het 
para-anastomotische aneurysma vereist een individuele benadering waarin 
zowel de anatomische configuratie van het aneurysma als de gewenste 
configuratie van de endoprothese moeten worden meegenomen.  
DEEL TWEE – FOLLOW‐UP NA ENDOVASCULAIRE ANEURYSMA 
BEHANDELING, DETECTIE VAN STENTGRAFT GERELATEERDE 
COMPLICATIES 
In een periode waarin (acute) EVAR in toenemende mate wordt toegepast, is 
het belangrijk de keerzijde van deze minimaal invasieve techniek te belichten, 
zoals de noodzaak van langdurige follow-up om stentgraft gerelateerde 
complicaties op te sporen. CTA is de meest gebruikte techniek in de follow-up 
na EVAR. Echter, het herhaaldelijk uitvoeren van een CTA heeft belangrijke 
nadelen waaronder cumulatieve stralingsdosis en het gebruik van nefrotoxisch 
contrast. Minder schadelijke alternatieven in de follow-up na EVAR zijn dan ook 
gewenst. Deze zouden gevonden kunnen worden in de ontwikkeling van 
alternatieve beeldvorming of adequate biomarkers. 
 
In hoofdstuk 7 worden verschillende strategieën voor de detectie van 
endoleaks tijdens de postoperatieve follow-up na EVAR met behulp van 
alternatieve beeldvorming en adequate biomarkers behandeld. CTA follow-up 
na EVAR wordt beschouwd als de gouden standaard. CTA is hoog-sensitief, 
breed toegankelijk, snel en heeft een grote mate van reproduceerbaarheid. 
Echter, de nadelen zijn de cumulatieve stralingsdoses en het herhaald gebruik 
van nefrotoxisch contrastmiddel. Daarnaast is het optimale protocol voor 
follow-up in deze patiëntenpopulatie nog niet uitgekristalliseerd. Veel-
belovende alternatieve modaliteiten voor de detectie van endoleaks zonder 
röntgenstraling of nefrotoxisch contrastmiddel zijn: contrastversterkte duplex 
(CEUS), magnetische resonantie angiografie (MRA) en circulerende biomarkers 
(matrix metalloproteïnases). Deze technieken zijn in staat endoleaks met 
toenemende sensitiviteit en specificiteit te detecteren en te classificeren. 
Hiermee nemen ze een optie op een prominente rol in de follow-up na EVAR. 
Echter, harde aanbevelingen voor de ideale follow-up na EVAR kunnen op basis 
van de hedendaagse literatuur nog niet worden gedaan. 
 
In hoofdstuk 8 gaan we verder in op de rol van CEUS als alternatief voor CTA in 
de follow-up van patiënten na EVAR waarbij we AAA-dimensies en endoleak 
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detectie behandelen. Er zijn 83 opeenvolgende patiënten geïncludeerd 
gedurende de follow-up na EVAR. Deze hebben in totaal 127 gepaarde 
beeldvormende onderzoeken ondergaan in de vorm van zowel CEUS als CTA. Er 
is een goede overeenkomst tussen de twee beeldvormende technieken 
gevonden in zowel antero-posterieure als transversale maximale diameter met 
een variatiecoëfficiënt van respectievelijk 8,0% en 8,6%. De interobserver 
variabiliteit is laag met een interclass correlatiecoëfficiënt van meer dan 0,98 in 
beiden richtingen. CEUS blijkt in vergelijking tot CTA significant meer endoleaks 
te detecteren (53% versus 22%). Additioneel laat CEUS 38 type II en 2 type I 
endoleaks zien, welke bij twee patiënten geresulteerd hebben in een 
reïnterventie. Er blijkt dan ook sprake van een geringe mate van overeenkomst 
(κ=0,237) waarbij slechts 61% van de onderzoeken corresponderen (77/127). 
De resultaten laten zien dat CEUS mogelijk gelijkwaardig is aan CTA in de follow-
up na EVAR zonder de risico’s van contrastnefropathie en blootstelling aan 
radiatie.  
 
In hoofdstuk 9 focussen we op de potentiële klinische toepasbaarheid van de 
biomarkers MMP-2, MMP-9 en TIMP-1 als diagnostische middelen om 
endoleaks aan te tonen. Er zijn 37 patiënten geïncludeerd, 17 patiënten met 
een endoleak op CTA (4 type I, 12 type II en 1 type III endoleak) en 20 gepaarde 
controlepatiënten zonder endoleak. Plasmaconcentraties van MMP-2, MMP-9 
en TIMP-1 zijn bepaald door gebruik te maken van enzyme-linked 
immunosorbent assay. Patiënten met een endoleak hebben een significant 
hogere plasmaconcentratie van MMP-9 dan patiënten zonder endoleak 
(P<0,001). De ROC-curve van de plasmaconcentraties van MMP-9 laat bij een 
afkapwaarde van 55,18 ng/ml een 100% sensitiviteit en 96% specificiteit zien 
met een oppervlakte onder de curve (AUC) van 0,988 (P<0,001). Echter, het 
blijkt niet mogelijk om op basis van plasmaconcentraties van MMP-9 te 
differentiëren tussen de verschillende typen endoleaks. Deze studie laat zien 
dat de plasmaconcentratie van MMP-9 in staat is om met hoge sensitiviteit en 
specificiteit te discrimineren tussen patiënten met en zonder endoleak. Een 
prospectieve klinische studie is vereist om de klinische toepasbaarheid van deze 
analyse te valideren.  
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Dankwoord 
Eindelijk, het is af…! 
Toch grappig, hetgeen dat het meest gelezen wordt in een wetenschappelijk 
proefschrift is het dankwoord, het enige hoofdstuk dat geen enkel cijfer, tabel 
of figuur bevat. Dit onderstreept maar weer dat je een proefschrift niet kunt 
schrijven door je vier jaar eenzaam op te sluiten. Veel mensen hebben direct of 
indirect een onmisbare bijdrage geleverd aan de uiteindelijke totstandkoming 
van “het boekje”. Ik vind het dan ook heerlijk dat ik een heel hoofdstuk kan 
weiden aan het bedanken van deze mensen, en een paar in het bijzonder. 
 
Allereerst wil ik alle patiënten en hun familie bedanken dat zij in tijden van 
spanning en onzekerheid bereid zijn geweest deel te nemen aan onze studies. 
Zonder jullie was dit proefschrift er überhaupt nooit geweest! 
 
Prof. dr. J.A.W. Teijink, beste Joep, 
Daar zat ik dan op die foeilelijke rode leren bank tijdens mijn sollicitatie als 
semi-arts. Ik had nooit durven hopen dat dit het begin zou worden van zo’n 
mooie en vruchtbare samenwerking. Qua energie doen we misschien niet voor 
elkaar onder, maar jij hebt me laten zien hoe je die energie ook voor 
productieve dingen in kunt zetten. Dit heeft bij mij geleid tot dit boekje en bij 
jou tot een hoogleraarschap dit jaar, iets wat we stiekem allemaal al zagen 
aankomen. 
Joep, al had ik dat boekje nooit afgeschreven, vanaf het moment op die rode 
bank heb ik er een maat voor het leven bij. Zet twee wervelwinden bij elkaar en 
dat staat garant voor de nodige brakke congresdagen, dwaze onderzoeks-trips 
en honderden verhalen die ik beter niet in een serieus proefschrift kan 
schrijven, maar waar ik met gemak een tweede boekje mee kan vullen.  
Joep, heel veel succes als Prof in Eindhoven, ontzettend bedankt voor de volle 
overgave waarin je me hebt gesteund en begeleid afgelopen jaren en ik hoop 
dat ik nog vaak pannenkoeken kan komen eten bij jou, Inez en de kids! 
 
Prof . dr. M.H. Prins, beste Martin 
Nog voor de eerste kop thee op was bij jou thuis in de ‘Rozenheuvel’ had je de 
onderzoeksvinger al op de zere plek. Daar waar ik weken mijn hoofd op zat te 
breken leek na een bezoek aan jou een makkie. Jij maakte iedere analyse zelfs 
voor mij begrijpelijk en inzichtelijk en daarmee onderzoek doen toegankelijk. 
Toch was een meeting van 1 uur voer voor minimaal twee maanden werk. 
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Martin, jouw ideeën, manier van orde scheppen, rust en bescheidenheid werkte 
inspirerend en ik heb zowel als onderzoeker als persoon veel van je geleerd. 
 
Dr. E.M. Willigendael, beste Edith, mijn onderzoeks‐mamma 
Je heb je taak volbracht, je kind gaat promoveren! Wie had gedacht dat we zo’n 
hecht team zouden vormen, een Raver zij aan zij met een Alto, Nike Air Max-jes 
hand in hand met Dr Martens! Je bent me voorgegaan als onderzoeker van Joep 
en weet als geen ander dat achterover leunen geen optie is. Je oppeppende 
mailtjes waren altijd van onschatbare waarde. Je bent een geweldige 
copromotor, je stond samen met Jan altijd direct klaar als ik je nodig had en ik 
hoop dat je in Alkmaar deze rol als onderzoeks-mamma voort kan zetten! Ik 
weet al lang wat je volgende mail gaat zijn: “En nu genieten manneke!” Nou, 
laat jullie motor maar vast warmdraaien dan… 
 
Leden van de beoordelingscommissie 
Graag zou ik de leden van de beoordelingscommissie, voorzitter Prof. dr. G.W. 
Schurink, Prof. dr. R. De Bie, Prof. dr. M.W. de Haan, Dr. J.A. van Herwaarden 
en Dr. M.R.H.M. van Sambeek enorm willen bedanken voor de tijd die u heeft 
willen besteden aan de beoordeling van mijn proefschrift.  
 
Dr. S.P.A. Nicolai, beste Sas 
Met zijn tweeën hebben we heel wat dagen gesleten in de bezemkast op de 
AOA, het aquarium. Vaak hebben we de vraag gehad, “wat doen jullie daar 
eigenlijk de hele dag”. Dat heb ik me ook vaak afgevraagd, want we hebben 
zoveel lopen ouwehoeren dat er veel dagen voorbij gingen dat mijn computer 
niet eens aan is geweest. Sasje, je bent een geweldige roommate geweest en ik 
wil je bedanken voor alle mooie momenten! 
 
Dr. L.M. Kruidenier, beste Lottie 
Mijn tweede roommate in het aquarium op de AOA. Wat ik zo heerlijk aan je 
vindt is dat je als klein vrouwtje op je hakjes letterlijk 6 trippel-pasjes moet 
zetten waar ieder ander 1 pas zet, maar je in werkelijkheid iedereen als een 
razende voorbij stoomt door je efficiënte en kordate manier van aanpakken. 
Daar heb ik stiekem een hoop van afgekeken. Je was dan wel het zoveelste 
meisje in de onderzoeks-reeks van Joep, maar voor mij deed je qua schuine 
humor, voetbalpraat (als enige FC-twente Hooligan in Limburg), bierdrinkend 
vermogen en heerlijk nuchtere kijk op het leven niet onder voor een goeie vent. 
Ik heb dan ook, naast een berg statistische hulp, met name een hele fijne tijd 
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met je gehad! Blijf een vrouwtje maar sta je mannetje, dan weet ik zeker dat je 
een grote vaatchirurg gaat worden! 
 
Dr. E.V. Rouwet, Elliebellie 
Met name tijdens het schrijven van de CEUS studie hebben we intensief 
samengewerkt. Je opgewekte persoonlijkheid, lekkere directe aanpak en no-
nonsense mentaliteit maakte samen sparren niet alleen gezellig maar ook 
uitermate efficiënt. Telkens kwam je de AOA weer binnengevlogen met 
kritische noten, nieuwe inzichten en waardevolle verbeteringen. Elliebellie, ik 
heb van je genoten en onthoud: “Een dag niet gegiecheld is een dag niet 
geleefd.” 
 
Dr. F.A.M.V.I. Hellenthal, beste Femke 
We hebben zowel wetenschappelijk als klinisch samen mogen werken. En 
hoewel we heel verschillend zijn hebben we een klik samen. Ik heb erg veel 
bewondering hoe je de afronding van je promotie hebt kunnen combineren met 
je klinische werk en met moeder zijn. Houd je heerlijke nuchtere droge humor 
en kijk op het leven vast! Je gaat een grote maar vooral relaxte vaatchirurg 
worden! 
 
Drs. R.A. Stokmans, beste Rutger 
Als opvolger binnen het aneurysma-onderzoek in het Catharina Ziekenhuis 
onder leiding van Joep ga je zoals verwacht als een speer. Daarnaast heb je nu 
ook je welverdiende opleidingsplek binnen! Heel veel succes met de afronding 
van je eigen promotie, ik ben ervan overtuigt dat jouw laatste loodjes vlotter 
gaan dan die van mij, nog effekes jonguh! 
 
Drs. S.W. Koning, beste Sam, Samwise the brave, ouwe levensgenieter. Toen ik 
als ANIOS begon en de kliniek nog nauwelijks kon bijbenen heb jij je als semi-
arts en tevens als m’n AAA-onderzoeks-mattie vol op de sAAA database gestort. 
En met succes, we hebben er een mooi artikel uit weten te persen, maar 
bovenal een te gekke tijd gehad als Jut en Jul van het AAA onderzoek. Ik zit nu 
tijdens het schrijven van dit stukje onze continue stroom van idiote mail-
conversaties van destijds te bekijken, heerlijk! Sam, ik ben je enorm dankbaar 
voor je tomeloze inzet! Heel veel succes met je eigen onderzoek en je verdere 
carrière!  
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Graag zou ik enkelen in het bijzonder bedanken voor de directe bijdrage aan 
diverse hoofdstukken. Allereerst Dr. M.R.H.M. van Sambeek, beste Marc, dank 
voor de kritische noten bij meerdere artikelen, je was nooit te beroerd om mee 
te denken. Altijd dacht ik achteraf: “ja, het is echt beter geworden”. Dr. 
Ph.W.M. Cuypers, beste Philip, Dr. J.P.P.M. de Vries, beste Jean‐Paul, Prof. dr. 
M.W. de Haan, beste Michiel, en Prof. dr. H.J.M. Verhagen, beste Hence, ook 
jullie wil ik enorm bedanken voor de actieve bijdrage aan verschillende 
hoofdstukken in dit boekje. Jullie mailtjes met gevat commentaar en de nodige 
tips and tricks waren van grote waarde! 
 
Dr. J.A. van Herwaarden, beste Joost  
Ik heb je leren kennen als een toegewijde vaatchirurg die enorm betrokken is bij 
zijn onderzoekers. Ik ben dan ook erg blij dat ik gedurende de naadaneurysma-
studie onderdeel mocht zijn van jouw club onderzoekers met als absolute 
hoogtepunt het SVS in Boston, een onvergetelijke trip! Joost, dank voor het 
gespreide warme bedje in het UMCU ten tijden van het inkloppen van de data 
voor de naadaneurysma-studie en dank voor je positieve perfectionisme bij ons 
artikel! 
 
Dr. E.J. Waasdorp, beste Evert, je nam me in het UMCU aan de hand om de 
Utrechtse naadaneurysma data in te kloppen en vervolgens hebben we heel 
wat lopen sparren om het artikel te perfectioneren. Ik heb veel waardering voor 
de snelheid waarmee jij je eigen promotie hebt kunnen afronden naast je 
klinische werk en wil je bedanken voor de gezellige samenwerking! Veel succes 
als vaatchirurg en we zullen elkaar op de nodige feestjes nog wel tegenkomen! 
 
Prof. dr. F.L. Moll, beste Frans, u ziet zo veel jonge onderzoekers voorbij komen 
en ik vond het dan ook erg bijzonder dat u zoveel tijd en aandacht had voor 
mijn onderzoek toen ik in Utrecht ‘langswipte’ om de data van de 
naadaneurysma studie te verzamelen. Het was bijzonder om even deel uit te 
mogen maken van jullie team. 
 
Prof. dr. Schurink, beste Geert Willem, jij had al ruime ervaring met het 
begeleiden van basaal-wetenschappelijk en aneurysma-onderzoek waardoor ik 
op een rijdende, zeg maar gerust racende MMP-trein kon stappen. Heel veel 
dank hiervoor! Ik vond het mooi om je de eerste drie jaar van mijn opleiding in 
de kliniek ‘in actie’ te zien en heb veel van je mogen leren. 
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Jeroen van den Akker, Toon van der Krieken, Gio Tuerlings, Gaby de Bresser 
en Viola Conradi van Medtronic, wat hebben we plezier gehad op OK, op 
congressen, op de EVAR themadagen en op de nodige feestjes. Ik dacht altijd 
dat ik goed was in doortrekken... 
Peter van Gendt, van W.L. Gore, bedankt voor de toptijd in Miami samen met 
Joep, het was dat ik een praatje moest geven anders hadden we het 
congresgebouw überhaupt niet gezien vrees ik… 
 
Semi‐artsen club 2007‐2008 van het Atrium MC 
36 weken deelden we samen ons hokkie met 9 computers, toen nog op de 
bovenste verdieping van het Atrium ziekenhuis naast de beddencentrale, 
waarvan de chirurgen zelf op dat moment geen enkel idee hadden waar het 
zich bevond (yesssss). Rik Dassen, Roy Sauren, Pascal Buijs, Anne Schellekens, 
Sophie Litjens, Kim van Pul, Judith Bek en Marieke Verspaget. Wat hebben wij 
een mooi jaar gehad, gelachen, gezopen en samen onze eerste 
wetenschappelijke stapjes gezet, hetgeen voor mij de basis werd voor dit 
proefschrift. Rik Dassen, zonder jou en die gruwelijke kerstman op z’n slee was 
dit boekje er minimaal driekwart jaar eerder geweest, maar was mijn stage niet 
half zo leuk. 
 
Chirurgen en arts‐assistenten Heelkunde in het Atrium MC 
Als semi-arts, onderzoeker en later als ANIOS hebben jullie dit groentje 
klaargestoomd voor de opleiding chirurgie. Het is bij jullie niet moeilijk om 
onderdeel te worden van het team. De werksfeer, vrijdagmiddagoverdrachten, 
borrels en natuurlijk de onvergetelijke winterbijscholingen hebben hier zeker 
aan bijgedragen. Ik kijk er dan ook erg naar uit om de laatste drie jaar van mijn 
opleiding ‘thuis’ te komen.  
Mijn speciale dank gaat uit naar een aantal chirurgen in het bijzonder: 
Dr. R.J.Th.J. Welten, beste Rob, bedankt voor het vertrouwen en de steun bij 
mijn keuze voor de chirurgische opleiding, dit heb ik enorm gewaardeerd. Ik 
ben ervan overtuigd dat we van de laatste drie jaar van mijn opleiding een 
toptijd tegemoet gaan! Dr. E.C.M. Bollen, beste Ewald, ik heb je interesse in het 
onderzoek en in mij altijd als bijzonder ervaren, evenals je wijze lessen van een 
‘oude’ vaatchirurg. Drs. B. Meesters, beste Berry, jouw gave om naast 
presteren op de werkvloer vol in het bruisende leven te staan werkt echt 
inspirerend. We gaan mooie jaren tegemoet, als m’n baas maar zeker ook als 
m’n maatje! Drs. E.R. de Loos, beste Erik, jij stond mede aan het begin van dit 
onderzoek en gaf me de ruimte om het onder leiding van Joep en Martin verder 
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af te maken. Toch hebben we menig jaartje in dezelfde tent doorgebracht. Ik 
vind het dan ook te gek we de laatste drie jaar van mijn opleiding opnieuw 
samen aan de overdrachtstafel zitten! Dr. M.N. Sosef, beste Meindert, je had 
me binnen 5 minuten overtuigd om mijn semi-arts stage in het Atrium te komen 
doen, m’n beste beslissing ooit! Ik vind het dan ook bijzonder dat ik de laatste 
fase van mijn opleiding onder jouw hoede mag afronden.  
Verder wil ik graag de voltallige assistentenpoel ten tijden van mijn semi-arts 
stage, onderzoeksjaar en ANIOS-periode in het Atrium MC bedanken voor de 
toptijd! In het bijzonder Zwelgje m’n party buddy, Ruuubschen, Zandhaas, 
Oerlemansje, Castelijnsje, Jean Paul, Frenkie, Speigner, Kimmie, Elfedalli, Joep 
en Woutje.  
 
Maar er zijn nog tientallen mensen uit het Atrium die ik graag zou willen 
bedanken en een dikke vette knuffel wil geven. Allereerst de heldinnen van het 
Vaatlab, Cecile Peters en Linda Jansen, the queens of CEUS! Het voltallige poli‐
personeel met in het bijzonder Ali en Christel, jullie maken van poli draaien een 
feestje! Ik heb eindeloos patiënten lopen includeren op jullie poli, klinkt saai, 
maar zodra ik de spreekkamer uitkwam was het non-stop lachen gieren brullen. 
Bedankt en tot de laatste drie jaar van mijn opleiding! De vepleegkundigen van 
de AOA, de 11 en de 12, bedankt voor de mooie tijd, you rock! Simone, de OK-
planster met nadruk op STER! Wat ben je toch een heerlijk gek wijf, een topper! 
Wanneer gaan we weer beschuitjes eten? Het secretariaat chirurgie, het 
gezelligste kippenhok van het ziekenhuis, Jolanda, Margot, Marlies, Caroline en 
Nancy, ik kon altijd bij jullie aankloppen, voor hulp, voor advies, maar ook altijd 
voor een praatje. Ik heb jullie gemist afgelopen 3 jaar!!! 
 
MUMC 
Allereerst de assistentenpoel, de meest gestoorde club assistenten ooit, 
iedereen maar dan ook iedereen van de afgelopen 3 jaar wil ik enorm bedanken 
voor deze dolle dwaze jaren. Als ik niet elke dag met zo’n dikke smile en 
buikpijn van het lachen thuiskwam had ik me er nooit toe kunnen zetten om dit 
boekje in de avonduren af te ronden! Een speciale dikke lebber aan de bende 
van ellende: Woutje, Hillybilly, Basje, Bransen, Smeetsje, Berende, Reinders en 
vd Pas.  
Maar natuurlijk ook de chirurgen, wat was het een mooie tijd en wat moest ik 
nog veel leren de eerste drie jaar van mijn opleiding. Ik wil iedereen bedanken 
voor de geweldige werksfeer, opleiding en stabiele basis om me verder te 
kunnen ontwikkelen. De winterbijscholingen, jaarlijkse BBQ en tussentijdse 
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feestjes en uitstapjes waren geweldig! Mijn speciale dank gaat ook uit naar 
Prof. dr. L.P.S. Stassen, beste Laurents, ik ben blij dat ik als AIOS mocht 
profiteren van jouw passie voor opleiding en onderwijs afgelopen jaren. Jouw 
bijzonder hoogleraarschap dit jaar is dan ook niet voor niets! Bedankt! 
Ook wil ik graag van deze gelegenheid gebruik maken om het secretariaat 
chirurgie, Tonneke, Manon, Claudia, Ingrid, Sandra, Evelien, Sabeth, Monique, 
Joyce, Mariëlle, en ook office manager Marianne Siep en natuurlijk niet te 
vergeten Marieke Koenen te bedanken. Het lukte me nooit om jullie tuintjes op 
de stafgang te passeren zonder veeeeeel te lang te blijven plakken. Ik heb nog 
nooit zo veel mamma’s gehad. Jullie stonden altijd vol overgave voor me klaar 
als ik jullie weer kwam bekogelen met (domme) vragen.  
 
Café 1900 
Lieve Gemma, vanaf de introductieweek in mijn eerste studiejaar kom ik met 
veel plezier DE daghap bij je eten. Jij hebt mij van broekie af aan ‘volwassen’ 
zien worden. En waar we ook komen te wonen later, jullie daghap zal op ons 
menu blijven staan! Boy, veel succes en maak je moeder trots!  
 
Tiny Wouters, je bent een bijzonder mens en ik weet niet hoe ik de ‘laatste 
loodjes’ van mijn boekje zonder jou had moeten volbrengen. Het was altijd leuk 
om je kamertje binnen te wandelen en niet alleen voor de snoepjes. Tiny, het is 
echt bijzonder om zoveel mensen te mogen ondersteunen in de afrondende 
fase van een van hun meest bijzondere levens-momenten. Ik wil je in ieder 
geval bedanken voor alles wat je voor mij hebt gedaan, ik zal het nooit 
vergeten! 
 
Nondejuke 
Maastrichts bruutste herendispuut, een grote club volslagen idioten. Samen 
met jullie heb ik gepiekt en letterlijk de goot gezien, en er vaak genoeg in 
gelegen. De wekelijkse borrels en zijn rituelen zijn aan geen mens uit te leggen, 
maar hebben mijn studentenleven gemaakt. 
 
HS, homies for life 
Echte vrienden hebben aan weinig woorden genoeg. Jossos Kolossos, Face en 
T_, zieke tijden waarin we létterlijk ALLES met elkaar hebben gedeeld! Wat prijs 
ik me gelukkig dat ik dan ook meerdere huizen met jullie heb mogen delen, 
Mufassa zou trots zijn. Joost van der Vorst, Jos, Jossos Kolossos, Renpaard, 
'Orse, da pussyfillah, wij versterken elkaar in alle opzichten, zoeken geen 
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grenzen op maar gaan er vol overtuiging overheen, je bent en blijft mijn mattie 
for life! Rick van de Langenberg, Face, the prettiest boy on planet earth, 'Jae...', 
ik verbleek naast iedere glimp van jou, dat jij het onze hele studententijd hebt 
uitgehouden in het HB en HS getuigt van de grootste vriendschapsband die er 
voor te stellen is. Ik heb nog nooit zo veel met en om iemand gelachen, ik hoop 
dat we altijd in elkaars stadje blijven wonen! Thijs van Herpt, T_, TTW Diherpio, 
Mr sorry, ‘prulleke’, jouw eeuwige enthousiasme en vermogen om chaos in 
orde te scheppen is werkelijk ongeëvenaard. Als je denkt dat het niet extremer 
kan kom jij om de hoek kijken en daarom maak jij ons viertal helemaal 
compleet! 
Zoals Face al in zijn proefschrift zei: waarom mag je maar twee paranimfen 
kiezen…? 
 
Schoonfamilie 
Een vriendin kun je ‘kiezen’ (hoewel ik voor die van mij toch nogal wat moeite 
heb moeten doen), je schoonfamilie krijg je er gratis bij. Wat is het dan toch 
heerlijk om in zo’n warme familie terecht te komen. Steph en Ellen, ook jullie 
wil ik enorm bedanken voor jullie oprechte interesse, alle steun en mooie 
momenten van afgelopen jaren. Ik ben enorm blij met jullie! 
Renéetje, mijn schoonzusje, ik kan met niemand zo goed stoeien, mensen 
irriteren en lachen als met jou. Je bent een topzusje! 
Svennieboy, schoonbroertje, hoe bijzonder is het dat je schoonbroer een van je 
beste maten wordt met (toevallig) dezelfde passie: draaien. Als ‘Brothers in 
Law’ – Sven Feijen B2B Jean de la Foret hebben we wekelijks het publiek (en 
menig organisator) gek gemaakt! Hierbij mocht één iemand nooit ontbreken, 
onze ras-positivist MC Handsome, Rob Vervoort. Rob, ik ken niemand met 
zoveel zelfspot als jij en ik geniet daar ieder moment dat we samen zijn van! 
Laten we elkaar in ieder geval blijven steunen in de strijd tegen onze kaalheid.  
(Schoon)opa en oma, ik vind het een eer dat jullie dit nog mogen meemaken, 
zeker gezien het feit dat jullie altijd zo enorm geïnteresseerd zijn en dat ik jullie 
stiekem ook een beetje als mijn eigen opa en oma zie. Ik hoop samen met 
Michelle nog heel lang van jullie te mogen genieten! 
 
Familie 
Lieve paps en mams, jullie hebben ons een onbezorgde jeugd gegeven en jullie 
hebben jezelf volledig weggecijferd om ons alle mogelijkheden te bieden om 
ons te kunnen ontwikkelen, op alle vlakken. Jullie wisten ons te motiveren en 
we hebben de perfecte balans meegekregen tussen genieten en presteren, 
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zowel in de sport als in de muziek als in het dagelijkse leven. ‘Het maakt niet uit 
wat je doet, als je maar je best doet’. Zonder jullie onvoorwaardelijke steun en 
zorgzaamheid was ik nooit gekomen waar ik nu sta. En al woon ik in het 
Zuidelijkste puntje van het Land, het blijft altijd fijn om weer even thuis te 
komen. Ik ben jullie ontzettend dankbaar en ik hoop dat ik mijn toekomstige 
kinderen hetzelfde kan bieden als wat jullie mij geboden hebben. Dit boekje is 
voor jullie! 
Pleun en Neeltje, hoe sterk kan een broer-zusjes band zijn, familie en tegelijk 
beste maatjes. Als wij samen zijn is het gegarandeerd feest. We hebben 
dezelfde mentaliteit en doorzettingsvermogen, maar bovenal dezelfde slechte 
humor, wat voor veel mensen rete irritant is. Pleunie, jouw gave om ondanks je 
eigen drukke praktijk en sociale leven ALTIJD oog en interesse te hebben voor 
iedereen om je heen vind ik echt bewonderenswaardig! Nelus, de manier 
waarop jij je omgeving kan inspireren met jouw onuitputtelijke positieve 
energie is minstens zo bijzonder. Ik ben zo trots op jullie en ik zal mijn hele 
leven proberen jullie grote broer te zijn. Onze band is niet kapot te krijgen! 
Jacolien Schellekens, tante Sjaco, als peettante heb je mijn hele leven zo dicht 
bij me gestaan en alles op de voet gevolgd. Ik ben me er heel erg van bewust 
dat ik enorm bof met zo’n betrokken, zorgzame en lieve peettante!!! 
En… wat was het mooi geweest als beide opa’s en oma’s dit hadden mogen 
meemaken, stiekem is dit boekje ook een beetje voor jullie. 
 
Lieve, lieve Michelle, mijn soulmate en allerlekkerste vriendinnetje! Jij bent 
mijn schot in de roos! Afgelopen jaren waren niet altijd even makkelijk, 
promoveren naast het dagelijkse werk gaat ten koste van een heleboel quality-
time samen. Nooit heb je gezeurd, nooit een droevig gezicht; altijd heb je me 
vol overgave gesteund, me geholpen waar nodig, allerlei taken op je genomen 
zodat ik weer eens aan ‘het boekje’ kon werken en me de energie en motivatie 
gegeven om door te zetten. En dat alles naast jouw eigen drukke baan en leven. 
Nu is het jouw tijd, want dat heb jij als geen ander verdiend! Schatje, ik hoop 
dat al onze jaren die komen gaan net zo mooi mogen zijn als onze afgelopen 
jaren. Ik ben ongelofelijk trots op je, ik geniet nog iedere minuut van je en je 
wordt een geweldige moeder van ons kindje! ‘Het past’. 
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